

CURRICULUM VITAE

David L. Dunn, M.D., Ph.D.

OFFICE ADDRESS: 323 East Chestnut Street
Louisville, KY 40202-1823

BIRTH: December 4, 1952
Pontiac, Michigan

EDUCATION: B.S. Zoology, 1973
University of Michigan Ann
Arbor, Michigan

M.D. 1977
University of Michigan Medical School
Ann Arbor, Michigan

Ph.D. Microbiology, 1985
University of Minnesota Graduate School
Minneapolis, Minnesota

Medical Fellow (General Surgery), 1977-1985
Fellow in Transplantation and Transplantation Immunology, 1985-1986
Department of Surgery
University of Minnesota
Minneapolis, Minnesota

UNIVERSITY OF MINNESOTA ACADEMIC APPOINTMENTS:

Assistant Professor of Surgery, 1986-1989
Associate Professor of Surgery with Tenure, 1989-1993
Professor of Surgery with Tenure, 1993-2005
Interim Chair, Department of Surgery, 1995
Jay Phillips Professor and Chairman of Surgery, 1996-2005
Associate Member, Graduate Faculty in Surgery, 1986-1989
Head, Division of Surgical Infectious Diseases, 1987-2005
Full Member, Graduate Faculty in Surgery, 1989-2005
Full Member, Biomedical Science Ph.D. Faculty, 1990-2005
Director of Graduate Studies, Department of Surgery, 1993-2005
Full Member, University of Minnesota Cancer Center, 1994-2005
Residency Program Director, Department of Surgery, 1995-2005
Chief, Division of General Surgery, 1995-2005

UNIVERSITY AT BUFFALO/SUNY ACADEMIC APPOINTMENTS:

Vice President for Health Sciences, 2005-2011
Professor of Surgery, Microbiology and Immunology with Tenure, 2006-2011

UNIVERSITY of LOUISVILLE ACADEMIC APPOINTMENTS

Executive Vice President for Health Affairs, 2011-date
Professor of Surgery, Microbiology and Immunology with Tenure, 2011-date

BOARD CERTIFICATION:

Diplomate, American Board of Surgery, 1986
Recertified, American Board of Surgery, 1994
Recertified, American Board of Surgery, 2005

FELLOWSHIP:

Candidate, American College of Surgeons, 1978-1989
American College of Surgeons, 1989-date

ACADEMIC AWARDS:

Regents-Alumni Scholarship, University of Michigan, 1971
B.S. Zoology with High Distinction, University of Michigan, 1973
Alpha Omega Alpha, University of Michigan Medical School, 1976
American College of Surgeons Schering Scholarship Award, 1983-1984
Phi Kappa Phi, University of Minnesota Graduate School, 1983
David Gavisier Surgical Research Award, Department of Surgery, University of Minnesota, 1985
American Society of Transplant Surgeons Sandoz Transplant Fellowship (first recipient), 1985-1987

OTHER AWARDS AND RECOGNITION:

Life Member, Fellowship Leadership Society, American College of Surgeons, 2005
Regents Circle, Fellowship Leadership Society, American College of Surgeons, 2007

ACADEMIC SOCIETY MEMBERSHIP:

Alpha Omega Alpha, 1976
American Society of Microbiology, 1983
Phi Kappa Phi, 1983
Surgical Infection Society, 1984
Association for Academic Surgery, 1986
American Society of Transplant Surgeons, 1986
Society of University Surgeons, 1987
Minnesota Surgical Society, 1987
Surgical Biology Club I, 1988
American Association of Immunologists, 1989
International Endotoxin Society, 1989
The Halsted Society, 1990
The Transplantation Society, 1990
Society of Critical Care Medicine, 1990
American Surgical Association, 1991
St. Paul Surgical Society, Honorary Member, 1993
Shock Society, 1994
Fellow, Infectious Diseases Society of America, 1994
Central Surgical Association, 1995

Society of Clinical Surgery, 1995

Society of Graduate Surgeons of the Los Angeles County/University of Southern California Medical Center, Honorary Member, 1995

Association for Surgical Education, 1995

Society of Surgical Chairmen, 1996

Minneapolis Surgical Society, 1996

James IV Association of Surgeons, 1999

Minnesota Academy of Medicine, 2003

ACADEMIC SOCIETY OFFICES, COMMITTEES and APPOINTMENTS

Membership Committee, Surgical Infection Society, 1985-1988

Program Committee, Surgical Infection Society, 1988-1991

Program Committee, Association for Academic Surgery, 1988, 1990-1991

Committee on Social and Legislative Issues, Society of University Surgeons, 1989-1991

Minnesota State Chairman, American College of Surgeons Commission on Cancer, Cancer Liaison Program 1989-1995

Recorder, Surgical Infection Society, 1989-1991

Chairman, Program Committee, Surgical Infection Society, 1989-1991

Chairman, Scientific Studies Committee, American Society of Transplant Surgeons, 1989-1993

Professional Education Committee, Minnesota Division of the American Cancer Society, 1989-1990

Councilman, Association for Academic Surgery, 1989-1990

Ad hoc Committee on Biological Agents, Surgical Infection Society, 1991

Chairman, Fellowship Committee, Surgical Infection Society, 1991-1992

Secretary, Association for Academic Surgery, 1991-1993

Councilman-at-Large, Society of University Surgeons, 1992-1995

President-Elect, Surgical Infection Society, 1992

Committee for the Forum on Fundamental Surgical Problems, American College of Surgeons, 1992-1998

Program Committee, The Halsted Society, 1993-1995

Councilor-at-Large, American Society of Transplant Surgeons, 1993-1996

President, Surgical Infection Society, 1993

Vice-President, Minnesota Chapter of the American College of Surgeons, 1993

President-Elect, Association for Academic Surgery, 1994

Pre- and Postoperative Care Committee, American College of Surgeons, 1993-1999

Newsletter Editor, Association for Academic Surgery, 1994

Newsletter Editor, Surgical Infection Society, 1994

President-Elect, Minnesota Chapter of the American College of Surgeons, 1994

President, Association for Academic Surgery, 1995

Chairman, Scholarship Committee, Society of University Surgeons, 1995

Chairman, Program Committee, The Halsted Society, 1995

President-Elect, Society of University Surgeons, 1995

President, Minnesota Chapter of the American College of Surgeons, 1995

President, Society of University Surgeons, 1996

Course Director, 7th Annual Fundamentals of Surgical Research Course, Association for Academic Surgery, 1996
Scientific Program Committee, International Endotoxin Society, 1996-1998
Admissions Committee, Society of Clinical Surgery, 1996
Treasurer, Society of University Surgeons Foundation, 1997-2000
Membership Committee, American Surgical Association, 1998
Flance/Karl Awards Committee, American Surgical Association, 1999
Pre- and Postoperative Care Committee, American College of Surgeons, Senior Member, 1999-2003
President, Society of University Surgeons Foundation, 2000-2002
Board of Governors, American College of Surgeons, 2001-2004
Director, James IV Association of Surgeons, Inc., 2002-2005
Chairman, Flance-Karl Award Committee, American Surgical Association, 2003-2004
President-Elect, Minneapolis Surgical Society, 2005

INTRAMURAL COMMITTEES and APPOINTMENTS:

University of Minnesota Medical School

Cancer Task Force, 1986-1996
Clinical Oncology Task Force, 1986-1996
Cancer Center
American Cancer Society Clinical Oncology Professor Selection Committee, 1989
Cancer Registry Biostatistics Committee, 1991
Facility Planning Committee, 1991-1992
Immunology Planning Committee, 1991-1992
Database Advisory Committee, 1994-1995
General Clinical Research Center:
General Advisory Committee, 1986-1989
Scientific Advisory Committee, 1986-1989, 1998-2005
M.D./Ph.D. Program:
Steering Committee, 1986-2005
Physician Scientist Subcommittee, 1989-1992
Biomedical Scientist Ph.D. Program Committee, 1989-2005
Program Development and Evaluation Task Force, 1991-1995
Dean's Scientific Seminar Committee, 1993-1995
Committee of Private Practice, 1994-1997
Medical Students and Residents Task Force, 1994-1995
Dean's Task Force on Graduate Medical Education, 1995-1996
Dean's Advisory Committee, 1996-2005
Search Committee Membership
Dean of Medical School, 1996
Head, Family Practice, 1996
Clinical Cancer Program Director, 1996-1997
Chair, Search Committee
Head, Urologic Surgery, 1995-1996
Head, Pediatrics, 1997-1998
Head, Anesthesiology 2003-2005
Medical School Education Council, 2001-2005
Chair, Medical School Finance Task Force, 2003
Chair, Medical School Finance Committee, 2003-2005 Clinical Scholar Tenure Committee, 2004-2005
Diversity Task Force, 2004-2005

University of Minnesota

Ad hoc Committee on Clinical Research Training and Graduate Degrees, 1991-1995
University Senate, 1992-1995; alternate, 1998-1999

University of Minnesota Hospital/Fairview University Medical Center

Antibiotic Subcommittee, Pharmacy and Therapeutics Committee, 1986-2005
Disaster Committee, 1986-1994
Infection Control Committee, 1986-2005
Co-director, Pancreaticobiliary Disease Center, 1986-2005
Emergency Department Committee, 1987-1989
Transplant Program Utilization Work Force, 1987-1994
Operating Rooms Resource Utilization Work Force, 1987-1995
Quality Assurance Steering Committee, 1988-1992
Quality Assurance Special Work Group, 1991-1992
Pharmacy and Therapeutics Committee *ad hoc* Subcommittee for Development of Criteria for Use of Antibody to Gram-negative Endotoxin (HA-1A), 1991-1992
Clinical Outcomes Task Force, 1992-1996
Clinical Outcomes Task Force Subcommittee on the Outcome of Solid Organ Transplantation, 1992-1996
Patient Care Delivery Systems and Processes Task Force, 1992-1995
Minimally Invasive Surgery Task Force, 1992-1996
Committee on Professional Credentialing and Staff Privileges, 1993-1996
Perioperative Drug Therapy Subcommittee of the Pharmacy and Therapeutics Committee, 1993-1995 Emerging Technology Task Force, 1993-1995
Operating Room Steering Committee, 1995-1997 Hospital Budget Committee, 1996-1997
Co-Chair, Operating Room Committee, 1997-1999 Co-Chief, Surgical Services, 1997-1999
Co-Medical Director, Transplant Services, 1997-2005 Co-Director, Transplant Partnership, 2000-2005 Co-Chair, Operating Room Committee, 2001-2005

University of Minnesota Clinical Associates

Program Development Committee, 1993-1996
Professional Liability Task Force, 1995-1996
Board Member, 1995-1997
Executive Committee, 1995-1997

University of Minnesota Physicians, Inc.

Board Member, 1997-2005
Chair, Governance Committee, 1997-2000
Chair, Patient Services Contracting Subcommittee, 1997-2000 Nominations and Bylaws Committee, 1997-2000
Surgery Clinical Service Unit Manager, 1997-2005
Executive Committee, 2000-2005
Committee on Committees, 2002-2005
Chair, Audit Committee, 2001-2005
Chair, Investment Committee, 2002-2005
Clinical Practice Committee, 2003-2005

University of Minnesota Department of Surgery

Quality Assurance Officer, 1990-1995
Promotion and Tenure Committee, 1993-2005
Private Practice Subcommittee of the Advisory Council, 1993-1995
Residency Review Committee, 1993-2005
Administrative Head, White Surgery Service, 1994-1995
Faculty Advisory Council, 1994-2005
Development Committee, 1995
Ad hoc Committee for Evaluation of the Residency Program, 1994-1995
Managing Partner, Department of Surgery Associates, 1995-2000

University at Buffalo/SUNY

Executive Technology Advisory Group
Faculty Recognition Committee
Institutional Policy and Compliance Advisory Group
Search Committee Membership
Dean, School of Engineering and Applied Sciences, 2006
Vice President, Development and Alumni Relations, 2006

Senior Leadership Strategy Committee
Co-Chair, South Campus Academic Unit Space Needs Work Group Space Management & Facilities
Planning Committee
Executive Committee, Student Systems Assessment
Acting Director, NYS Center of Excellence in Bioinformatics and Life Sciences Planning Board

University at Buffalo Associates, Inc.

President and Chief Executive Officer, 2005-date

UB/MD

Executive Committee and Management Committee Member, 2005-date

Buffalo 2020 Development Corporation

President, 2009-2011

University of Louisville

Chair, Health Sciences Center Compliance Committee
Member, UofL Compliance Oversight Council
Chair, UofL Veterans Administration Task Group

University of Louisville Foundation

Member, University of Louisville Research Foundation Board of Directors

University of Louisville Hospital (University Medical Center)

Member, University Medical Center, Inc. Board of Directors
Member, University Medical Center, Inc. Finance, Audit and Compliance Committee
Member, University Hospital Medical Executive Committee
Member, University Medical Center Strategy Committee

University of Louisville Physicians

Member, University of Louisville Physicians Board of Directors and Executive Committee
Member, University Physician Associates Board of Directors and Executive Committee

EXTRAMURAL COMMITTEES, POSITIONS and BOARDS:

Cancer Liaison Physician, American College of Surgeons Cancer Liaison Program, 1988-1994
Lifesource Advisory Board, 1989-1995
General Surgery Subcommittee of the Medica Medical Policy Council, 1993-1998
Kimberly Clark Advisory Board, 1993-1997 Chair, Bayer Surgery Advisory Board, 1994-1998
Fugisawa Surgery Advisory Board, 1994-2001
Rhone-Poulenc-Rohrer Advisory Board, 1995-2001
Zeneca Council of Surgical Consultants, 1997-2001
Chair, Western New York Regional Advisory Committee, New York State Commission on Health
Care Facilities in the 21st Century, 2005-2006
Buffalo Niagara Medical Campus, 2005-2011
HealthLink, 2006-2011
Secretary/Treasurer, Great Lakes Health System, 2007-2011
Hauptman-Woodward Medical Research Institute, 2010-2011
Chair, Quality and Charity Care Trust Board of Directors
Member, Nucleus Advisory Board of Directors
Member, Passport Health Plan Board of Directors
Member, Subscribers Advisory Committee (Kentuckiana Medical Reciprocal Risk Retention Group)
Treasurer, Cardiovascular Innovation Institute Board of Directors, 2011-12
Chair, Cardiovascular Innovation Institute Board of Directors, 2012-2013
President and Chief Executive Officer, Health DataStream, 2012-date

EDITORIAL BOARDS:

Clinical Transplantation, 1989-2006
Critical Care Medicine, 1990-2008
Journal of Surgical Research, 1991-2000
Annals of Surgery, 1991-date
Transplantation Science, 1991-1997
Medical Intelligence Unit, 1991-1997
Circulatory Shock, 1993-1997
Surgical Infections: Index & Reviews, 1993-1997
Transplantation, 1993-2011
Associate Editor, SHOCK: Molecular, Cellular, Systemic Pathobiological Aspects and Therapeutic Approaches, 1993-2001
Sepsis, 1996-2000
Surgical Infections, 1998-date
Journal of Investigative Surgery, 2001-date

EXTRAMURAL REVIEW COMMITTEES:

Member, National Institutes of Health: Surgery, Anesthesiology and Trauma Study Section, Division of Research Grants, 1993-1997
Reviewer, National Institutes of Health: Special Emphasis Panel ZGM1TB-2 (GG), Office of Scientific Review, 2002

EXTRAMURAL GRANT SUPPORT: *Previously Funded Projects*

National Institutes of Health National Research Service Award *Pathogenic Factors in Experimental Peritonitis*. AM 0635301 (1981-1983).
National Institutes of Health Young Investigator's Research Award *Mechanisms of Immunotherapeutic Protection during Gram-negative Bacterial Sepsis*. R29 GM32414 (Principal Investigator, 1983-1986).
National Institutes of Health Public Health Service Grant *Pathogenesis and Treatment of Experimental Peritonitis*. R01 AI 14032 (Co-investigator, 1985-1988; Principal Investigator: Richard L. Simmons, M.D.).
National Institutes of Health Public Health Service Grant *Translocating Bacteria: Role in Post-surgical Sepsis* R01 AI 23484 (Co-investigator, 1986-1995; Principal Investigator: Carol L. Wells, Ph.D., Direct Costs = \$101,877.00 per year).
National Institutes of Health Public Health Service Program Project Grant *Studies of Organ Transplantation in Animals and Man* P01 DK13083 (Co-investigator, 1987-1992; Program Director: John S. Najarian, M.D., Direct Costs = \$830,332.00 per year).
Clinical Project IA (Co-investigator): *Comparative effect of OKT3 and ALG for prophylactic immunosuppression in clinical renal transplantation: a prospective randomized study*.
Clinical Project IE (Co-investigator): *Continuing retrospective, prospective, and pilot studies in renal transplantation*.
Clinical Project IIA (Co-investigator): *Cytomegalovirus infections in transplant recipients*.
National Institutes of Health Research Career Development Award *Mechanisms of immunotherapeutic protection during gram-negative bacterial sepsis* GM 00517 (Principal Investigator, 1988-1993, Direct Costs = \$65,375.00 per year).

National Institutes of Health Public Health Service Postdoctoral Training Grant *Research training for surgical scientists* T32 DK07566 (Co-investigator, 1988-1993; Principal Investigator: John S. Najarian, M.D., Direct Costs = \$168,675.00 per year).

National Cancer Institute Public Health Service Program Project Grant *Cancer and leukemia group B: Minnesota oncology group* P01 CA16450 (Co-investigator, 1988-1993; Principal Investigator: Bruce A. Peterson, M.D., Direct Costs = \$159,084.00 per year).

Minnesota Medical Foundation Research Grant *Detection of rejection and graft versus host disease after rat small bowel and multivisceral organ transplantation* (Principal Investigator, 1990-1991, Direct Costs = \$10,000.00).

National Institutes of Health Public Health Service Program Project Grant *Studies of organ transplantation in animals and man* P01 DK13083 (Co-investigator, 1992-1997; Program Director: John S. Najarian, M.D., Direct Costs = \$716,278 per year).

Clinical Project IIa (Principal Investigator): *Prophylaxis, treatment, and pathogenesis of cytomegalovirus disease in solid organ transplant recipients.*

Care-Tech Laboratories Grant *Clinical Trial to Reduce Wound Infection Rates in Pancreas Transplant Recipients and Compare Techni-Care to Conventional Wound Care in the Treatment of Open Wounds* (Principal Investigator, 1996-1998, Direct Costs = \$60,000).

Roche Laboratories Grant *Randomized, prospective trial of IV ganciclovir plus either oral ganciclovir or oral acyclovir in the prevention and treatment of CMV disease in recipients of solid organ allografts* (Principal Investigator, 1996-2001, Direct Costs = \$173,394).

National Institutes of Health Public Health Service Grant *Mechanisms of Immunotherapeutic Protection during Gram-negative Bacterial Sepsis* R01 GM32414 (Principal Investigator, 1986-2003, Direct Costs = \$368,481 per year).

New York State Department of Health Award *Management of End Stage Renal Disease in a Patient Centered Medical Home Model* (Principal Investigator, 2009-date, Direct Costs = \$7M).

TRAINEES AND ADVISEES:

Advanced Admission Mentor Program

Kirsten R. Martinson 1989-1990

Undergraduate Honor Students

Christopher M. Schoonover 1989-1990

Rania A. Habib 2003-2004

Undergraduate Summer Research Students

Donnette K. Morris 1991

Medical Students (Clinical Advisor)

Kevin R. Miller, B.S. 1987-1988

Stephen T. Erickson, B.S. 1987-1988

Todd A. Kellogg, B.S. 1991-1992

Karla M. Kurrelmeyer, B.S. 1992-1993

Mark T. Eginton, B.S. 1994-1995

Christopher J. Hansen, B.S. 1995-1996

Donavon J. Hess, B.S. 1995-1996

Brent Nykamp, B.A. 2002-2003

Medical Students (Laboratory)

Cyril J. Schweich, B.S. 1988

Dat T. Nguyen, B.S. 1989

Nancy E. Brass, B.S. 1989

Michael Momont, B.S. 1991

Todd A. Kellogg, B.S. 1992

Mark T. Eginton, B.S. 1994

Christopher D. Leville, B.A. 1995

Cassie Carlone Jambor, B.S. 1996

Vadim Pisarenko, B.S. 2000

<i>Martin D. Zielinski, B.S.</i>	2002
<i>Hoai D. Pham, B.S.</i>	2002
<i>David R. Eng, B.A.</i>	2004

Medical Fellows (Surgical Infectious Diseases)

<i>Ginny L. Bumgardner, M.D.</i>	1987-1988
<i>Carlos G. Fasola, M.D.</i>	1988-1989
<i>Richard J. Fischel, M.D.</i>	1988-1989
<i>Russell A. Shatford, M.D.</i>	1988-1989
<i>Jaime L. Mayoral, M.D.</i>	1988-1990
<i>Cynthia M. Loeffler, M.D.</i>	1989-1990
<i>Alan C. Farney, M.D.</i>	1990-1991
<i>Edic Stephanian, M.D.</i>	1990-1991
<i>Carolyn S. Cody, M.D.</i>	1990-1992
<i>Mark D. Sawyer, M.D.</i>	1990-1992
<i>Randall S. Burd, M.D.</i>	1990-1993
<i>Darla K. Granger, M.D.</i>	1991-1993
<i>Mitchell S. Farber, M.D.</i>	1991-1994
<i>Sung K. Kim, M.D.</i>	1991-1994
<i>Richard J. Battafarano, M.D.</i>	1991-1995
<i>David C. Wahoff, M.D.</i>	1992-1994
<i>Jeffrey E. Everett, M.D.</i>	1992-1995
<i>Timothy D. Sielaff, M.D.</i>	1992-1995
<i>Peter S. Dahlberg, M.D.</i>	1993-1996
<i>Daniel A. Saltzman, M.D.</i>	1993-1996
<i>Karen J. Brasel, M.D.</i>	1994-1996
<i>Paul H. Bloch, M.D.</i>	1994-1996
<i>Robert D. Acton, M.D.</i>	1994-1997
<i>Marc E. Uknis, M.D.</i>	1994-1997
<i>Karol A. Gutowski, M.D.</i>	1995-1997
<i>Eric M. Johnson, M.D.</i>	1995-1997
<i>Stephen R. Kerr, M.D.</i>	1995-1997
<i>Christopher T. Salerno, M.D.</i>	1995-1998
<i>Jeffrey W. Kronson, M.D.</i>	1996-1997
<i>Stanley V. DeTurris, M.D.</i>	1996-1998
<i>Renae E. Stafford, M.D.</i>	1996-1998
<i>Charles A. Svendsen, M.D.</i>	1996-1998
<i>Todd A. Kellogg, M.D.</i>	1996-1999
<i>Carl A. Weiss, III, M.D.</i>	1996-1999
<i>James V. Harmon, M.D.</i>	1997-1998
<i>John W. Cromwell, M.D.</i>	1997-1999
<i>Sharon L. Dykes, M.D.</i>	1997-1998
<i>Benjamin D. Suhr, M.D.</i>	1997-1999
<i>Christine C. Toevs, M.D.</i>	1997-1999
<i>Brad A. Feltis, M.D.</i>	1998-2001
<i>John F. Grehan, M.D.</i>	1998-2002
<i>Victor Lazaron, M.D., Ph.D.</i>	1998-2002
<i>Brian C. Grubbs, M.D.</i>	1998-2001
<i>Bradley C. Linden, M.D.</i>	1999-2003
<i>Donovan J. Hess, M.D.</i>	1999-2003
<i>Peter V. Chung, M.D.</i>	2000-2003
<i>Jonathan D ' Cunha, M.D.</i>	2000-2003
<i>Kambi Kosari, M.D.</i>	2000-2003
<i>Daniel B. Leslie, M.D.</i>	2000-2003
<i>Karen E. Hodgson, M.D.</i>	2001-2002
<i>Robert P. Gallegos, M.D.</i>	2001-2004
<i>Chuong D. Hoang, M.D.</i>	2001-2004
<i>Kaysie L. Banton, M.D.</i>	2003-2005

Medical Fellows (Basic Research)

<i>Brian P. Priest, M.D.</i>	1986-1988
<i>Jaime L. Mayoral, M.D.</i>	1988-1991

<i>W. Graham Williams, B.Sc., M.Ch.</i>	1989-1990
<i>Carlos G. Fasola, M.D.</i>	1989-1990
<i>Jacques Pirenne, M.D.</i>	1989-1990
<i>Carolyn S. Cody, M.D.</i>	1990-1992
<i>Mark D. Sawyer, M.D.</i>	1990-1992
<i>Randall S. Burd, M.D.</i>	1990-1993
<i>Sung K. Kim, M.D.</i>	1991-1994
<i>Richard J. Battafarano, M.D.</i>	1991-1995
<i>Mitchell S. Farber, M.D.</i>	1992-1994
<i>Peter S. Dahlberg, M.D.</i>	1993-1996
<i>Robert D. Acton, M.D.</i>	1994-1997
<i>Hans G. Klaerner, M.D.</i>	1994-1997
<i>Marc E. Uknis, M.D.</i>	1994-1997
<i>Todd A. Kellogg, M.D.</i>	1996-1999
<i>Carl A. Weiss, III, M.D.</i>	1996-1999
<i>Christine C. Toevs, M.D.</i>	1997-1999
<i>Victor Lazaron, M.D., Ph.D.</i>	1998-2001
<i>Daniel B. Leslie, M.D.</i>	2000-2004
<i>Paul S. Vietzen, M.D.</i>	2001-2004
<i>Kaysie L. Banton, M.D.</i>	2004-2005

M.S. Candidates

<i>Jacques Pirenne, M.D. (M.S. Experiential Surgery)</i>	1990
<i>Thesis Research Advisor and Committee Chair</i>	
<i>Rebecca Ann Redepenning Diekmann (M.S. Nursing)</i>	1994
<i>Thesis Reviewer and Committee Member</i>	

Ph.D. Candidates

<i>Michael A. West, M.D. (Ph.D. Surgery)</i>	1988
<i>Thesis Reviewer and Committee Member</i>	
<i>Randall S. Burd, M.D. (Ph.D. Surgery)</i>	1994
<i>Thesis Research Advisor</i>	
<i>Dixon Kaufman, M.D. (Ph.D. Surgery)</i>	1995
<i>Thesis Committee Chair</i>	
<i>Richard J. Battafarano, M.D. (Ph.D. Biomedical Sciences)</i>	1997
<i>Thesis Research Advisor</i>	
<i>Jeffrey E. Everett, M.D. (Ph.D. Surgery)</i>	1997
<i>Thesis Research Advisor</i>	
<i>David C. Wahoff, M.D. (Ph.D. Surgery)</i>	1997
<i>Thesis Research Advisor</i>	
<i>Peter S. Dahlberg, M.D. (Ph.D. Surgery)</i>	1997
<i>Thesis Research Advisor</i>	
<i>Carl A. Weiss, III, M.D. (Ph.D. Surgery)</i>	2000
<i>Thesis Research Advisor</i>	

Fellow Awards

<i>Jaime L. Mayoral, M.D.</i>	
<i>10th Annual Meeting of the Surgical Infection Society, Best Poster</i>	1990
<i>Carolyn S. Cody, M.D.</i>	
<i>Surgical Infection Society, Stuart Pharmaceuticals Fellow</i>	1990-1992
<i>Randall S. Burd, M.D.</i>	
<i>11th Annual Meeting of the Surgical Infection Society, Resident Award</i>	1991
<i>Randall S. Burd, M.D.</i>	
<i>25th Annual Meeting of the Association for Academic Surgery,</i>	
<i>Resident Research Award</i>	1991
<i>Randall S. Burd, M.D.</i>	
<i>NIH/PHS National Research Service Award Immunotherapy of Neonatal</i>	
<i>Gram-Negative Bacterial Peritonitis, GM14344</i>	1991-1994
<i>Richard J. Battafarano, M.D.</i>	
<i>Association for Academic Surgery Davis & Geck Surgical Research Award</i>	1992-1994
<i>Randall S. Burd, M.D.</i>	
<i>David Gavisier Surgical Research Award, Department of Surgery,</i>	
<i>University of Minnesota</i>	1994

Peter S. Dahlberg, M.D.
American College of Surgeons Merck Scholarship for the Study of Surgical Infection 1994-1996

Richard J. Battafarano, M.D.
David Gaviser Surgical Research Award, Department of Surgery, University of Minnesota 1995

Peter S. Dahlberg, M.D.
16th Annual Meeting of the Surgical Infection Society, Resident Award 1996

Carl A. Weiss, III, M.D.
Surgical Infection Society, Marion Merrell Dow Fellow 1996-1997

Carl A. Weiss, III, M.D.
NIH/PHS National Research Service Award Characterization of BPI-derived Endotoxin Antagonists, GM18835 1997-1999

Todd A. Kellogg, M.D.
NIH/PHS National Research Service Award Anti-idiotypic Antibodies as Endotoxin Antagonists, GM19030 1997-1999

Victor Lazaron, M.D., Ph.D.
NIH/PHS National Research Service Award LBP-BPI-Based Endotoxin Antagonists 1999-2001

Daniel B. Leslie, M.D.
Society of University Surgeons-Ethicon Fellowship Award Native Limulus Anti-lipopolysaccharide Factor (LALF)-based Endotoxin Antagonist 2001-2003

Paul S. Vietzen, M.D.
Surgical Infection Society Fellowship Award Biological Basis of Endotoxin Antagonism by LALF 2003-2004

BIBLIOGRAPHY

Published Manuscripts

- *1. **Dunn DL**, Simmons RL. The mechanism of bacterial trapping by polymerizing fibrin. Surg Forum 32:42-4, 1981.
- *2. **Dunn DL**, Ferguson R. Immunotherapy of gram-negative bacterial sepsis: enhanced survival in a guinea pig model by use of rabbit antiserum to Escherichia coli J-5. Surgery 92:212-9, 1982.
- *3. **Dunn DL**, Simmons RL. Fibrin in peritonitis. III. The mechanism of bacterial trapping by polymerizing fibrin. Surgery 92:513-9, 1982.
- *4. **Dunn DL**, Barke RA, Condie RM, Humphrey EW, Simmons RL. The effect of stroma-free hemoglobin on clearance of bacteria from the peritoneal cavity. Surg Forum 33:28-30, 1982.
5. **Dunn DL**, Simmons RL. Enlarged lymph glands and fear of Hodgkin's disease. Collected letters in Surgery. The Correspondence Society of Surgeons 5:2-3, 1982.
- *6. **Dunn DL**, Nelson RD, Condie RM, Simmons RL. Mechanisms of the adjuvant effect of hemoglobin in experimental peritonitis. VI. Effects of stroma-free hemoglobin and red blood cell stroma on mortality and neutrophil function. Surgery 93:653-9, 1983.
- *7. **Dunn DL**, Simmons RL. The meaning of research in experimental peritonitis. Surgery 93:471-4, 1983.
- *8. **Dunn DL**, Barke RA, Lee JT Jr, Condie RM, Humphrey EW, Simmons RL. Mechanisms of the adjuvant effect of hemoglobin in experimental peritonitis. VII. Hemoglobin does not inhibit clearance of Escherichia coli from the peritoneal cavity. Surgery 94:487-93, 1983.
- *9. **Dunn DL**, Simmons RL. Rational empiric antibiotic therapy of peritonitis and intraabdominal infection. Infect Surg 2:466-83, 1983.
- *10. **Dunn DL**, Mach PA, Cerra FB, Ferguson RM. The role of heparin in guinea pig gram-negative bacterial sepsis. J Surg Res 34:479-85, 1983.
- *11. **Dunn DL**, Mach PA, Cerra FB. Monoclonal antibodies protect against lethal effects of gram-negative bacterial sepsis. Surg Forum 34:142-4, 1983.
- *12. Barke RA, **Dunn DL**, Dalmasso AP, Orser M, Simmons RL, Humphrey EW. The effect of Ibuprofen treatment versus Ibuprofen pretreatment on pulmonary microvascular permeability and pulmonary function following E. coli peritoneal contamination. Surg Forum 34:144-6, 1983.
- *13. **Dunn DL**, Simmons RL. The role of anaerobic bacteria in intraabdominal infections. Rev Infect Dis 6:S139-46, 1984.
- *14. Barke RA, **Dunn DL**, Johnson J, Dalmasso A, Orser M, Simmons RL, Humphrey EW. The pulmonary effects of live vs. dead E. coli peritonitis. Arch Surg 119:173-9, 1984.
- *15. **Dunn DL**, Rotstein OD, Simmons RL. Fibrin in peritonitis. IV. Synergistic intraperitoneal infection due to Escherichia coli and Bacteroides fragilis within fibrin clots. Arch Surg 119:134-44, 1984.
- *16. **Dunn DL**, Barke RA, Ahrenholz DA, Humphrey EW, Simmons RL. The adjuvant effect of peritoneal fluid in experimental peritonitis: mechanism and clinical implications. Ann Surg 199:37-43, 1984.
17. **Dunn DL**, Simmons RL. Peculiar behavior of an appendectomy wound. Collected letters in Surgery. The Correspondence Society of Surgeons 7:6-8, 1984.
- *18. **Dunn DL**, Mach PA, Condie RM, Cerra FB. Anti-core endotoxin F(ab')₂ equine immunoglobulin fragments protect against lethal effects of gram-negative bacterial sepsis. Surgery 96:440-6, 1984.
- *19. **Dunn DL**, Matas AJ, Fryd DS, Simmons RL, Najarian JS. Association of concurrent herpes simplex virus and cytomegalovirus with detrimental effects after renal transplantation. Arch Surg 119:812-7, 1984.
- *20. **Dunn DL**, Barke RA, Lee JT, Jr, Simmons RL. Use of a bacterial mutant to study the adjuvant effect of hemoglobin in experimental Escherichia coli peritonitis. Surg Forum 35:132-4, 1984.

- *21. **Dunn DL**, Bogard WC, Cerra FB. Enhanced survival during murine gram-negative bacterial sepsis by use of a murine monoclonal antibody. *Arch Surg* 120:50-3, 1985.
- *22. **Dunn DL**, Mach PA, Dalmaso AP, Ferguson RM, Cerra FB. Metabolic effects of pretreatment with Escherichia coli J5 antiserum on guinea pig gram-negative bacterial sepsis. *J Surg Res* 38:298-304, 1985.
- *23. **Dunn DL**, Barke RA, Ewald DC, Simmons RL. Effects of Escherichia coli and Bacteroides fragilis on peritoneal host defenses. *Infect Immun* 48:287-91, 1985.
- *24. **Dunn DL**, Bogard WC, Cerra FB. Efficacy of type specific and cross reactive murine monoclonal antibodies directed against endotoxin during experimental sepsis. *Surgery* 98:283-90, 1985.
- *25. **Dunn DL**, Barke RA, Knight NB, Humphrey EW, Simmons RL. Role of resident macrophages, peripheral neutrophils, and translymphatic absorption in bacterial clearance from the peritoneal cavity. *Infect Immun* 49:257-64, 1985.
- *26. **Dunn DL**, Ewald DP, Chandan N, Cerra FB. Immunotherapy of gram-negative bacterial sepsis: a single murine monoclonal antibody provides cross-genera protection. *Arch Surg* 121:58-62, 1986.
- *27. Bogard WC, **Dunn DL**, Abernethy K, Kilgarriff, C, Kung PC. Isolation and characterization of murine monoclonal antibodies specific for gram-negative bacterial lipopolysaccharide: association of cross-genus reactivity with lipid A specificity. *Infect Immun* 55:899-908, 1987.
- *28. **Dunn DL**, Barke RA, Ewald DC, Simmons RL. Macrophages and translymphatic absorption represent the first line of host defense of the peritoneal cavity. *Arch Surg* 122:105-10, 1987.
- *29. **Dunn DL**. Immunotherapeutic advances in the treatment of gram-negative bacterial sepsis. *World J Surg* 11:233-40, 1987.
- *30. **Dunn DL**. Vaccines and antibody immunotherapy in surgical patients. *Am J Surg* 153:409-16, 1987.
- *31. **Dunn DL**. Antibody immunotherapy of gram-negative bacterial sepsis. *Pharmacotherapy* 7:S3 1-5, 1987.
- *32. Stock PG, Snover D, Payne W, **Dunn DL**, Simmons RL, Najarian JS, Ascher NL. Biopsy guided immunosuppressive therapy in treatment of liver transplant rejection: an individualized approach. *Clin Transplantation* 1:179-86, 1987.
- 33. **Dunn DL**. Management of recurrent retroperitoneal liposarcoma. *Collected letters in Surgery. The Correspondence Society of Surgeons*, 10:2-4, 1987.
- 34. **Dunn DL**, Simmons RL. Management of unsuspected carcinoma of the appendix. *Collected letters in Surgery. The Correspondence Society of Surgeons*, 10:7-8, 1987.
- *35. **Dunn DL**. Antibody immunotherapy of gram-negative bacterial sepsis in an immunosuppressed animal model. *Transplantation* 45:424-9, 1988.
- *36. Billiar TR, Maddaus MA, West MA, **Dunn DL**, Simmons RL. The role of intestinal flora on the interactions between non-parenchymal cells and hepatocytes in coculture. *J Surg Res* 44:397-403, 1988.
- 37. Gruber SA, Simmons RL, Vercellotti G, Najarian JS, Ascher NL, **Dunn DL**, Payne WD, Sutherland DER, Fryd DS. Erythrocytosis and thromboembolic complications after renal transplantation: results from a randomized trial of cyclosporine versus azathioprine-antilymphocyte globulin. *Transplant Proc* 20(S3):948-50, 1988.
- *38. Chan GL, Canafax DM, Ascher NL, **Dunn DL**, Payne WD, Fryd DS, Noreen H, Sutherland DER, Simmons RL, Najarian JS. HLA-identical sibling renal transplants: no rejections with a cyclosporine-azathioprine-prednisone protocol. *Clin Transplantation* 2:9-14, 1988.
- *39. Gruber SA, Simmons RL, Najarian JS, Vercellotti G, Ascher NL, **Dunn DL**, Payne WD, Sutherland DER, Fryd DS. Posttransplant erythrocytosis and the risk of thromboembolic complications: correlation from a prospective randomized study of cyclosporine versus azathioprine-antilymphocyte globulin. *Clin Transplantation* 2:60-6, 1988.

40. Roberts JP, Fryd DS, Ascher NL, Migliori R, Payne WD, **Dunn DL**, Sutherland DER, Simmons RL, Najarian JS. Living related kidneys continue to provide superior results over cadaveric kidneys in the cyclosporine era. *Transplant Proc* 20, S 1:26-7, 1988.
41. Najarian JS, Migliori RJ, Simmons FL, Ascher NL, Payne WD, **Dunn DL**, Sutherland DER, Fryd DS. Effects of HLA matching in cadaver renal transplants. *Transplant Proc* 20, S3:249-56, 1988.
42. Ford HR, Fryd DS, Canafax DM, Ascher NL, **Dunn DL**, Sutherland DER, Najarian JS, Simmons RL. Adjunctive azathioprine and antilymphocyte serum immunosuppressive with cyclosporine. *Transplant Proc* 20, S3:8-12, 1988.
- *43. Sutherland DER, Kendall DM, Moudry KC, Navarro X, Kennedy WR, Ramsay RC, Steffes MW, Mauer SM, Goetz FC, **Dunn DL**, Najarian JS. Pancreas transplantation in nonuremic, type I diabetic recipients. *Surgery* 104:453-64, 1988.
- *44. Priest BP, Bankey PE, Cerra FB, **Dunn DL**. An immunoprotective antibody directed against lipopolysaccharide inhibits tumor necrosis factor production *in vitro*. *Surg Forum* 39:29-30, 1988.
- *45. **Dunn DL**, Priest BP, Condie RM. Protective capacity of polyclonal and monoclonal antibodies directed against endotoxin during experimental sepsis. *Arch Surg* 123:1389-93, 1988.
46. **Dunn DL**. Use of antibiotics in the treatment of minor wounds. *Collected letters in Surgery. The Correspondence Society of Surgeons* 11:4-5, 1988.
- *47. Billiar TR, West MA, Hyland BJ, Cerra FB, Simmons RL, **Dunn DL**. Murine monoclonal antibody directed against lipopolysaccharide (LPS) inhibits Kupffer cell activation by endotoxin *in vitro*. *Prog Clin Biol Res* 264:367-72, 1988.
- *48. Fischel RJ, Freise CE, Bonser RS, Hertz MI, Jamieson SW, **Dunn DL**. Successful management of fulminant cytomegalovirus induced acute lung injury following double lung transplantation. *Clin Transplantation* 2:33 1-5, 1988.
- *49. Bumgardner GL, Payne WD, **Dunn DL**, Sutherland DER, Fryd DS, Mauer MS, Ascher NL, Simmons RL, Najarian JS. Single center 1-15 year results of renal transplantation in patients with systemic lupus erythematosus. *Transplantation* 46:703-9, 1988.
- *50. Sutherland DER, Moudry MC, **Dunn DL**, Goetz FC, Najarian JS. Pancreas transplant outcome in relation to presence or absence of end-stage renal disease, timing of transplant, surgical technique, and donor source. *Diabetes* 38(S1): 10-2, 1989.
- *51. Barke RA, **Dunn DL**, Dalmaso AP, O'Connor-Allen M, Simmons RL, Humphrey EW. The association of E.coli virulence and pulmonary microvascular damage. *Arch Surg* 124:449-52, 1989.
52. Bumgardner GL, Mauer SM, Ascher NL, Payne W, **Dunn DL**, Fryd DS, Sutherland DER, Simmons RL, Najarian JS. Long-term outcome of renal transplantation in patients with systemic lupus erythematosus. *Transplant Proc* 21:2031-2, 1989.
- *53. **Dunn DL**, Simmons RL. Opportunistic infections after renal transplant. I. Viral and bacterial infections. *Infect Surg* 8:164-75, 1989.
- *54. Priest BP, Schlievert PM, **Dunn DL**. Treatment of toxic shock syndrome with endotoxin-neutralizing antibody. *J Surg Res* 46:527-31, 1989.
- *55. Canafax DM, Min DI, Gruber SA, Fryd DS, Matas AJ, Payne WD, **Dunn DL**, Sutherland DER, Simmons RL, Najarian JS. Immunosuppression of cadaveric renal allograft recipients: a risk-factor matched comparison of the Minnesota randomized trial with an antilymphoblast globulin, azathioprine, cyclosporine, and prednisone protocol. *Clin Transplantation* 3:110-9, 1989.
- *56. Pescovitz MD, **Dunn DL**, Sutherland DER. Use of the circular stapler in construction of the duodenoneocystostomy for drainage into the bladder in transplants involving the whole pancreas. *Surgery, Gynecol Obstet* 169:169-71, 1989.
- *57. **Dunn DL**, Simmons RL. Opportunistic infections after renal transplant. II. Fungal and protozoan infections. *Infect Surg* 8:277-84, 1989.

- *58. Priest BP, Brinson DN, Schroeder DA, **Dunn DL**. Treatment of experimental gram-negative bacterial sepsis with murine monoclonal antibodies directed against lipopolysaccharide. *Surgery* 106:147-55, 1989.
- *59. Gruessner RWG, Matas AJ, Lloveras G, Fryd DS, **Dunn DL**, Payne WD, Sutherland DER, Najarian JS. A comparison of single and double pediatric cadaver donor kidneys for transplantation. *Clin Transplantation* 3:209-14, 1989.
60. Sawyer MD, **Dunn DL**. Minimal medullary carcinoma of the breast-how much treatment is enough? *Collected letters in Surgery. The Correspondence Society of Surgeons* 12:3-4, 1989.
61. Matas AJ, Sutherland DER, Payne WD, **Dunn DL**, Perry E, Najarian JS. New approaches to living donor renal transplantation. *Minnesota Med* 72:589-92, 1989.
- *62. Sutherland DER, **Dunn DL**, Goetz FC, Kennedy W, Ramsay RC, Steffes MW, Mauer SM, Gruessner R, Moudry-Munns KC, Morel P, Viste A, Robertson RP, Najarian JS. A ten year experience with 290 pancreas transplants at a single institution. *Ann Surg* 2 10:274-88, 1989.
- *63. Roberts JP, Ascher NL, Fryd DS, Hunter DW, **Dunn DL**, Payne WD, Sutherland DER, Castaneda-Zuniga W, Najarian JS. Transplant renal artery stenosis. *Transplantation* 48:580-3, 1989.
- *64. Tzardis PJ, Gruessner RWG, Matas AJ, Payne WD, **Dunn DL**, Sutherland DER, Najarian JS. Renal transplantation in patients with polycystic kidney disease: a single center experience. *Clin Transplantation* 3:325-30, 1989.
- *65. Mayoral JM, Schweich CJ Jr, **Dunn DL**. Decreased tumor necrosis factor production during the initial stages of infection correlates with survival during murine gram-negative sepsis. *Arch Surg* 125:24-8, 1990.
- *66. **Dunn DL**. Autochthonous microflora of the gastrointestinal tract. *Perspect Colon Rectal Surg* 2:105-19, 1990.
- *67. Morel P, Moudry-Munns KC, Najarian JS, Gruessner RWG, **Dunn DL**, Sutherland DER. Influence of preservation time on outcome and metabolic function of bladder-drained pancreatic transplants. *Transplantation* 49:294-303, 1990.
68. Gruessner RWG, Matas AJ, **Dunn DL**, Lloveras G, Payne WD, Sutherland DER, Najarian JS. A comparison of pediatric versus adult cadaver donor kidneys for transplantation. *Transplant Proc* 22:361-2, 1990.
69. **Dunn DL**, Schlumpf RB, Gruessner RWG, Morel P, Mayoral JL, Payne WD, Matas AJ, Sutherland DER, Moudry-Munns KC, Najarian JS. Maximal use of liver and pancreas from cadaveric organ donors. *Transplant Proc* 22:423-4, 1990.
70. Gores PF, Viste A, Hesse U, Moudry-Munns KC, **Dunn DL**, Sutherland DER. The influence of donor hyperglycemia and other factors on long-term pancreatic allograft function. *Transplant Proc* 22:437-8, 1990.
71. Morel P, Moudry-Munns KC, Balakumar M, Najarian JS, **Dunn DL**, Sutherland DER. Influence of preservation time on the early function of pancreas transplants. *Transplant Proc* 22:527-8, 1990.
72. Gruessner RWG, **Dunn DL**, Tzardis PJ, Nakhleh RE, Najarian JS, Sutherland DER. Complications occurring after whole organ duodenopancreatic transplantation: relation to the allograft duodenal segment. *Transplant Proc* 22:578-9, 1990.
73. Morel P, Schlumpf RB, Moudry-Munns KC, **Dunn DL**, Sutherland DER. Pancreatic retransplants: an analysis of the outcome. *Transplant Proc* 22:620-1, 1990.
74. Gruessner RWG, **Dunn DL**, Tzardis PJ, Tomadze G, Moudry-Munns KC, Matas AJ, Najarian JS, Sutherland DER. Simultaneous pancreas and kidney transplants versus single kidney transplants and previous kidney transplants in uremic patients and single pancreas transplants in nonuremic diabetic patients: comparison of rejection, morbidity, and long-term outcome. *Transplant Proc* 22:622-3, 1990.

75. Burke GW III, Gruessner RWG, **Dunn DL**, Sutherland DER. Conversion of whole pancreaticoduodenal transplants from bladder to enteric drainage for metabolic acidosis or dysuria. *Transplant Proc* 22:651-2, 1990.
76. **Dunn DL**, Gruessner RWG, Tzardis PJ, Nakhleh RE, Sutherland DER, Najarian JS. Pancreatic allograft loss secondary to periallograft gastrointestinal cytomegalovirus ulceration. *Transplant Proc* 22:678-9, 1990.
77. Kaufman DB, Platt JL, Rabe F, **Dunn DL**, Sutherland DER. Effect of host immunomodulation on the prevention of islet allograft primary nonfunction in a murine model. *Transplant Proc* 22:857-8, 1990.
78. Schlumpf R, Morel P, Sutherland D, Moudry-Munns K, Gruessner R, Payne W, **Dunn D**. Combined procurement of pancreas and liver grafts does not affect transplant outcome. *Transplant Proc* 22:2074-5, 1990.
- *79. Tzardis PJ, Gruessner RWG, Matas AJ, Payne WD, **Dunn DL**, Sutherland DER, Najarian JS. Long-term follow-up of renal transplantation for Wegener's disease. *Clin Transplantation* 4:108-11, 1990.
- *80. Gruessner RWG, Tzardis PJ, Matas AJ, **Dunn DL**, Payne WD, Sutherland DER, Najarian JS. Ileal and colon conduits in renal transplantation. *Clin Transplantation* 4:125-8, 1990.
- *81. Fabrega AJ, Matas AJ, Payne WD, Fryd DS, **Dunn DL**, Sutherland DER, Najarian JS. Ten to twenty year followup of 123 consecutive HLA-identical living related transplants. *Clin Transplantation* 4:145-52, 1990.
- *82. Kaufman DB, Platt JL, Rabe FL, **Dunn DL**, Bach FH, Sutherland DER. Differential roles of Mac-1+ cells, and CD4+ and CD8+ T lymphocytes in primary nonfunction and classic rejection of islet allografts. *J Exp Med* 172:291-302, 1990.
- *83. Wrenshall LE, Matas AJ, Canafax DM, Min DI, Sibley RJ, **Dunn DL**, Payne WD, Sutherland DER, Najarian JS. An increased incidence of late acute rejection episodes in recipients of cadaver renal allografts given azathioprine, cyclosporine and prednisone. *Transplantation* 50:233-7, 1990.
- *84. Mayoral JL, Ortiz M, Singh H, **Dunn DL**. The protective capacity of anti-E.coli J5 murine monoclonal antibodies is dependent on binding to specific epitopes within the lipopolysaccharide molecule. *Surg Forum* 41:83-5, 1990.
- *85. Pirenne JM, Degiovanni G, Franchimont N, Scheppens G, Meagher T, **Dunn DL**. Graft versus host disease after small bowel transplantation is associated with the appearance of tumor necrosis factor alpha in the serum. *Surg Forum* 41:389-91, 1990.
- *86. **Dunn DL**, Najarian JS. Solid organ transplantation: where has it been, where is it going? *Crit Care Clinics* 6:813-9, 1990.
- *87. **Dunn DL**. Problems related to immunosuppression: infection and malignancy occurring after solid organ transplantation. *Crit Care Clinics* 6:955-77, 1990.
- *88. Alexander JW, Boyce S, Babcock GF, Gianotti L, Peck MD, **Dunn DL**, Pyles T, Childress CP, Ash SK. The process of microbial translocation. *Ann Surg* 212:496-512, 1990.
- *89. Mayoral JL, **Dunn DL**. Cross-reactive murine monoclonal antibodies directed against the core/lipid A region of endotoxin inhibit production of tumor necrosis factor. *J Surg Res* 49:287-92, 1990.
- *90. **Dunn DL**, Sawyer MD. Deep soft tissue infections. *Curr Opinion Infect Dis* 3:691-96, 1990.
- *91. Tzardis PJ, Gruessner RWG, Matas AJ, Payne WD, **Dunn DL**, Sutherland DER, Najarian JS. Fate of native polycystic kidneys left in situ after renal transplantation. *Clin Transplantation* 4:309-10, 1990.
- *92. Bumgardner GL, Matas AJ, Payne WD, **Dunn DL**, Sutherland DER, Najarian JS. Renal transplantation in patients with paraproteinemias. *Clin Transplantation* 4:399-405, 1990.
- *93. Matas AJ, Frey DJ, Gillingham KJ, Noreen HJ, Reinsmoen NL, Payne WD, **Dunn DL**, Sutherland DER, Najarian JS. The impact of HLA matching on graft survival and on sensitization after a failed transplant evidence that failure of poorly matched renal transplants does not result in increased sensitization. *Transplantation* 50:599-607, 1990.

94. Gruessner RWG, **Dunn DL**, Tzardis PJ, Tomadze G, Adamec M, Moudry-Munns KC, Sutherland DER. An immunological comparison of pancreas transplants alone in nonuremic patients versus simultaneous pancreas/kidney transplants in uremic diabetic patients. *Transplant Proc* 22:1581, 1990.
- *95. Barke RA, **Dunn DL**, Dalmaso AP, O'Connor-Allen M, Humphrey EW. Enterococcal sepsis and lung microvascular injury in sheep. *Arch Surg* 125:437-40, 1990.
- *96. **Dunn DL**. Development and potential use of antibody directed against lipopolysaccharide for the treatment of gram-negative sepsis. *J Trauma* 30:S100-6, 1990.
- *97. Longley DG, **Dunn DL**, Gruessner R, Halvorsen RA Jr, Sutherland DER, Letourneau JG. Detection of pancreatic fluid and urine leakage after pancreatic transplantation: value of CT and cystography. *Am J Roentgenol* 155:997-1000, 1990.
98. Schlumpf RB, Morel P, Moudry-Munns KC, **Dunn DL**, Sutherland DER. An analysis of pancreatic retransplants with bladder drainage. *Transplant Proc* 22:1602, 1990.
- *99. Pirenne JM, Williams JG, Mayoral JL, Nakhleh RE, **Dunn DL**. Resistance to graft-versus-host disease following small bowel transplantation. *Transplantation* 51:51-7, 1991.
- *100. **Dunn DL**, Mayoral JL, Gillingham KJ, Loeffler CM, Brayman KL, Kramer MA, Erice A, Balfour HH, Fletcher CV, Bolman III RM, Matas AJ, Payne WD, Sutherland DER, Najarian JS. Treatment of invasive cytomegalovirus disease in solid organ transplant patients with ganciclovir. *Transplantation* 51:98-106, 1991.
- *101. Fischel RJ, Payne WD, Gillingham KJ, **Dunn DL**, Sutherland DER, Matas AJ, Najarian JS. Long-term outlook for renal transplant recipients with one-year function: "Doctor, what are my chances?" *Transplantation* 51:118-22, 1991.
- *102. **Dunn DL**, Morel P, Schlumpf R, Mayoral JL, Gillingham KJ, Moudry-Munns KC, Krom RAF, Gruessner RWG, Payne WD, Sutherland DER, Najarian JS. Evidence that combined procurement of pancreas and liver grafts does not affect transplant outcome. *Transplantation* 51:150-7, 1991.
- *103. **Dunn DL**, Najarian JS. New approaches to the diagnosis, prevention, and treatment of cytomegalovirus infection after transplantation. *Am J Surg* 161:250-5, 1991.
104. Aeder MI, Fasola CG, Dunning M, Payne WD, **Dunn DL**, Najarian JS, Sutherland DER. Successful canine small intestinal allotransplantation: ex vivo irradiation and cyclosporine pretreatment. *Transplant Proc* 23:685-7, 1991.
105. Frey DJ, Matas AJ, Gillingham KJ, Canafax D, Payne WD, **Dunn DL**, Sutherland DER, Najarian JS. MALG vs OKT3 following renal transplantation: a randomized prospective trial. *Transplant Proc* 23:1048-9, 1991.
106. Gruber SA, Skjei KL, Sothorn RB, Robison L, Tzardix P, Moss A, Gillingham K, Canafax DM, Matas AJ, **Dunn DL**. Cancer development in renal allograft recipients with conventional and cyclosporine immunosuppression. *Transplant Proc* 23:1104-5, 1991.
107. Fasola CG, Kim YS, Morel P, **Dunn DL**, Sutherland DER, Payne WD, Matas AJ, Najarian JS. Kidney retransplantation: patients with a failed second kidney transplant should be considered for a third transplant. *Transplant Proc* 23:1336, 1991.
108. Fischel RJ, Matas AJ, Payne WD, Gillingham KJ, **Dunn DL**, Sutherland DER, Najarian JS. Long-term outcome in 1-year graft survivors: comparison of diabetic and nondiabetic populations. *Transplant Proc* 23:1337, 1991.
109. Troppmann C, Almond PS, Escobar FS, Morel P, Papalois AE, **Dunn DL**, Payne WD, Sutherland DER, Matas AJ, Najarian JS. Donor age and cause of death affect cadaver renal allograft outcome. *Transplant Proc* 23:1365-6, 1991.
110. Gruber SA, Chavers B, Skjei KL, Sothorn RB, Robison L, Tzardis P, Moss A, Gillingham K, Canafax DM, Najarian JS, Matas AJ, **Dunn DL**. De novo cancer after pediatric kidney transplantation. *Transplant Proc* 23:1373-4, 1991.

111. Almond PS, Morel P, Matas AJ, Gillingham KJ, Chau KS, Brown A, Kashtan CE, Mauer SM, Chavers B, Nevins TE, **Dunn DL**, Sutherland DER, Payne WD, Najarian JS. Transplanted children with long-term graft functions have an excellent quality of life. *Transplant Proc* 23:1380-1, 1991.
112. Nakhleh RE, Gruessner RWG, Tzardis PJ, Brayman K, **Dunn DL**, Sutherland DER. Pancreas transplant pathology: an immunohistochemical comparison of allografts with rejection, syngeneic grafts, and chronic pancreatitis. *Transplant Proc* 23:1598-9, 1991.
113. Morel P, Gillingham KJ, Moudry-Munns KC, **Dunn DL**, Najarian JS, Sutherland DER. Factors influencing pancreas transplant outcome: Cox proportional hazard regression analysis of a single institution's experience with 357 cases. *Transplant Proc* 23:1630-3, 1991.
114. Sutherland DER, Moudry-Munns KC, Gillingham KJ, Najarian JS, **Dunn DL**. Solitary pancreas transplantation: alone in nonuremic and after a kidney in uremic diabetic patients. *Transplant Proc* 23:1637-9, 1991.
115. Morel P, Gillingham KJ, Schlumpf R, Chau C, Moudry-Munns KC, Payne WD, Najarian JS, Sutherland DER, **Dunn DL**. Effect of simultaneous liver retrieval team, retrieval team, and preservation time on cadaver whole-organ bladder-drained pancreatic allograft survival rates. *Transplant Proc* 23:1640-3, 1991.
- *116. Mayoral JL, Loeffler CM, Fasola CG, Kramer MA, Orrom WJ, Matas AJ, Najarian JS, **Dunn DL**. Diagnosis and treatment of cytomegalovirus disease in transplant patients based upon gastrointestinal tract manifestations. *Arch Surg* 126:202-6, 1991.
- *117. Nakhleh RE, Gruessner RWG, Swanson PE, Tzardis PJ, Brayman KL, **Dunn DL**, Sutherland DER. Pancreas transplant pathology: a morphologic, immunohistochemical, and electron microscopic comparison of allogeneic grafts with rejection, syngeneic grafts, and chronic pancreatitis. *Am J Surg Path* 15:246-56, 1991.
118. Balfour HH Jr, Fletcher CV, **Dunn DL**. Prevention of cytomegalovirus disease with oral acyclovir. *Transplant Proc* 23:17-9, 1991.
- *119. Gruessner RWG, Manivel C, **Dunn DL**, Sutherland DER. Pancreaticoduodenal transplantation with enteric drainage following native total pancreatectomy for chronic pancreatitis: a case report. *Pancreas* 6:479-88, 1991.
- *120. Nakhleh RE, Gruessner RWG, Tzardis PJ, **Dunn DL**, Sutherland DER. Pathology of transplanted human duodenal tissue: a histologic study, with comparison to pancreatic pathology in resected pancreaticoduodenal transplants. *Clin Transplantation* 5:241-7, 1991.
- *121. Pirenne J, Nakhleh RE, **Dunn DL**. Graft-versus-host disease after multiorgan transplantation. *J Surg Res* 50:622-8, 1991.
- *122. Fletcher CV, Englund JA, Edelman CK, Gross CR, **Dunn DL**, Balfour HH. Pharmacologic basis for high-dose oral acyclovir prophylaxis of cytomegalovirus disease in renal allograft recipients. *Antimicrob Agents Chemother* 35:938-43, 1991.
123. **Dunn DL**. Applications of immunology in clinical surgery: Infection. Proceedings from the 1990 Surgical Research and Education Symposium of the American College of Surgeons 2:7-12, 1991.
- *124. Erice A, Rhame FS, Heussner R, **Dunn DL**, Balfour HH. Human immunodeficiency virus infection in solid organ transplantation: report of 5 cases and review of the literature. *Rev Infect Dis* 13:537-47, 1991.
- *125. Pirenne J, Degiovanni G, **Dunn DL**. Mechanisms of graft-versus-host disease produced by small bowel transplantation. *Acta Chirurgica Austriaca* 1:11-16, 1991.
- *126. Mayoral JL, Cody CS, Burd RS, Sawyer MD, Raymond CS, **Dunn DL**. Lipopolysaccharide uptake by macrophages is enhanced by anti-lipopolysaccharide monoclonal antibodies. *Surg Forum* 42:110-2, 1991.

- *127. **Dunn DL**. Role of endotoxin and host cytokines in septic shock. *Chest* 100:164S-8S, 1991.
- *128. Morel P, Sutherland DER, Almond PS, Stoblen F, Matas AJ, Najarian JS, **Dunn DL**. Assessment of renal function in Type I diabetic patients after kidney, pancreas or combined kidney-pancreas transplantation. *Transplantation* 51:1184-9, 1991.
- *129. Sawyer MD, **Dunn DL**. Deep soft tissue infections. *Curr Opin Infect Dis* 4:649-54, 1991.
- *130. Morel P, Schlumpf R, **Dunn DL**, Moudry-Munns KC, Najarian JS, Sutherland DER. Pancreas retransplants compared with primary transplants. *Transplantation* 51:825-33, 1991.
- *131. Morel P, Brayman KL, Goetz FC, Kendall DM, Moudry KC, Chau C, Balakumar M, Stevens B, **Dunn DL**, Sutherland DER. Long-term metabolic function of pancreas transplants and influence of rejection episodes. *Transplantation* 51:990-1000, 1991.
- *132. Sawyer MS, **Dunn DL**. Appropriate use of antimicrobial agents. Nine principles. *Postgrad Medicine* 90:115-22, 1991.
- 133. **Dunn DL**. Microbial translocation. *Surgical Residents' Newsletter* 2:2-6, 1991.
- *134. Gudnason T, **Dunn DL**, Brown NA, Balfour HH Jr. Human herpes virus 6 infections in hospitalized renal transplant recipients. *Clin Transplantation* 5:359-64, 1991.
- *135. Greenman RL, Schein RMH, Martin MA, Wenzel RP, MacIntyre NR, Emmanuel G, Chmel H, Kohler RB, McCarthy M, Plouffe J, Russell JA, and the XOMA Sepsis Study Group. A controlled clinical trial of E5 murine monoclonal IgM antibody to endotoxin in the treatment of gram-negative sepsis. *JAMA* 266:1097-1102, 1991.
- *136. Williams JG, Pirenne J, Mayoral JM, Orrom WJ, Nakhleh RE, Condie R, **Dunn DL**. Effect of donor pre-treatment with anti-lymphocyte globulin on small bowel transplantation in rats. *Br J Surgery* 78:1176-7, 1991.
- *137. Morel P, Troppmann C, Almond PS, Schlumpf R, Gillingham KJ, Sutherland DER, **Dunn DL**, Payne WD, Matas AJ, Najarian JS. Multiorgan procurement does not affect the immediate outcome of kidney transplants. *Clin Transplantation* 5:381-5, 1991.
- *138. Schweitzer EJ, Matas AJ, Gillingham KJ, Payne WD, Gores PF, **Dunn DL**, Sutherland DER, Najarian JS. Causes of renal allograft loss: progress in the 1980s, challenges for the 1990s. *Ann Surg* 214:679-88, 1991.
- *139. Pirenne J, D'Silva M, Nakhleh RE, Lee S, **Dunn DL**. Multiorgan transplantation in the rat: development of a new microsurgical model. *Microsurgery* 12:378-84, 1991.
- *140. Stephanian E, Gruber SA, **Dunn DL**, Matas AJ. Posttransplant lymphoproliferative disorders. *Transplantation Reviews* 5:120-9, 1991.
- *141. Fasola CG, Kim YS, Aeder MI, Dunning M, Mueller R, Nakhleh RE, Almond S, Payne WD, **Dunn DL**. Pretransplant immunotherapy can prolong function of small bowel allografts in dogs. *Curr Surgery* 48:469-73, 1991.
- *142. Almond PS, Matas AJ, Gillingham KJ, Troppmann C, Payne WD, **Dunn DL**, Sutherland DER, Najarian JS. Risk factors for second renal allografts immunosuppressed with cyclosporine. *Transplantation* 258:253-8, 1991.
- *143. Sutherland DE, Gruessner R, Gillingham K, Moudry-Munns K, **Dunn DL**, Brayman K, Morel P, Najarian JS. A single institution's experience with solitary pancreas transplantation: a multivariate analysis of factors leading to improved outcome. *Clin Transplant* 141-52, 1991.
- *144. Schlumpf R, Morel P, **Dunn DL**, Payne W, Sutherland D. Simultaneous removal of liver and pancreas does not have an effect on results of transplantation of these organs. *Helvet Chirug Acta* 57:859-63, 1991.
- 145. Nakhleh RE, Gruessner RW, Tzardis PJ, Brayman K, **Dunn DL**, Sutherland DE. Pancreas transplant pathology: an immunohistochemical comparison of allografts with rejection, syngeneic graft, and chronic pancreatitis. *Transplant Proc* 23:1589-9, 1991.

146. Moudry-Munns KC, Gillingham K, **Dunn DL**, Sutherland DE. Mortality risk for technically successful vs. technically failed bladder drained pancreas transplants and causes of death. *Transplant Proc* 24:863-5, 1992.
- *147. Brayman KL, Stephanian E, Matas AJ, Schmidt W, Payne WD, Sutherland DER, Gores PF, Najarian JS, **Dunn DL**. Analysis of infectious complications occurring after solid-organ transplantation. *Arch Surg* 127:38-48, 1992.
- *148. Almond PS, Matas AJ, Gillingham K, Moss A, Mauer M, Chavers B, Nevins T, Kashtan K, **Dunn DL**, Payne W, Sutherland D, Gores P, Najarian JS. Pediatric renal transplants--Results with sequential immunosuppression. *Transplantation* 53:46-51, 1992.
- *149. Almond PS, Gillingham KJ, Sibley R, Moss A, Melin M, Leventhal J, Manivel C, Kyriakides P, Payne WD, **Dunn DL**, Sutherland DER, Gores PF, Najarian JS, Matas AJ. Renal transplant function after ten years of cyclosporine. *Transplantation* 53:316-23, 1992.
- *150. Cerra FB, Maddaus MA, **Dunn DL**, Wells CL, Konstantinides NN, Lehmann SL, Mann HJ. Selective gut decontamination reduces nosocomial infections and length of stay but not mortality or organ failure in surgical intensive care unit patients. *Arch Surg* 127:163-9, 1992.
- *151. Matas AJ, Payne WD, Gillingham KJ, **Dunn DL**, Sutherland DER, Najarian JS. Optimizing the immediate posttransplant prednisone dose - a prospective randomized trial. *Clin Transplantation* 6:73-6, 1992.
- *152. Cody CS, Burd RS, Mayoral JL, **Dunn DL**. Protective anti-lipopolysaccharide monoclonal antibodies inhibit tumor necrosis factor production. *J Surg Res* 52:314-9, 1992.
- *153. Wells CL, Barton RG, Walvatne CS, **Dunn DL**, Cerra FB. Intestinal bacterial flora, intestinal pathology, and lipopolysaccharide-induced translocation of intestinal bacteria. *Circ Shock* 37:117-23, 1992.
- *154. Sutherland DER, **Dunn DL**, Moudry-Munns K, Gillingham K, Najarian JS. Pancreas transplants in nonuremic and posturemic diabetic patients. *Transplant Proc* 24:780-1, 1992.
155. Stephanian E, Gruessner RWG, Brayman KL, Gores P, **Dunn DL**, Sutherland DER. Converting exocrine drainage from bladder to bowel in recipients of whole pancreaticoduodenal transplants. *Transplant Proc* 24:808-10, 1992.
156. Morel P, Chau C, Brayman K, Moudry-Munns K, Gillingham K, Stevens B, **Dunn DL**, Goetz FC, Najarian JS, Sutherland DER. Quality of metabolic control at 2 to 12 years after a pancreas transplant. *Transplant Proc* 24:835-8, 1992.
157. Cheung AHS, Sutherland DER, **Dunn DL**, Moudry-Munns KC, McHugh LE, Gillingham KJ, Najarian JS, Matas AJ. Morbidity following simultaneous pancreas-kidney transplants vs kidney transplants alone in diabetic patients. *Transplant Proc* 24:866-8, 1992.
158. Brayman KL, Moss A, Morel P, Nakhleh R, **Dunn DL**, Sutherland DER. Exocrine dysfunction evaluation of bladder-drained pancreaticoduodenal transplants using a transcystoscopic biopsy technique. *Transplant Proc* 24:901-2, 1992.
159. Pirenne J, D'Silva M, Nakhleh RE, Lee S, Jaquet N, **Dunn DL**. Pancreas induces graft-vs-host disease when transplanted en bloc with liver and small bowel. *Transplant Proc* 24:915-7, 1992.
160. Mayoral JL, Brayman KL, Gillingham KJ, Sutherland DER, Najarian JS, **Dunn DL**. Influence of pretransplant cytomegalovirus serology and treatment of rejection upon disease after kidney and kidney plus pancreas transplantation. *Transplant Proc* 24:929-31, 1992.
- *161. Cheung AHS, Sutherland DER, Gillingham KJ, McHugh LE, Moudry-Munns KC, **Dunn DL**, Najarian JS, Matas AJ. Simultaneous pancreas-kidney transplant versus kidney transplant alone in diabetic patients. *Kidney International* 41:924-9, 1992.

- *162. Berg LC, Copenhaver CM, Morrison VA, Gruber SA, **Dunn DL**, Gajl-Peczalska K, Stickler JG. B-cell lymphoproliferative disorders in solid-organ transplant patients: detection of Epstein-Barr virus by in situ hybridization. *Hum Pathol* 23:159-63, 1992.
- *163. Burd RS, Raymond CS, **Dunn DL**. Endotoxin promotes synergistic lethality during concurrent Escherichia coli and Candida albicans infection. *J Surg Res* 52:537-42, 1992.
- *164. Frey DJ, Matas AJ, Gillingham KJ, Canafax D, Payne WD, **Dunn DL**, Sutherland DER, Najarian JS. Sequential therapy a prospective randomized trial of MALG versus OKT3 for prophylactic immunosuppression in cadaver renal allograft recipients. *Transplantation* 54:50-6, 1992.
- *165. Gores PF, Gillingham KJ, **Dunn DL**, Moudry-Munns KC, Najarian JS, Sutherland DER. Donor hyperglycemia as a minor risk factor and immunologic variables as major risk factors for pancreas allograft loss in a multivariate analysis of a single institution's experience. *Ann Surg* 215:217-30, 1992.
- 166. Sawyer MD, **Dunn DL**. Antimicrobial therapy of intra-abdominal sepsis. *Infect Dis Clin North Am* 6:545-70, 1992.
- 167. Farber MS, **Dunn DL**. Preventing CMV infection in cardiac transplant recipients. *J Crit Illness*, 7:1758- 61, 1992.
- *168. Camarata PJ, **Dunn DL**, Farney AC, Parker RG, Seljeskog EL. Continual intracavitary administration of amphotericin B used as an adjunct in the treatment of Apergillus brain abscess: case report and review of the literature. *Neurosurg* 3 1:575-9, 1992.
- *169. Erice A, Holm MA, Gill PC, Henry S, Dirksen CL, **Dunn DL**, Hillam RP, Balfour HH. Cytomegalovirus (CMV) antigenemia assay is more sensitive than shell vial cultures for rapid detection of CMV in polymorphonuclear blood leukocytes. *J Clin Microbiol* 30:2822-5, 1992.
- *170. Stephanian E, Brayman KL, Manivel JC, Sutherland DER, **Dunn DL**. Fulminant post-transplant lymphoproliferative disorder presenting as multisystem organ failure. *Clin Transplantation* 6:361-8, 1992.
- *171. **Dunn DL**, Mayoral JL, Gillingham KJ, Sawyer MD, Kramer MA, Statz CL, McHugh L, Matas AJ, Gores PF, Payne WD, Sutherland DER, Najarian JS. Simultaneous treatment of concurrent rejection and tissue invasive cytomegalovirus disease without detrimental effects upon patient or allograft survival. *Clin Transplantation* 6:413-20, 1992.
- *172. Nevins TE, **Dunn DL**. Use of ganciclovir for cytomegalovirus infection. *J Am Soc Nephrol* 2:S270-3, 1992.
- *173. Stephanian E, Gruessner RWG, Brayman KL, Gores P, **Dunn DL**, Najarian JS, Sutherland DER. Conversion of exocrine secretions from bladder to enteric drainage in recipients of whole pancreaticoduodenal transplants. *Ann Surg* 216:663-72, 1992.
- *174. Boivin G, Erice A, Crane DD, **Dunn DL**, Balfour HH. Acyclovir susceptibilities of herpes simplex virus strains isolated from solid organ transplant recipients after acyclovir or ganciclovir prophylaxis. *Antimicrob Agents Chemother* 37:357-9, 1993.
- *175. Burd RS, Cody CS, Raymond CS, **Dunn DL**. Anti-endotoxin monoclonal antibodies protect by enhancing bacterial and endotoxin clearance. *Arch Surg* 128:145-51, 1993.
- *176. Sawyer MD, Mayoral JL, Gillingham KJ, Kramer MA, **Dunn DL**. Treatment of recurrent cytomegalovirus disease in patients receiving solid organ transplants. *Arch Surg* 128:165-70, 1993.
- 177. Troppmann C, Almond PS, Payne WD, **Dunn DL**, Gores PF, Gruessner RW, Sutherland DE, Matas AJ, Najarian JS. Does acute tubular necrosis affect renal transplant outcome? The impact of rejection episodes. *Transplant Proc* 25:905, 1993.
- 178. Basadonna GP, Matas AJ, Gillingham KJ, Payne WD, **Dunn DL**, Sutherland DE, Gores PF, Gruessner RW, Arrazola L, Najarian JS. Relationship between early versus late acute rejection and onset of chronic rejection in kidney transplantation. *Transplant Proc* 25:910-1, 1993.

179. Almond PS, Matas AJ, Gillingham KJ, **Dunn DL**, Payne WD, Gores P, Gruessner R, Najarian JS. Predictors of chronic rejection in renal transplant recipients. *Transplant Proc* 25:936, 1993.
180. Gruessner RW, Stephanian E, **Dunn DL**, Gruessner AC, Najarian JS, Sutherland DE. Cystoenteric conversion after whole pancreaticoduodenal transplantation: indications, risk factors, and outcome. *Transplant Proc* 25:1179-81, 1993.
181. Cheung AH, Matas AJ, Gruessner RW, **Dunn DL**, Moudry-Munns KC, Najarian JS, Sutherland DE. Should uremic diabetic patients who want a pancreas transplant receive a simultaneous cadaver kidney-pancreas transplant or a living related donor kidney first followed by cadaver pancreas transplant? *Transplant Proc* 25:1184-5, 1993.
182. Casanova D, Gruessner R, Brayman K, Jessurun J, **Dunn DL**, Xenos E, Sutherland DE. Retrospective analysis of the role of pancreatic biopsy (open and transcystoscopic technique) in the management of solitary pancreas transplants. *Transplant Proc* 25:1192-3, 1993.
183. Gruessner A, Gruessner R, Moudry-Munns K, Dunn DL, Najarian JS, Sutherland DE. Influence of multiple factors (age, transplant number, recipient category, donor source) on outcome of pancreas transplantation at one institution. *Transplant Proc* 25:1303-5, 1993.
184. Kaufman DB, Matas AJ, Arrazola L, Gillingham KJ, Sutherland DE, Payne WD, **Dunn DL**, Gores PF, Najarian JS. Transplantation of kidneys from zero haplotype-matched living donors and from distantly related and unrelated donors in the cyclosporine era. *Transplant Proc* 25:1530-1, 1993.
185. Fasola CG, Kim YS, Dunning M, Condie RM, Kurle J, Manivel JC, Schlumpf R, Payne WD, Sutherland DER, Najarian JS, **Dunn DL**. Successful canine small bowel preservation in simple cold storage for 48 hours using a dextran-40-based solution. *Transplant Proc* 25:1576-9, 1993.
186. Canafax DM, Carleton BC, Matas AJ, Payne WD, **Dunn DL**, Sutherland DE, Najarian JS. Effects of three immunosuppressive drug protocols on cadaver renal transplantation costs after four years of therapy. *Transplant Proc* 25:1692-3, 1993.
- *187. Burd RS, Raymond CS, Ratz CA, **Dunn DL**. A rapid procedure for purifying IgM monoclonal antibodies from murine ascites using a DEAE-disk. *Hybridoma* 12:135-42, 1993.
- *188. Almond PS, Matas A, Gillingham K, **Dunn DL**, Payne WD, Gores P, Gruessner R, Najarian JS. Risk factors for chronic rejection in renal allograft recipients. *Transplantation* 55:752-7, 1993.
- *189. Basadonna GP, Matas AJ, Gillingham KJ, Payne WD, **Dunn DL**, Sutherland DER, Gores PF, Gruessner RWG, Najarian JS. Early versus late acute renal allograft rejection: impact on chronic rejection. *Transplantation* 55:993-5, 1993.
- *190. Battafarano RJ, Burd RS, Cody CS, Kellogg TA, Raymond CS, Ratz CA, **Dunn DL**. Anti-lipopolysaccharide monoclonal antibodies inhibit macrophage TNF messenger RNA synthesis *in vitro*. *J Surg Res* 54:342-8, 1993.
- *191. Burd RS, Battafarano RJ, Cody CS, Farber MS, Ratz CA, **Dunn DL**. Anti-endotoxin monoclonal antibodies inhibit secretion of tumor necrosis factor- by two distinct mechanisms. *Ann Surg* 218:250-61, 1993.
- *192. Boivin G, Erice A, Crane DD, **Dunn DL**, Balfour HH. Ganciclovir susceptibilities of cytomegalovirus (CMV) isolates from solid organ transplant recipients with CMV viremia after antiviral prophylaxis. *J Infect Dis* 168:332-5, 1993.
- *193. Pirenne J, D'Silva M, Degiovanni G, Jacquet N, **Dunn DL**. Relevance of tumor necrosis factor to graft-versus-host disease after small bowel transplantation. *Transpl International* 6:258-62, 1993.
- *194. **Dunn DL**. Use of novel therapeutic agents for the treatment of serious infection. *Am J Surg* 166:449-55, 1993.
- *195. Sutherland DER, Gores P, Farney A, Wahoff DC, Matas AJ, **Dunn DL**, Gruessner RWG, Najarian JS. Evolution of kidney, pancreas, and islet transplantation for diabetes at the University of Minnesota. *Am J Surg* 166:456-89, 1993.

- *196.**Dunn DL**. Monoclonal antibodies for diagnosis and treatment. *Arch Surg* 128:1274-80, 1993.
- 197.**Dunn DL**. Controversies regarding the use of anti-endotoxin monoclonal antibodies. *Infect Dis Clin Practice* 2:456-62, 1993.
- 198.**Dunn DL**. Anti-cytokine therapies in sepsis. *Perspect Gen Laparoscopic Surg* 1:45-57, 1993.
- 199.Gruessner AC, Barrou B, Jones J, **Dunn DL**, Moudry-Munns K, Najarian JS, Sutherland DER, Gruessner RW. Donor impact on outcome of bladder-drained pancreas transplants. *Transplant Proc* 25:3114-5, 1993.
- 200.**Dunn DL**. Presidential Address. History repeats itself: Connections and causality in the study of surgical infections. *Arch Surg* 129:21-6, 1994.
- *201.Jones JW, Gillingham KJ, Sutherland DER, Payne WD, **Dunn DL**, Gores PF, Gruessner RWG, Najarian JS, Matas AJ. Successful long-term outcome with 0-haplotype-matched living-related kidney donors. *Transplantation* 57:512-5, 1994.
- *202.Battafarano RJ, Burd RS, Kurrelmeyer KM, Ratz CA, **Dunn DL**. Inhibition of splenic macrophage tumor necrosis factor- secretion in vivo by antilipoplysaccharide monoclonal antibodies. *Arch Surg* 129:179- 86, 1994.
- *203.**Dunn DL**, Gillingham KJ, Kramer MA, Schmidt WJ, Erice A, Balfour HH, Gores PF, Gruessner RWG, Matas AJ, Payne WD, Sutherland DER, Najarian JS. A prospective randomized study of acyclovir versus ganciclovir plus human immune globulin prophylaxis of cytomegalovirus infection after solid organ transplantation. *Transplantation* 57:876-84, 1994.
- 204.**Dunn DL**. Gram-negative bacterial sepsis and sepsis syndrome. *Surg Clin North Am* 74:621-35, 1994.
- *205.Gruessner RWG, **Dunn DL**, Gruessner AC, Matas AJ, Najarian JS, Sutherland DER. Recipient risk factors have an impact on technical failure and patient and graft survival rates in bladder-drained pancreas transplants. *Transplantation* 57:1598-1606, 1994.
- *206.Burd RS, Gillingham KJ, Farber MS, Statz CL, Kramer MA, Najarian JS, **Dunn DL**. Diagnosis and treatment of cytomegalovirus disease in pediatric renal transplant recipients. *J Pediatr Surg* 29:1049-54, 1994.
- *207.Gruber SA, Gillingham K, Sothorn RB, Stephanian E, Matas AJ, **Dunn DL**. De novo cancer in cyclosporine-treated and non-cyclosporine-treated adult primary renal allograft recipients. *Clin Transplantation* 8:388-95, 1994.
- 208.Sutherland DER, Gruessner RWG, **Dunn DL**, Moudry-Munns K, Gruessner A, Najarian JS. Pancreas transplants from living related donors. *Transplant Proc* 26:443-5, 1994.
- 209.Gruessner RWG, Troppmann C, Barrou B, **Dunn DL**, Moudry-Munns KC, Najarian JS, Sutherland DER, Gruessner AC. Assessment of donor and recipient risk factors on pancreas transplant outcome. *Transplant Proc* 26:437-8, 1994.
- *210.Morrison VA, **Dunn DL**, Manivel JC, Gajl-Peczalska KJ, Peterson BA. Clinical characteristics of post-transplant lymphoproliferative disorders. *Am J Med* 97:14-24, 1994.
- 211.Gruber SA, Stephanian E, **Dunn DL**. A complicated case of skin cancer in a renal allograft recipient. *Transplantation Science* 1:17-9, 1994.
- 212.Gruber SA, Gillingham KJ, Sothorn RB, Stephanian E, Chavers B, Matas AJ, **Dunn DL**. Cancer development in pediatric primary renal allograft recipients. *Transplant Proc* 26:3-4, 1994.
- 213.Granger DK, Burd RS, Schmidt WJ, **Dunn DL**, Matas AJ. Incidence and timing of infections in pediatric renal transplant recipients in the cyclosporine era. *Transplant Proc* 26:64, 1994.
- 214.**Dunn DL**. Prophylaxis and treatment of cytomegalovirus infection in solid organ transplant patients. *Transplant Immunol Letters* 4:4, 16-9, 1994.
- *215.Kim SK, Battafarano RJ, Dahlberg PS, **Dunn DL**. Protective effect of monophosphoryl lipid A (MPLA) during systemic candidiasis in neutropenic and normal mice. *Surg Forum* 65:50-1, 1994.

- *216. Everett JE, Wahoff DC, Statz C, Gillingham KJ, Gruessner A, Gruessner RWG, Gores PF, Sutherland DER, **Dunn DL**. Characterization and impact of wound infection after pancreas transplantation. *Arch Surg* 129:1310-7, 1994.
- *217. Hakim NS, Benedetti E, Pirenne J, Gillingham KJ, Payne WD, **Dunn DL**, Sutherland DE, Gruessner R, Gores PF, Matas AJ, et al. Complications of ureterovesical anastomosis in kidney transplant patients: the Minnesota experience. *Clin Transplantation* 8:504-7, 1994.
- *218. Benedetti E, Fryer J, Matas AJ, Sutherland DE, Payne WD, **Dunn DL**, Gores PF, Gruessner RW, Najarian JS. Kidney transplant outcome with and without right renal vein extension. *Clin Transplantation* 8:416-7, 1994.
219. Troppmann C, Gruessner RW, **Dunn DL**, Fasola C, Najarian JS, Sutherland DER. Is transplant pancreatectomy after graft failure necessary? *Transplant Proc* 26:455, 1994.
220. Troppmann C, **Dunn DL**, Najarian JS, Sutherland DER, Gruessner AC, Gruessner RW. Operative reintervention following early complications after pancreas transplantation. *Transplant Proc* 26:454, 1994.
221. Troppmann C, Gruessner RW, Matas AJ, **Dunn DL**, Stevens RB, Najarian JS, Sutherland DER. Results with renal transplants performed after previous solitary pancreas transplants. *Transplant Proc* 26:448-9, 1994.
222. Gruessner RW, Troppmann C, Barrou B, **Dunn DL**, Moudry-Munns KC, Najarian JS, Sutherland DER, Gruessner AC. Assessment of donor and recipient risk factors on pancreas transplant outcome. *Transplant Proc* 26:437-8, 1994.
223. Fasola CG, Gillingham KJ, Troppmann C, Gruessner RW, Gores PF, **Dunn DL**, Payne WD, Sutherland DER, Matas AJ, Najarian JS. Kidney transplant or retransplant can effectively treat congenital nephrotic syndrome: a single-center experience. *Transplant Proc* 26:9, 1994.
224. Fasola CG, Gillingham KJ, Troppmann C, Gruessner RW, Gores PF, **Dunn DL**, Payne WD, Sutherland DER, Matas AJ, Najarian JS. Pediatric kidney retransplantation: 30 years of experience at a single institution. *Transplant Proc* 26:48, 1994.
225. Troppmann C, Almond PS, Fasola C, Benedetti E, Gruessner RW, **Dunn DL**, Gores PF, Payne WD, Matas AJ, Najarian JS. Effect of Minnesota antilymphocyte globulin on T-lymphocytes and their subsets during induction therapy in pediatric renal transplantation. *Transplant Proc* 26:26-7, 1994.
- *226. Carlson JW, Fowler JM, Saltzman AK, Carter JR, Chen MD, Mitchell SK, **Dunn DL**, Carson LF, Adcock LL, Twiggs LB. Chemoprophylaxis with oral ciprofloxacin in ovarian cancer patients receiving taxol. *Gynecol Oncol* 55:415-20, 1994.
- *227. Wells CL, Juni BA, Cameron SB, Mason KA, **Dunn DL**, Ferrieri P, Rhame FS. Stool carriage, clinical isolation, and mortality during an outbreak of vancomycin-resistant enterococci in hospitalized medical and/or surgical patients. *Clin Infect Dis* 21:45-50, 1995.
- *228. Battafarano RJ, Dahlberg PS, Ratz CA, Johnston JW, Gray BH, Haseman JR, Mayo KH, **Dunn DL**. Peptide derivatives of three distinct lipopolysaccharide binding proteins inhibit lipopolysaccharide-induced tumor necrosis factor- secretion *in vitro*. *Surgery* 118:318-24, 1995.
- *229. Dahlberg PS, Battafarano RJ, Acton RD, Ratz CR, Johnston JW, **Dunn DL**. Active but not passive immunization protects against gram-negative bacterial infection. *Surg Forum* 66:63-5, 1995.
- *230. Mauch T, Crouch NA, Freese DK, Braunlin EA, **Dunn DL**, Kashton CE. Antibody response of pediatric solid organ transplant recipients to immunization against influenza virus. *J Ped* 127:957-60, 1995.
- *231. Matas AJ, Almond PS, Moss A, Gillingham KJ, Sibley R, Payne WD, **Dunn DL**, Gruessner RWG, Sutherland DER, Manivel C, Najarian JS. Effect of cyclosporine on renal function in kidney transplant recipients: a 12-year follow-up. *Clin Transplant* 9:450-3, 1995.

- *232. Battafarano RJ, Kim SK, Dahlberg PS, Farber MS, Ratz CA, Johnston JW, **Dunn DL**. Lymphocyte-derived cytokines augment macrophage tumor necrosis factor- and interleukin-6 secretion during experimental gram-negative bacterial sepsis. *J Surg Res* 58:739-45, 1995.
233. Wahoff DC, Papalois BE, Najarian JS, Nelson LA, **Dunn DL**, Farney AC, Sutherland DE. Clinical islet autotransplantation after pancreatectomy: determinants of success and implications for allotransplantation? *Transplant Proc* 27:3 161, 1995.
- *234. Wahoff DC, Papalois BE, Najarian JS, Kendall DM, Farney AC, Leone JP, Jessurun J, **Dunn DL**, Robertson RP, Sutherland DE. Autologous islet transplantation to prevent diabetes after pancreatic resection. *Ann Surg* 222:562-75, 1995.
- *235. Gruessner RW, Fryer JP, Fasola C, Nakhleh RE, Gruessner AC, Kim S, **Dunn DL**, Pirenne J, Bekersky I, Benedetti E, Troppmann C. A prospective study of FK506 versus CsA and pig ATG in a porcine model of small bowel transplantation. *Transplantation* 59:164-71, 1995.
- *236. Erice A, Holm MA, Sanjuan MV, **Dunn DL**, Gill PC, Balfour HH Jr. Evaluation of CMV-vue antigenemia assay for rapid detection of cytomegalovirus in mixed-leukocyte blood fractions. *J Clin Micro* 33:1014-5, 1995.
- *237. Benedetti E, Troppmann C, Gillingham K, Sutherland DE, Payne WD, **Dunn DL**, Matas AJ, Najarian JS, Gruessner RW. Short- and long-term outcomes of kidney transplants with multiple renal arteries. *Ann Surg* 221:406-14, 1995.
- *238. Troppmann C, Papalois BE, Chiou A, Benedetti E, **Dunn DL**, Matas AJ, Najarian JS, Gruessner RW. Incidence, complications, treatment, and outcome of ulcers of the upper gastrointestinal tract after renal transplantation during the cyclosporine era. *J Am Coll Surg* 180:433-43, 1995.
239. Beebe DS, Kim S, Belani KG, Fryer J, Benedetti E, Moon S, Fasola C, Pirenne J, **Dunn DL**, Gruessner RW. Endotoxemia during small bowel transplantation in pigs. *Transplant Proc* 27:593-4, 1995.
240. Pirenne J, Williams JG, Kim S, Fryer J, Benedetti E, Hakim NS, Medot M, Najarian JS, Gruessner RW, **Dunn DL**. Importance of lymphoid tissue for survival of small bowel allografts. *Transplant Proc* 27:1359-60, 1995.
- *241. Sielaff TD, Everett JE, Shumway SJ, Wahoff DC, Bolman RM III, **Dunn DL**. *Mycoplasma hominis* infections occurring in cardiovascular surgical patients. *Ann Thoracic Surg* 61:99-103, 1996.
- *242. Fryer JP, Kim S, Wells CL, Fasola C, Jechorek RP, **Dunn DL**, Pirenne J, Arazola L, Gruessner RWG. Bacterial translocation in a large-animal model of small-bowel transplantation: portal vs systemic venous drainage and the effect of tacrolimus immunosuppression. *Arch Surg* 131:77-84, 1996.
- *243. Dahlberg PS, Sielaff TD, **Dunn DL**. Emerging resistance in *Staphylococci* and *Enterococci*. *Infect Dis Clin Practice* 5:S49-S56, 1996.
- *244. Gruessner RWG, Fasola C, Fryer J, Nakhleh RE, Kim S, Gruessner AC, Beebe D, **Dunn DL**, Troppmann C, Najarian JS. Quadruple immunosuppression in a pig model of small bowel transplantation. *J Surg Res* 61:260-6, 1996.
245. Sawyer MD, **Dunn DL**. Serious bacterial infections of the skin and soft tissues. *Curr Opin Infect Dis* 8:293-7, 1995.
246. Pirenne J, Medot, Battafarano R, Benedetti E, Kim S, **Dunn DL**. Does endotoxin accelerate rejection in a cardiac allograft model? *Transplant Proc* 28:2463-4, 1996
247. **Dunn DL**. Presidential Address. Projections. *J Surg Res* 63:1-5, 1996.
248. Ulevitch RJ, **Dunn DL**, Fink MP, Taylor CE. Endotoxin related intracellular pathways: implications for therapeutic intervention. *Shock* 6:1-2, 1996.
- *249. Troppmann C, Gruessner AC, Benedetti E, Papalois BE, **Dunn DL**, Najarian JS, Sutherland DE, Gruessner RW. Vascular graft thrombosis after pancreatic transplantation: univariate and multivariate operative and nonoperative risk factor analysis. *J Am Coll Surg* 182:362-3, 1996.

- *250. Matas AJ, Lawson W, McHugh L, Gillingham K, Payne WD, **Dunn DL**, Gruessner RWG, Sutherland DER, Najarian JS. Employment patterns after successful kidney transplantation. *Transplantation* 61:729-33, 1996.
251. Uknis ME, **Dunn DL**. Nosocomial infections and sepsis syndrome in critically ill surgical patients. *Current Opinion in Critical Care* 2:304-10, 1996.
- *252. Dahlberg PS, Acton RD, Battafarano RJ, Uknis ME, Ratz CA, Johnston JW, Haseman JR, Gray BH, **Dunn DL**. A novel endotoxin antagonist attenuates tumor necrosis factor alpha secretion. *J Surg Res* 63:44-8, 1996.
- *253. Benedetti E, Troppmann C, Gruessner AC, Sutherland DER, **Dunn DL**, Gruessner RWG. Pancreas graft loss caused by intra-abdominal infection. *Arch Surg* 131:1054-60, 1996.
- *254. Troppmann C, Gillingham KJ, Gruessner RW, **Dunn DL**, Payne WD, Najarian JS, Matas AJ. Delayed graft function in the absence of rejection has no long-term impact. A study of cadaver kidney recipients with good graft function at 1 year after transplantation. *Transplantation* 61:1331-7, 1996.
- *255. Benedetti E, Gruessner AC, Troppmann C, Papalois BE, Sutherland DER, **Dunn DL**, Gruessner RW. Intra-abdominal fungal infections after pancreatic transplantation: incidence, treatment, and outcome. *J Am Coll Surg* 183:307-16, 1996.
- *256. Dahlberg PS, Acton RD, Uknis ME, Klaerner HG, Johnston JW, Levelle CD, Gray BH, **Dunn DL**. Macrophages expressing a fusion protein derived from bactericidal/permeability-increasing protein and IgG are resistant to endotoxin. *Arch Surg* 131:1173-8, 1996.
- *257. Acton RD, Dahlberg PS, Uknis ME, Klaerner HG, Fink GS, Norman JG, **Dunn DL**. Differential sensitivity to *Escherichia coli* infection of mice lacking tumor necrosis factor p55 and IL-1 p80 receptors. *Arch Surg* 131:1216-21, 1996
258. Bullard KM, **Dunn DL**. Diagnosis and treatment of bacteremia and intravascular catheter infections. *Am J Surg* 172:S13-9, 1996.
259. Doutrelepont JM, DePauw L, Gruber SA, **Dunn DL**, Qunibi W, Kinnaert P, Verserstraeten P, Penn I, Abramowicz D. Renal transplantation exposes patients with previous Kaposi's sarcoma to a high risk of recurrence. *Transplantation* 62:463-6, 1996.
- *260. Wrenshall LW, McHugh L, Felton P, **Dunn DL**, Matas AJ. Pregnancy after donor nephrectomy. *Transplantation* 62:1934-6, 1996.
- *261. Matas AJ, Gillingham KJ, Payne WD, **Dunn DL**, Gruessner RW, Sutherland DE, Schmidt W, Najarian JS. A third kidney transplant: cost-effective treatment for end-stage renal disease? *Clin Transplantation* 10:516-20, 1996.
- *262. Pirenne J, Benedetti E, **Dunn DL**. Graft versus host response: clinical and biological relevance after transplantation of solid organs. *Transplant Rev* 10:46-68, 1996.
- *263. Hakim NS, Gruessner AC, Papalois BE, Troppmann C, **Dunn DL**, Sutherland DE, Gruessner RW. Duodenal complication in bladder-drained pancreas transplantation. *Surgery* 121:618-24, 1997.
- *264. Gruessner RW, Sutherland DE, Troppmann C, Benedetti E, Hakim N, **Dunn DL**, Gruessner AC. The surgical risk of pancreas transplantation in the cyclosporine era: an overview. *J Am Coll Surg* 185:128-44, 1997.
- *265. Klaerner HG, Uknis ME, Acton RD, Dahlberg PS, Carlone-Jambor C, **Dunn DL**. *Candida albicans* and *Escherichia coli* are synergistic pathogens during experimental microbial peritonitis. *J Surg Res* 70:161-5, 1997.
- *266. Klaerner HG, Dahlberg PS, Acton RD, Battafarano RJ, Uknis ME, Johnston JW, **Dunn DL**. Immunization with antibodies that mimic LPS protects against gram negative bacterial sepsis. *J Surg Res* 70:249-54, 1997.
267. Casanova D, Sanjuan MV, Gruessner RW, **Dunn DL**, Sutherland DE. Infecciones en el trasplante de reñon y pancreas. *Enferm Infec Microbiol Clin* 2:104-11, 1997.
268. **Dunn DL**. Presidential Address. *Discovery. Surgery* 122:123-8, 1997.

- *269.Uknis ME, Wasiluk KR, Acton RD, Klaerner HG, Dahlberg PS, Ilyina E, Haseman JR, Gray BH, Mayo KH, **Dunn DL**. Design of a potent novel endotoxin antagonist. *Surgery* 122:380-5, 1997.
- 270.Acton RD, Uknis ME, Klaerner HG, Dahlberg PS, Haseman JR, Gray BH, **Dunn DL**. A novel D-isomer peptide inhibits gram-negative bacterial endotoxin. *Surg Forum* 68:65-7, 1997.
- *271.Matas AJ, Gillingham KJ, **Dunn DL**, Gruessner RWG, Payne WD, Sutherland DER, Najarian JS. Risk factors for prolonged hospitalization after kidney transplants. *Clin Transplantation* 11:259-64, 1997.
- *272.Gruessner RW, Sutherland DER, Najarian JS, **Dunn DL**, Gruessner AC. Solitary pancreas transplantation for nonuremic patients with labile insulin-dependent diabetes mellitus. *Transplantation* 64:1572-7, 1997.
- *273.Humar A, Johnson EM, Payne WD, **Dunn DL**, Wrenshall LE, Najarian JS, Gruessner RWG, Matas AJ. The acutely ischemic extremity after kidney transplant: an approach to management. *Surgery* 123:344-50, 1998.
- *274.Humar A, Johnson EM, Gillingham KJ, Sutherland DE, Payne WD, **Dunn DL**, Wrenshall LE, Najarian JS, Gruessner RW, Matas AJ. Venous thromboembolic complications after kidney and kidney-pancreas transplantation: a multivariate analysis. *Transplantation* 65:229-34, 1998.
- *275.Troppmann C, Gruessner AC, **Dunn DL**, Sutherland DE, Gruessner RW. Surgical complications requiring early relaparotomy after pancreas transplantation: a multivariate risk factor and economic impact analysis of the cyclosporine era. *Ann Surg* 227:255-68, 1998.
- *276.Matas AJ, McHugh L, Payne WD, Wrenshall LE, **Dunn DL**, Gruessner RWG, Sutherland DER, Najarian JS. Long-term quality of life after kidney and simultaneous pancreas-kidney transplantation. *Clin Transplantation* 12:233-42, 1998.
- *277.Dahms RA, Johnson EM, Statz CL, Lee JT, **Dunn DL**, Beilman GJ. Third generation cephalosporin and vancomycin as risk factors for postoperative vancomycin-resistant *Enterococcus* infection. *Arch Surg* 133:1343-6, 1998.
- *278.Humar A, Uknis M, Carlone-Jambor C, Gruessner RW, **Dunn DL**, Matas A. Cytomegalovirus disease recurrence after ganciclovir treatment in kidney and kidney-pancreas transplant recipients. *Transplantation* 67:94-7, 1999.
- *279.Kellogg TA, Weiss CW, Johnston JW, Wasiluk KW, **Dunn DL**. Antiendotoxin agents share molecular homology within their lipopolysaccharide binding domains. *J Surg Res* 85:136-41, 1999.
- 280.Weiss III CA, Wasiluk KR, Kellogg TA, Gray BH, Mayo KH, **Dunn DL**. —Designerl peptides derived from bactericidal/permeability-increasing protein (BPI) recapitulate its endotoxin binding region. *Surg Forum L* :217-9, 1999.
- 281.Kellogg TA, Johnston JW, Weiss III CA, Wasiluk KR, **Dunn DL**. Use of genetic engineering to create a potent single chain Fv endotoxin antagonist. *Surg Forum L*:226-8, 1999.
- *282.Humar A, Gillingham KJ, Payne WD, **Dunn DL**, Sutherland DER, Matas AJ. Association between cytomegalovirus disease and chronic rejection in kidney transplantation recipients. *Transplantation* 68:1879-83, 1999.
- *283.Matas AJ, Humar A, Payne WD, Gillingham KJ, **Dunn DL**, Sutherland DER, Najarian JS. Decreased acute rejection in kidney transplant recipients is associated with decreased chronic rejection. *Ann Surg* 230:493-500, 1999.
- *284.Weiss III CA, Statz CL, Dahms RA, Remucal MJ, **Dunn DL**, Beilman GJ. Six years of surgical wound infection surveillance at a tertiary care center: review of the microbiologic and epidemiological aspects of 20,007 wounds. *Arch Surg* 134:1041-8, 1999.
- *285.West M, Pirenne J, Chavers B, Gillingham K, Sutherland DER, **Dunn DL**, Matas AJ. *Clostridiurn difficile* colitis after kidney and kidney-pancreas transplantation. *Clin Transplantation* 13:318-23, 1999.

- *286. Nichols RL, Graham DR, Barriere SL, Rodgers A, Wilson SE, Zervos M, **Dunn DL**, Kreter B. Treatment of hospitalized patients with complicated gram-positive skin and skin structure infections: two randomized, multicentre studies of quinupristin/dalfopristin versus cefazolin, oxacillin or vancomycin. Synercid Skin and Skin Structure Infection Group. *J Antimicrobial Chemotherapy*. 44:263-73, 1999.
- *287. Matas AJ, Gillingham K, Humar A, **Dunn DL**, Sutherland DER, Najarian JS. Immunologic and nonimmunologic factor. Different risks for cadaver and living-donor transplantation. *Transplantation* 69:54-8, 2000.
288. **Dunn DL**. Diagnosis and treatment of opportunistic infections in immunocompromised surgical patients. *Amer Surg* 66:117-25, 2000.
- *289. Matas AJ, Gillingham K, Payne WD, Humar A, **Dunn DL**, Sutherland DER, Najarian JS: Should I accept this kidney? *Clin Transplantation* 14:90-5, 2000.
- *290. Grubbs BC, Statz CL, Johnson EM, Uknis ME, Lee JT, **Dunn DL**, Salvage therapy of open, infected surgical wounds: A retrospective review using Techni-Care. *Surg Infections* 1:109-114, 2000.
291. Nichols RL, Martone WJ, Barie PS, Bohnen JMA, Chambers HF, Christou NV, Condon RE, Dellinger EP, **Dunn DL**, Fabian TC, Fry DE, Ginzburg E, Gorbach SL, Hardin WD, Ledger WJ, Lee JT, Linden PK, Malangoni MA, Newell K, Rotstein OD, Wilson SE. Deliberations on the risks and antibiotic management of surgical infections. *Surgery* 128:S1-30, 2000.
- *292. Weiss CA 3rd, Wasiluk KR, Kellogg TA, **Dunn DL**. Bactericidal and endotoxin neutralizing activity of a peptide derived from Limulus antilipopolysaccharide factor. *Surgery* 128:339-44, 2000.
293. Uknis ME, **Dunn DL**. Cytomegalovirus infection and disease after solid-organ transplantation: Epidemiology, prevention, and therapy. *Transplantation Reviews* 14:199-209, 2000.
294. **Dunn DL**. Prevention and treatment of multiple organ dysfunction syndrome: Lessons learned and future prospects. *Surg Infections* 1:227-37, 2000.
- *295. Kellogg TA, Lazon V, Wasiluk KR, **Dunn DL**. Binding specificity of polymyxin B, BPI, LALF, and anti-deep core/lipid A monoclonal antibody to lipopolysaccharide partial structures. *Shock* 15:124-9, 2001.
- *296. Sutherland DER, Gruessner RWG, **Dunn DL**, Matas AJ, Humar A, Kandaswamy R, Mauer SM, Kennedy WR, Goetz FC, Robertson RP, Gruessner AC, Najarian JS. Lessons learned from more than 1,000 pancreas transplants at a single institution. *Ann Surg* 233:463-501, 2001.
297. Kandaswamy R, Humar A, Payne WD, **Dunn DL**, Sutherland DE, Matas AJ. Risk factors for kidney transplant acute rejection: a multivariate analysis. *Transplant Proc* 33:1112, 2001.
298. Kandaswamy R, Gillingham K, Humar A, Payne WD, **Dunn DL**, Sutherland DE, Najarian JS, Matas AJ. Impact of HLA-ABDR match on chronic rejection in kidney transplants. *Transplant Proc* 33:1292, 2001.
- *299. Matas AJ, Payne WD, Sutherland DER, Humar A, Gruessner RWG, Kandaswamy R, **Dunn DL**, Gillingham KJ, Najarian JS. 2,500 living donor kidney transplants: A single-center experience. *Ann Surg* 234:149-64, 2001.
300. Lazon V, Leslie DB, Wasiluk KR, **Dunn DL**. Inhibition of proinflammatory response to endotoxin by peptides from the extracellular domain of toll-like receptor 4 (TLR4). *Surg Forum LII*:196-8, 2001.
- *301. Lazon V, Leslie DB, Wasiluk KR, **Dunn DL**. Accelerated internalization and detoxification of endotoxin by anti-lipopolysaccharide antibody is a Fc-receptor-mediated process. *Surgery* 130:192-7, 2001.
- *302. Gruessner AC, Sutherland DER, **Dunn DL**, Najarian JS, Humar A, Kandaswamy R, Gruessner RWG. Pancreas after kidney transplants in posturemic patients with Type I diabetes mellitus. *J Amer Soc Nephrology* 12:2490-9, 2001.
303. Sutherland DER, Gruessner RG, Humar A, Kandaswamy R, Najarian JS, **Dunn DL**, Gruessner A. Pretransplant immunosuppression for pancreas transplants alone in nonuremic diabetic recipients. *Transplant Proc* 33:1656-8, 2001.

- *304. Matas AJ, Ramcharan T, Paraskevas S, Gillingham KJ, **Dunn DL**, Gruessner RW, Humar A, Kandaswamy R, Najarian JS, Payne WD, Sutherland DE. Rapid discontinuation of steroids in living donor kidney transplantation: a pilot study. *Amer J Transplantation* 1:278-83, 2001.
304. **Dunn DL**. Hazardous crossing: Immunosuppression and nosocomial infections in solid organ transplant recipients. *Surgical Infections* 2:103-112, 2002.
305. Lazon V, **Dunn DL**. Molecular biology of endotoxin antagonism. *World J Surg* 26:790-798. 2002.
- *306. Matas AJ, Humar A, Gillingham KJ, Payne WD, Gruessner RWG, Kandaswamy R, **Dunn DL**, Najarian JS, Sutherland DE. Five preventable causes of kidney graft loss in the 1990s: A single-center analysis. *Kidney International* 62:704-714, 2002.
- *307. Everett JE, Busick NP, Sielaff T, Wahoff DC, **Dunn DL**. A deeply invasive *Phoma* species infection in a renal transplant recipient. *Transplant Proc.* 35:1387-9, 2003.
- *308. Paraskevas S, Kandaswamy R, Humar A, Gillingham K, Gruessner RW, Payne WD, Najarian JS, **Dunn DL**, Sutherland DE, Matas AJ. Predicting long-term kidney graft survival: can new trials be performed? *Transplantation.* 75:1256-9, 2003.
- *309. Gruessner RW, Sutherland DE, **Dunn DL**, Najarian JS, Jie T, Hering BJ, Gruessner AC. Transplant options for patients undergoing total pancreatectomy for chronic pancreatitis. *J Amer Coll Surg* 198:559- 67, 2004.
- *310. Wasiluk KR, Leslie DB, Vietzen PS, Mayo KH, **Dunn DL**. Structure/function studies of an endotoxin neutralizing peptide derived from bactericidal/permeability-increasing protein. *Surgery* 136:253-260, 2004.
311. Vietzen PS, Leslie DB, Lazon V, Wasiluk KR, **Dunn DL**. The carboxyl terminus of TIRAP is critical to MyD88-dependent TLR-4 signaling. *J Am Coll Surg* 199:S41, 2004.
- *312. Fiorini RN, Shafizadeh SF, Polito C, Rodwell DW, Cheng G, Evans Z, Wan C, Belden S, Haines JK, Birsner J, Lewin D, Wasiluk KR, **Dunn DL**, Schmidt MG, Chavin KD. Anti-endotoxin monoclonal antibodies are protective against hepatic ischemia/reperfusion injury in steatotic mice. *Amer J Transplant* 4:1567-1573, 2004.
- *313. Matas AJ. Kandaswamy R. Humar A. Payne WD. **Dunn DL**. Najarian JS. Gruessner RW. Gillingham KJ. McHugh LE. Sutherland DE. Long-term immunosuppression, without maintenance prednisone after kidney transplantation. *Ann Surg.* 240:510-6, 2004.
- *314. Krabbenhoft DM. Hoang CD. Morris A. Hunter DW. Payne WD. **Dunn DL**. Bullard KM. Complications of chronic pelvic radiation injury. *J Amer Coll Surg* 198:1022-3, 2004.
- *315. Khwaja K, Asolati M, Harmon JV, Melancon JK, Dunn TB, Gillingham KJ, Kandaswamy R, Humar A, Gruessner RW, Payne WD, Najarian JS, Dunn DL, Sutherland DE, Matas AJ. Rapid discontinuation of prednisone in higher-risk kidney transplant recipients. *Transplantation* 78:1397-9, 2004.
316. Nath DS, Kandaswamy R, Gruessner R, Sutherland DE, **Dunn DL**, Humar A. Fungal infections in transplant recipients receiving alemtuzumab. *Transplant Proc* 37:934-6, 2005.
317. Jie T, Matas AJ, Gillingham KJ, Sytherland DE, Dunn DL, Humar A. Mycobacterial infections after kidney transplant. *Transplant Proc* 937-9, 2005.
- *318. Kandaswamy R, Melancon JK, Dunn T, Tan M, Casingal V, Humar A, Payne WD, Gruessner RW, **Dunn DL**, Najarian JS, Sutherland DE, Gillinham KJ, Matas AJ. A prospective randomized trial of steroid-free maintenance regimens in kidney transplant recipients--an interim analysis. *Am J Transplant* 1529-36, 2005.
- *319. Blaes AH, Peterson BA, Bartlett N, **Dunn DL**, Morrison VA. Rituximab therapy is effective for posttransplant lymphoproliferative disorders after solid organ transplantation: results of a phase II trial. *Cancer* 104:1661-7, 2005.
320. **Dunn DL**, Knatterud ME. Department of Surgery, University of Minnesota, Minneapolis. *Arch Surg* 140:823-6, 2005.

*321. Wasiluk KR, McCulloch KA, Banton KL, **Dunn DL**. Sp1 elements regulate transcriptional activity within the murine Toll-like receptor 4 promoter. *Surg Infect* 6:489-99, 2006.

*322. Leslie DB, Vietzen PS, Lazaron V, Wasiluk KR, **Dunn DL**. Comparison of endotoxin antagonism of linear and cyclized peptides derived from limulus anti-lipopolysaccharide factor. *Surg Infect* 7:45-52, 2006.

**Indicates refereed journal publication*

Ph.D. Thesis

Dunn DL. Host defenses of the peritoneal cavity: Determination of the mechanism of action of hemoglobin, 1985.

Published Books

1. Burd RS, Cody CS, **Dunn DL**. Immunotherapy of Gram-Negative Bacterial Sepsis. Medical Intelligence Unit. R.G. Landes Company, Austin, TX, 1992.

2. Schwartz's Principles of Surgery: *Self-Assessment and Board Review*, 8th Edition. FC Brunicaudi, DK Anderson, TR Billiar, **DL Dunn**, JG Hunter, RE Pollock (eds). McGraw Hill, New York, NY, 2007.

Published Book Chapters

1. **Dunn DL**, Simmons RL. Paraneoplastic syndromes. In *Endocrine Surgery*. JS Najarian, JP Delaney (eds), Appleton Century Crofts, New York, NY, 1981, pp. 357-64.

2. **Dunn DL**, Simmons RL. Surgical techniques in the prevention of soft tissue infections. In *Emergency Surgery*. JS Najarian, JP Delaney (eds), Year Book Medical Publishers, Chicago, IL, 1982, pp. 365-9.

3. **Dunn DL**, Simmons RL. Anaerobic microorganisms in intraabdominal infection: Significance and treatment. In *Topics in Intraabdominal Surgical Infection Vol II*. RL Simmons (ed), Appleton Century Crofts, New York, NY, 1984, pp. 1-16.

4. **Dunn DL**, Najarian JS. Diagnosis and treatment of insulin producing tumors. In *Breast and Endocrine Surgery*. JS Najarian, JP Delaney (eds), Appleton Century Crofts, New York, NY, 1986, pp. 493-8.

5. **Dunn DL**. Intra-abdominal sepsis. In *Common Problems in Trauma*. JM Hurst (ed), Year Book Medical Publishers, Chicago, IL, 1987, pp. 392-8.

6. **Dunn DL**, Cerra FB. General monitoring. In *Manual of Critical Care*. FB Cerra (ed), CV Mosby Company, St. Louis, MO, 1987, pp. 90-116.

7. **Dunn DL**, Najarian JS. Abdominal catastrophes in the immuno suppressed patient. In *Trauma and Critical Care Surgery*. JS Najarian, JP Delaney (eds), Year Book Medical Publishers, Chicago, IL, 1987, pp. 271-9.

8. **Dunn DL**, Meakins JL. Humoral immunity to infection and the complement system. In *Surgical Infectious Diseases*, 2nd Edition. RJ Howard, RL Simmons (eds), Appleton & Lange, East Norwalk, CT, 1988, pp. 175-88.

9. **Dunn DL**, Vascular access procedures. In *Progress in Vascular Surgery*. JS Najarian, JP Delaney (eds), Year Book Publishers, Chicago, IL, 1988, pp. 435-44.

10. Fryd DS, Migliori RL, Simmons RL, Chavers BL, **Dunn DL**, Payne WD, Canafax DM, Sutherland DER, Mauer SM, Najarian JS. Renal transplantation at the University of Minnesota during the 1980's. In *Clinical Transplants 1987*, PI Terasaki (ed), UCLA Tissue Typing Laboratory, Los Angeles, CA, 1987, pp. 167-81.

11. Fryd DS, Canafax DM, Matas AJ, **Dunn DL**, Payne WD, Sutherland DER, Najarian JS. A comparison of two cyclosporin protocols at the University of Minnesota during the 1980's. In *Clinical Transplants 1988*, PI Terasaki (ed), UCLA Tissue Typing Laboratory, Los Angeles, CA, 1988, pp. 79-90.
12. Carson LF, Barke RA, Brooker DC, Savage JE, Twigg LB, **Dunn DL**. Infection and pelvic malignancies. In *Problems in Urology (Vol. 2)*, JL Carson (ed), JB Lippincott, 1989, pp. 499-510.
13. **Dunn DL**. The role of infection and use of antimicrobial agents during multiple system organ failure. In *Multiple Organ Failure. Pathophysiology and basic concepts of therapy*, EA Deitch (ed), Thieme Medical Publishers, Inc. New York, NY, 1990, pp. 150-71.
14. Chavers BM, Matas AJ, Nevins TE, Mauer SM, Sutherland DER, Payne WP, **Dunn DL**, Gillingham KJ, Najarian JS. Results of pediatric kidney transplantation at the University of Minnesota. In *Clinical Transplants 1989*, PI Terasaki (ed), UCLA Tissue Typing Laboratory, Los Angeles, CA, 1990, pp. 253-66.
15. **Dunn DL**, Najarian JS. Infectious complications in transplant surgery. In *Principles and Management of Surgical Infection*. GT Shires, J Davis (eds), JB Lippincott, Philadelphia, PA, 1990, pp. 425-64.
16. Sutherland DER, **Dunn DL**, Gruessner RWG, Najarian JS. Pancreas and islet transplantation for treatment of type I diabetes and as a surgical adjuvant for treatment of pancreatic disease. In *Progress in Hepatic, Biliary and Pancreatic Surgery*. JS Najarian, JP Delaney (eds), Year Book Publishers, Chicago, IL, 1990, pp. 357-69.
17. Tzardis PJ, Gruessner RWG, Matas AJ, Fryd DS, Payne WD, **Dunn DL**, Sutherland DER, Najarian JS. Renal transplantation in patients with polycystic kidney disease: a single center experience. In *Chrysophillis. B Golematis (ed)*, Athens, Greece, 1990, pp. 395-406.
18. Wells CL, Barton RG, Erlandsen SL, Cerra FB, Jechorek RP, **Dunn DL**. Parenteral endotoxin and intestinal function. In *Cellular and Molecular Aspects of Endotoxin Reactions*. A Nowotny, JJ Spitzer, EJ Ziegler (eds), Elsevier Science Publishers BV (Biomedical Division), 1990, pp. 509-19.
19. Chavers BM, Matas AJ, Nevins TE, Mauer SM, Sutherland DER, Payne WD, **Dunn DL**, Gillingham K, Najarian JS. Present status of kidney transplantation in children at the University of Minnesota. In *P Chrysophillis, B Golematis (eds)*, Athens, Greece, 1990, pp. 601-12.
20. **Dunn DL**, Najarian JS. Clinical and surgical considerations in renal transplantation. In *Radiology of Organ Transplantation*. DL Day, NL Ascher, WR Castaneda-Zuniga, JG Letourneau (eds), Year Book Medical Publishers, 1991, pp. 71-82.
21. **Dunn DL**, Sutherland DER. Pancreatic transplantation. In *Radiology of Organ Transplantation*. DL Day, NL Ascher, WR Castaneda-Zuniga, JG Letourneau (eds), Year Book Medical Publishers, 1991, pp. 237-48.
22. Sutherland DER, Moudry-Munns KC, **Dunn DL**. Surgical pancreas transplantation. In *Clinical Diabetes Mellitus*. JK Davidson (ed), Thieme Medical Publishers, Inc, New York, NY, 1991, pp. 354-66.
23. Sutherland DER, Moudry-Munns KC, **Dunn DL**. Pancreas transplantation as endocrine replacement therapy in type I diabetes mellitus. In *The Endocrine Pancreas*. E Samols (ed), Raven Press, New York, NY, 1991, pp. 457-86.
24. Wells CL, Erlandsen SL, **Dunn DL**, Simmons RL. Bacterial translocation across a histologically intact intestinal mucosa. In *Shock, Sepsis, and Organ Failure*. G Schlag, H Redl, JH Siegel, DL Traber (eds), Springer-Verlag, New York, NY, 1991, pp. 91-117.
25. Perez RV, Matas AJ, Gillingham KJ, Payne WD, Canafax DM, **Dunn DL**, Gores PF, Sutherland DER, Najarian JS. Lessons learned and future hopes: three thousand renal transplants at the University of Minnesota. In *Clinical Transplants 1990*. P Terasaki (ed), UCLA Tissue Typing Laboratory, Los Angeles, CA, 1991, pp. 217-31.
26. **Dunn DL**. Immune modulation. In *Medical Intelligence Unit. Trauma 2000: Strategies for the New Millennium*. DJ Dries, RL Gamelli (eds), R.G. Landes Company, Austin, TX, 1992, pp. 91-100.

27. **Dunn DL**. Infection. In *Surgery: Scientific Principles and Practice*. LJ Greenfield (ed), JB Lippincott Co., Philadelphia, PA, 1992, pp. 148-70.
28. **Dunn DL**. Infection in the immunocompromised patient. In *Essentials of Surgical Critical Care*. FB Cerra, JH Abrams (eds), Quality Medical Publishing, Inc., St. Louis, MO, 1992, pp. 491-503.
29. Sutherland DER, Gruessner R, Gillingham K, Moudry-Munns K, **Dunn DL**, Brayman K, Morel P, Najarian JS. A single institution's experience with solitary pancreas transplantation: a multivariate analysis of factors leading to improved outcome. In *Clinical Transplants 1991*. P Terasaki (ed), UCLA Tissue Typing Laboratory, Los Angeles, CA, 1992, pp. 141-52.
30. **Dunn DL**. New modalities in the treatment of sepsis. In *Progress in Trauma and Critical Care Surgery*. JS Najarian, JP Delaney (eds), Mosby-Year Book, Inc., St. Louis, MO, 1992, pp. 371-7.
31. **Dunn DL**, Najarian JS. Critical care of the immunocompromised patient in the intensive care unit. In *Progress in Trauma and Critical Care Surgery*. JS Najarian, JP Delaney (eds), Mosby-Year Book, Inc., St. Louis, MO, 1992, pp. 379-87.
32. Basadonna G, Matas AJ, Gillingham K, Sutherland DE, Payne WD, **Dunn DL**, Gores PF, Gruessner RW, Arrazola L, Najarian JS. Kidney transplantation in patients with type I diabetes: 26-year experience at the University of Minnesota. In *Clinical Transplants 1992*. P Terasaki (ed), UCLA Tissue Typing Laboratory, Los Angeles, CA, 1992, pp. 227-35.
33. **Dunn DL**, Simmons RL. Surgical infections. In *Surgical Basic Science*. JE Fischer (ed), Mosby-Year Book, Inc., St. Louis, MO, 1993, pp. 171-203.
34. **Dunn DL**. Infection in the immunocompromised patient. In *Essentials of Surgical Critical Care: Clinical Cases and Practical Solutions*. JH Abrams, FB Cerra (eds), Quality Medical Publishing, Inc., St. Louis, MO, 1993, pp. 158-61.
35. **Dunn DL**. Immunomodulation. In *Scientific American Medicine: Care of the Surgical Patient* DW Wilmore, LY Cheung, AH Harken, JW Holcroft, JL Meakins (eds) Scientific American, Inc., New York, NY, 1993, IX:13:1-18.
36. Cody CS, **Dunn DL**. Endotoxins in septic shock. In *Handbook of Mediators in Septic Shock*. E Neugebauer, J Holaday (eds), CRC Press, Inc., Boca Raton, FL, 1993, pp. 1-37.
37. **Dunn DL**. Immunomodulation in surgical sepsis. In *Problems in General Surgery: Surgical Sepsis: 1993 and Beyond*. RL Nichols (ed), J.B. Lippincott Company, Philadelphia, PA, 1993, 10:517-25.
38. Battafarano RJ, **Dunn DL**. Immunotherapy in critically ill patients. In *The Pharmacologic Approach to the Critically Ill Patient*. 3rd Edition. B Chernow (ed), Williams & Wilkins, Baltimore, MD, 1994, pp. 365-77.
39. **Dunn DL**. Surgical infections and antibiotics. In *Essentials of Surgery*, 2nd Edition. DC Sabiston, HK Lyerly (eds), W.B. Saunders Company, Philadelphia, PA, 1994, pp. 104-20.
40. **Dunn DL**. Immunomodulation. In *Surgical Infections: Diagnosis and Treatment*. JL Meakins (ed), Scientific American, Inc., New York, NY, 1994, pp. 475-91.
41. **Dunn DL**, Meakins JL. Humoral immunity to infection and the complement system. In *Surgical Infectious Diseases*. 3rd Edition. RJ Howard, RL Simmons (eds), Appleton & Lange, Norwalk, CT, 1995, pp. 295-312.
42. **Dunn DL**. Postoperative wound infection. In *Current Surgical Therapy*, 5th Edition. JL Cameron (ed), Mosby-Year Book, Inc., St. Louis, MO, 1994, pp. 937-42.
43. Troppmann C, **Dunn DL**. Management of the organ donor. In *Intensive Care Medicine*. 3rd Edition. JM Rippe, RS Irwin, FB Cerra, MP Fink (eds), Little, Brown and Co., Boston, MA, 1996, pp. 2099-117.
44. **Dunn DL**. Section editor, XIV. Transplantation. In *Intensive Care Medicine*. 3rd Edition. JM Rippe, RS Irwin, FB Cerra, MP Fink (eds), Little, Brown and Co., Boston, MA, 1996, pp. 2057-133.
45. **Dunn DL**. Host defenses of the peritoneal cavity. In *The Immune Consequences of Trauma, Shock and Sepsis - Mechanisms and Therapeutic Approaches*. E Faist, AE Baue, FW Schildber (eds), Pabst Science Publishers, Berlin, 1996, pp. 456-61.

46. Morrison VA, Peterson BA, **Dunn DL**. Post-transplant lymphoproliferative disorders: pathogenesis, presentation, and approaches to therapy. In *The Immune Consequences of Trauma, Shock and Sepsis - Mechanisms and Therapeutic Approaches*. E Faist, AE Baue, FW Schildber (eds), Pabst Science Publishers, Berlin, 1996, pp. 592-602.
47. **Dunn DL**. Current status of anti-endotoxin monoclonal antibodies. In *The Immune Consequences of Trauma, Shock and Sepsis - Mechanisms and Therapeutic Approaches*. E Faist, AE Baue, FW Schildber (eds), Pabst Science Publishers, Berlin, 1996, pp. 1084-91.
48. **Dunn DL**. Infection. In *Surgery: Scientific Principles and Practice*. 2nd Edition. LJ Greenfield (ed), JB Lippincott Co., Philadelphia, PA, 1997, pp. 159-82.
49. **Dunn DL**. Infection. In *Essentials of Surgery: Scientific Principles and Practice*. LJ Greenfield, MW Mulholland, KT Oldham, GB Zelenock, KD Lillemoe (eds), Lippincott-Raven Publ, Philadelphia, PA, 1997, pp. 52-61.
50. Dahlberg PS, **Dunn DL**. Endotoxins and sepsis. In *Sepsis and Multiorgan Failure: Mechanisms for Treatment Strategies*. AM Fein, EM Abraham, RA Balk, GR Bernard, RC Bone, DR Dantzer, MP Fink (eds), Williams & Wilkins, Baltimore, MD, 1997, pp. 45-61.
51. **Dunn DL**. Immunomodulation. In *Scientific American Surgery*, JL Meakins (ed), Scientific American, Inc., New York, NY 1998, IX:13:1-17.
52. **Dunn DL**. Section editor. Transplantation. In *Intensive Care Medicine*. 4th Edition. JM Rippe, RS Irwin, FB Cerra, MP Fink (eds), Little, Brown and Co., Boston, MA, 1999, pp. 2 145-236.
53. Troppmann C, **Dunn DL**. Management of the organ donor. In *Intensive Care Medicine*. 4th Edition. JM Rippe, RS Irwin, FB Cerra, MP Fink (eds), Little, Brown and Co., Boston, MA, 1999, pp. 2184-202.
54. **Dunn DL**, Acton RD. Solid organ transplantation. In *Infectious Diseases*. D Armstrong, J Cohen (eds), Mosby International London, England, 1999, Section 4, pp.3.1-3.16.
55. **Dunn DL**. Endotoxin antagonists. In *Multiple Organ Failure*. A Baue, E Faist, D Fry (eds), Springer-Verlag, New York, NY, 2000, pp. 492-500.
56. **Dunn DL**. Infection in solid organ transplant recipients. In *2000 Educational Review Manual in Surgery*. S. E. Wilson (ed) Castle Connolly Graduate Medical Publishing, LLC, New York, NY, 2000, pp. IV:1-18.
57. Humar A, **Dunn DL**. Critical care of organ transplant recipients - Introduction. In *Manual of Intensive Care Medicine*. J.M. Rippe and R. Irwin (eds), Lippincott William & Wilkins, Philadelphia, PA, 2000, pp.811-813.
58. Humar A, Gruessner RWG, **Dunn DL**. Critical care of kidney transplant recipients. In *Manual of Intensive Care Medicine*. J.M. Rippe and R. Irwin (eds), Lippincott William & Wilkins, Philadelphia, PA, 2000, pp. 814-816.
59. Humar A, Gruber S, **Dunn DL**. Critical care of pancreas transplant recipients. In *Manual of Intensive Care Medicine*. J.M. Rippe and R. Irwin (eds), Lippincott William & Wilkins, Philadelphia, PA, 2000, pp. 817-820.
60. Humar A, Gruessner RWG, **Dunn DL**. Critical care of liver transplant recipients. In *Manual of Intensive Care Medicine*. J.M. Rippe and R. Irwin (eds), Lippincott William & Wilkins, Philadelphia, PA, 2000, pp. 821-824.
61. Humar A, Shumway SJ, **Dunn DL**. Critical care of heart, heart-lung, and lung transplant patients. In *Manual of Intensive Care Medicine*. J.M. Rippe and R. Irwin (eds), Lippincott William & Wilkins, Philadelphia, PA, 2000, pp. 825-827.
62. Humar A, Troppmann C, **Dunn DL**. Critical care of the cadaver organ donor. In *Manual of Intensive Care Medicine*. J.M. Rippe and R. Irwin (eds), Lippincott William & Wilkins, Philadelphia, PA, 2000, pp. 828-830.
63. Humar A, Brayman KL, **Dunn DL**. Rejection, infection, and malignancy in solid organ transplant recipients. In *Manual of Intensive Care Medicine*. J.M. Rippe and R. Irwin (eds), Lippincott William &

- Wilkins, Philadelphia, PA, 2000, pp. 83 1-835.
64. Moss A, Najarian JS, Sutherland DE, Payne WD, Gruessner RW, Humar A, Kandaswamy R, Gillingham KJ, **Dunn DL**, Matas AJ. 5,000 kidney transplants--a single-center experience. In *Clinical Transplants 2000*. P Terasaki (ed), UCLA Tissue Typing Laboratory, Los Angeles, CA, 2000, pp.159-71.
65. **Dunn DL**. Diagnosis and treatment of infection. In *Surgery: Basic Science and Clinical Evidence*. J. Norton, et al. (eds). Springer-Verlag, New York, NY, 2000, pp. 193-219.
66. Bullard KM, **Dunn DL**: Bloodstream and intravascular catheter infections. In: *Surgical Treatment – Evidence-Based and Problem-Oriented*. RG Holzheimer and JA Mannick (eds), W Zuckschwerdt Verlag, Munich, Germany, 2001, pp 715-721.
67. **Dunn DL**, Rotstein OD. Diagnosis, prevention, and treatment of infection in surgical patients. In *Surgery Scientific Principles and Practice*. LJ Greenfield, MW Mulholland, KT Oldham, GB Zelenock, and KD Lillemoe (eds), Lippincott Williams and Wilkins, Philadelphia, PA, 2001, pp. 178-202.
68. **Dunn DL**. Intraabdominal Infection. In *Current Surgical Therapy*. JL Cameron (ed), Harcourt Health Sciences, Philadelphia, PA, 2001, pp. 1283-1286.
69. **Dunn DL**. The Biological Rationale. In *Source Control. A Guide to the Mangement of Surgical Infections*. M Schein, JC Marshall (eds), Springer-Verlag, New York, NY 2003, pp. 9-13.
70. **Dunn DL**. Diagnosis and treatment of infection. In *Essential Practice of Surgery: Basic Science and Clinical Evidence*. J. Norton, et al. (eds). Springer-Verlag, New York, NY, 2003, pp. 61-76.
71. **Dunn DL**. Section editor. Transplantation. In *Intensive Care Medicine*. 5th Edition. RS Irwin, JM Rippe (eds), Lippincott Williams and Wilkins, pp. 1935-2050.
72. Kandaswamy R, **Dunn DL**, Sutherland DER. Care of the pancreas transplant recipient. In *Intensive Care Medicine*. 5th Edition. RS Irwin, JM Rippe (eds), Lippincott Williams and Wilkins, 2003, pp. 1963-73.
73. Troppmann C, **Dunn DL**. Management of the organ donor. In *Intensive Care Medicine*. 5th Edition. RS Irwin, JM Rippe (eds), Lippincott Williams and Wilkins, 2003, pp. 1973-92.
74. Lazon V, **Dunn DL**. Diagnosis and management of rejection, infection, and malignancy in transplant recipients. In *Intensive Care Medicine*. 5th Edition. RS Irwin, JM Rippe (eds), Lippincott Williams and Wilkins, 2003, pp. 1993-2009.
75. **Dunn DL**. Infection in solid organ transplant recipients. In *2003 Educational Review Manual in Surgery*. S. E. Wilson (ed) Castle Connolly Graduate Medical Publishing, LLC, New York, NY, 2003, pp. IV:1-18.
76. Leslie DB, **Dunn, DL**. Hepatic abscess. In *Current Surgical Therapy*. JL Cameron (ed), Elsevier Mosby, Philadelphia, PA, 2004, pp 298-303.
77. Lazon V, **Dunn DL**. Posttransplant infections. In *Transplantation of the Pancreas*. RWG Gruessner, DER Sutherland (eds), Springer-Verlag, New York, NY, 2004, pp.238-48.
78. **Dunn DL**, Beilman GJ. Surgical Infections. In *Schwartz's Principles of Surgery*, 8th Edition. FC Brunicaardi, DK Anderson, TR Billiar, **DL Dunn**, JG Hunter, RE Pollock (eds). McGraw Hill, New York, NY, 2005, pp. 109-128.
79. Humar A, **Dunn DL**. Transplantation. In *Schwartz's Principles of Surgery*, 8th Edition. FC Brunicaardi, DK Anderson, TR Billiar, **DL Dunn**, JG Hunter, RE Pollock (eds). McGraw Hill, New York, NY, 2005, pp. 295-332.
80. Beilman GJ, **Dunn DL**. Surgical Infections. In *Schwartz's Manual of Surgery*, 8th Edition. FC Brunicaardi, DK Anderson, TR Billiar, **DL Dunn**, JG Hunter, RE Pollock (eds). McGraw Hill, New York, NY, 2006, pp. 78-96.
81. Humar A, **Dunn DL**. Transplantation. In *Schwartz's Manual of Surgery*, 8th Edition. FC Brunicaardi, DK Anderson, TR Billiar, **DL Dunn**, JG Hunter, RE Pollock (eds). McGraw Hill, New York, NY, 2006, pp. 216-44.

82. Beilman GJ, **Dunn DL**. Surgical Infections. In Schwartz's Principles of Surgery, 9th Edition. FC Brunicaudi, DK Anderson, TR Billiar, **DL Dunn**, JG Hunter, JB Mathews, RE Pollock (eds). McGraw Hill, New York, NY, 2010, pp. 113-134.
83. Humar A, **Dunn DL**. Transplantation. In Schwartz's Principles of Surgery, 9th Edition. FC Brunicaudi, DK Anderson, TR Billiar, **DL Dunn**, JG Hunter, JB Mathews, RE Pollock (eds). McGraw Hill, New York, NY, 2010, pp. 271-312.

Brief Communications, Letters, Editorials, Reviews, and Symposium Proceedings

1. Simmons RL, **Dunn DL**. Invited editorial comment. Arch Surg 117:367, 1982. 2. **Dunn DL**, Simmons RL. Invited editorial comment. Arch Surg 121:1039, 1986.
3. **Dunn DL**, Simmons RL. Mechanisms of clearance from the peritoneal cavity [editorial]. Am J Surg 151:446-7, 1986.
4. **Dunn DL**, Simmons RL. Invited editorial. Arch Surg 121:799, 1986.
5. **Dunn DL**. Book review. Kidney Transplant Rejection: Diagnosis and Treatment. GM Williams, JF Burdick, K Solez. 536 pp. New York, Marcel Dekker, Inc., 1986. Ann Surg 205:108, 1987.
6. Erice A, Rhame FS, **Dunn DL**, Chinnock B, Balfour Jr HH. Neutropenia in an HIV-1 infected renal transplant recipient treated with zidovudine [letter]. JAMA 259:3407-8, 1988.
7. Balfour Jr HH, Rhame FS, **Dunn DL**, Erice A. Lithium for zidovudine induced neutropenia in AIDS [editorial reply]. JAMA 260:3588, 1988.
8. Canafax DM, Matas AJ, **Dunn DL**, Sutherland DER, Payne WD, Najarian JS. Cyclosporine and immunosuppressive regimens in renal transplantation [letter]. N Engl J Med 319:1287-8, 1988.
9. Balfour HH Jr, Erice A, Fletcher CV, **Dunn DL**. Editorial reply. N Eng J Med 321:1268-9, 1989.
10. **Dunn DL**. Clinical relevance statement. Arch Surg 126:224, 1991.
11. **Dunn DL**. Antibiotic treatment for surgical peritonitis [editorial]. Ann Surg 214:550-2, 1991.
12. **Dunn DL**. Phagocyte-monokine interactions during intra-abdominal sepsis: potential for immunointervention [editorial]. Crit Care Med 20:5, 1992.
13. Battafarano RJ, **Dunn DL**. The role of nitric oxide during sepsis [editorial]. Crit Care Med 20:1504-5, 1992.
14. Battafarano RJ, **Dunn DL**. Contribution of local cytokine production to the systemic host septic response [editorial]. Crit Care Med 22:7-8, 1994.
15. **Dunn DL**. From the President. Surgical Infection Society Newsletter, 1994.
16. **Dunn DL**. Through adversity, opportunity. Association for Academic Surgery Newsletter. Spring, 1995.
17. **Dunn DL**. Predicting mortality in septic patients [editorial]. Crit Care Med 23:228-9, 1995.
18. **Dunn DL**. Academic surgery under the knife. Association for Academic Surgery Newsletter. Fall, 1995.
19. **Dunn DL**. Do surgeons have a role as infectious disease consultants [invited commentary]? Arch Surg 131:994, 1996.
20. **Dunn DL**. Augmented enhancement of in vitro production of inflammatory cytokines... [editorial]. Crit Care Med 27:859-60, 1999.
21. Lazon V, **Dunn DL**. No barrier too tight [editorial]. Crit Care Med 27:2318-9, 1999.
22. **Dunn DL**. Gram-negative Bacterial Infection and Sepsis Syndrome. In Emerging Resistance in Bacteria and Fungus: A Global Problem. GH Karam (ed), Medical Education Collaborative, Golden, CO, 2000, pp. 13-19.
23. **Dunn DL**. Editorial Commentary. Surg Infect 1:125-126, 2000. 24. **Dunn DL**. Invited Commentary. J Am Coll Surg. 190:680-681, 2000.

Published Abstracts

1. **Dunn DL**, Matas AJ, Simmons RL, Najarian JS. The effect of herpes simplex virus infection on renal transplant recipients. 6th Annual Scientific Meeting of the American Society of Transplant Surgeons, Abstract #4. May 30-31, 1980, Chicago, IL.
2. **Dunn DL**, Ferguson RM. Increased survival after passive immunization against gram-negative sepsis. 43rd Annual Meeting of the Society of University Surgeons, p. 20. February 11-13, 1982, New York, NY.
3. **Dunn DL**, Ferguson RM. The role of heparin in guinea pig gram-negative sepsis. 16th Annual Meeting of the Association for Academic Surgery, p. 106. November 7-10, 1982, San Diego, CA.
4. Kung PC, Hornberger E, Rosen E, **Dunn DL**, Ferguson RM. Human monoclonal antibodies against *E.coli*. Fed Proc 42:435, 1983.
5. Barke RA, **Dunn DL**, Johnson J, Dalmaso A, Orser M, Simmons RL., Humphrey, EW. The pulmonary effects of live vs dead *E.coli* peritonitis. Fed Proc 42:797, 1983.
6. **Dunn DL**, Simmons RL. Synergistic intraperitoneal infection due to *E.coli* and *B.fragilis* within fibrin clots. 3rd Annual Meeting of the Surgical Infection Society, p. 19. May 9-10, 1983. Fort Lauderdale, FL.
7. **Dunn DL**, Mach PA, Dalmaso AP, Ferguson RM, Cerra FB. Protection from the metabolic derangements of gram-negative bacterial sepsis by *E.coli* J5 antiserum. 17th Annual Meeting of the Association for Academic Surgery, p. 94. November 2-5, 1983, Syracuse, NY.
8. Barke RA, **Dunn DL**, Dalmaso AP, Simmons RL, Humphrey EH. Increased *E.coli* virulence results in increased lung microvascular injury following *E.coli* peritonitis. Fed Proc 43:885, 1984.
9. **Dunn DL**, Mach PA, Condie RM, Cerra FB. Anti-core endotoxin F(ab')₂ equine immunoglobulin fragments protect against lethal effects of gram-negative bacterial sepsis. 45th Annual Meeting of the Society of University Surgeons, p. 78. February 9-11, 1984, Chicago, IL.
10. **Dunn DL**, Bogard WC. An anti-*E.coli* 0111:B4 lipopolysaccharide murine monoclonal antibody protects against lethal bacterial sepsis. American Society of Microbiology, p. 50. March 4-9, 1984, St. Louis, MO.
11. **Dunn DL**, Mach PA, Bogard WC, Cerra FB. Prevention of lethal effects of bacteremia and endotoxemia by a murine monoclonal antibody directed against endotoxin. 4th Annual Meeting of the Surgical Infection Society, p. 35. April 30-May 1, 1984, Montreal, Canada.
12. Bogard WC, **Dunn DL**. Monoclonal antibodies against gram-negative bacterial core-glycolipid. *Pseudomonas aeruginosa*: new approaches from basic research, June 4-6, 1984, Vancouver, Canada.
13. Bogard WC, Abernethy K, **Dunn DL**, Kung PC. Murine monoclonal antibodies against gram-negative bacterial core-glycolipid: criteria for cross-genera reactivity. Fed Proc 43:1682, 1984.
14. **Dunn DL**, Bogard WC, Cerra FB. Murine monoclonal antibodies against endotoxin: comparison of type specific and cross reactive murine monoclonal antibodies directed against endotoxin during experimental sepsis. 46th Annual Meeting of the Society of University Surgeons, p. 69. February 6-9, 1985, Boston, MA.
15. **Dunn DL**, Chandan N, Ewald DC, Bogard WC, Cerra FB. A single murine monoclonal antibody provides cross-genera protection during murine gram-negative sepsis. 5th Annual Meeting of the Surgical Infection Society, p. 67. April 29-30, 1985, New Orleans, LA.
16. **Dunn DL**. Modulation of host defenses: Antimicrobial immunotherapy. American College of Surgeons Postgraduate Course on Pre- and Postoperative Care: Management of the Critically Ill Patient, pp. 59-61. October 13-18, 1985, San Francisco, CA.
17. **Dunn DL**. Host defenses of the peritoneal cavity: Determination of the mechanism of action of hemoglobin. Dissert Abstr, 1985.

18. **Dunn DL**, Barke RA, Ewald DC, Simmons RL. Macrophages and translymphatic absorption represent the first line of host defense of the peritoneal cavity. 6th Annual Meeting of the Surgical Infection Society, p. 70. April 21-22, 1986, Chicago, IL.
19. **Dunn DL**. Antibody immunotherapy of gram-negative bacterial sepsis in an immunosuppressed animal model. 13th Annual Scientific Meeting of the American Society of Transplant Surgeons, p. 37. May 28-29, 1987, Chicago, IL.
20. Billiar T, West M, Hyland B, Simmons RL, **Dunn DL**. Murine monoclonal antibody to lipopolysaccharide inhibits Kupffer cell activation by endotoxin *in vitro*. *Circ Shock*, 21:4, 1987.
21. Billiar TR, Maddaus MA, West MA, **Dunn DL**, Simmons RL. The role of intestinal flora in maintaining and modulating Kupffer cell populations and function. 21st Annual Meeting of the Association for Academic Surgery, p. 109. November 1-4, 1987. Orlando, FL.
22. **Dunn DL**, Priest BP, Condie RM. Protective capacity of polyclonal and monoclonal antibodies directed against endotoxin during experimental sepsis. 8th Annual Meeting of the Surgical Infection Society, p. 79. May 5-6, 1988, San Francisco, CA.
23. Priest BP, Schlievert PM, **Dunn DL**. Treatment of toxic shock syndrome with anti-lipopolysaccharide monoclonal antibody. 22nd Annual Meeting of the Association for Academic Surgery, p. 40. November 16-19, 1988, Salt Lake City, UT.
24. Priest BP, **Dunn DL**. Experimental treatment of gram-negative sepsis with monoclonal antibodies directed against lipopolysaccharide. 50th Annual Meeting of the Society of University Surgeons, p. 18. February 9-11, 1989, Baltimore, MD.
25. **Dunn DL**. Immunotherapy of gram-negative bacterial sepsis. *Zeitschrift Antimikrob Antineoplast Chemother* S1:246, 1989.
26. Mayoral JM, Schweich CJ Jr, **Dunn DL**. Decreased tumor necrosis factor production during the initial stages of infection correlates with survival during murine gram-negative sepsis. 9th Annual Meeting of the Surgical Infection Society, p. 13. April 13-14, 1989, Denver, CO.
27. Fasola C, **Dunn DL**. Nuevas perspectivas in el tratamiento de la sepsis por organismos gram negativos. Chilean Chapter of the American College of Surgeons. April 12, 1989, Santiago, Chile.
28. Gorelick K, Jacobs R, Chmel H, Trenholme G, Greenman R, and the Xoma sepsis study group. Efficacy results of a randomized multicenter trial of E5 antiendotoxin monoclonal antibody in patients with suspected gram-negative sepsis. Interscience Conference on Antimicrobial Agents and Chemotherapy, Abstract #2. September 17, 1989, Houston, TX.
29. Martin MA, Wenzel RP, Gorelick KJ, and the Xoma sepsis study group. Prospective national study of gram-negative sepsis-natural history in the 1980s. Interscience Conference on Antimicrobial Agents and Chemotherapy, Abstract #3 17. September 18, 1989, Houston, TX.
30. **Dunn DL**. Immunotherapy of gram-negative bacterial sepsis. *Zentraleuropaischer Anesthesiekongress, Der Anaesthesist* 38:106. September 14, 1989, Innsbruck, Austria.
31. **Dunn DL**, Schlumpf RB, Gruessner RWG, Morel P, Mayoral JL, Payne WD, Matas AJ, Sutherland DER, Moudry-Munns KC, Najarian JS. Maximal utilization of liver and pancreas from cadaveric organ donors. 4th International Symposium on Organ Procurement and Preservation, p. 3. September 18, 1989, Minneapolis, MN.
32. Gruessner RWG, Matas AJ, **Dunn DL**, Lloveras G, Payne WD, Sutherland DER, Najarian JS. A comparison of pediatric versus adult cadaver donor kidneys for transplantation. 4th International Symposium on Organ Procurement and Preservation, p. 3. September 18, 1989, Minneapolis, MN.
33. Gores PF, Viste A, Hesse U, **Dunn DL**, Sutherland DER. The influence of donor hyperglycemia and other factors on long-term pancreatic allograft function. 4th International Symposium on Organ Procurement and Preservation, p. 19. September 18, 1989, Minneapolis, MN.

34. Gruessner RWG, **Dunn DL**, Tzardis PJ, Tomadze G, Moudry-Munns KC, Matas AJ, Sutherland DER, Najarian JS. Simultaneous pancreas and kidney transplants versus single kidney transplants and previous kidney transplants in uremic, and single pancreas transplants in non-uremic diabetic patients: comparison of rejection, morbidity, and long-term outcome. 2nd International Congress on Pancreatic and Islet Transplantation, p. 2. September 21, 1989, Minneapolis, MN.
35. Morel P, Schlumpf RB, Moudry-Munns KC, **Dunn DL**, Sutherland DER. Pancreatic retransplants: an analysis of outcome. 2nd International Congress on Pancreatic and Islet Transplantation, p. 4. September 22, 1989, Minneapolis, MN.
36. Gruessner RWG, **Dunn DL**, Tzardis PJ, Nakhleh RE, Sutherland DER, Najarian JS. Complications occurring after whole organ duodenopancreatic transplantation: relation to the allograft duodenal segment. 2nd International Congress on Pancreatic and Islet Transplantation, p. 33. September 22, 1989, Minneapolis, MN.
37. Burke GW III, Gruessner RWG, **Dunn DL**, Sutherland DER. Conversion of whole pancreaticoduodenal transplants from bladder to enteric drainage for metabolic acidosis or dysuria. 2nd International Congress on Pancreatic and Islet Transplantation, p. 35. September 22, 1989, Minneapolis, MN.
38. Kaufman DB, Platt JL, Rabe F, **Dunn DL**, Sutherland DER. An immunological basis for islet allograft primary non-function. 2nd International Congress on Pancreatic and Islet Transplantation, p. 36. September 22, 1989, Minneapolis, MN.
39. **Dunn DL**. Surgical infections related to colon and rectal surgery. 52nd Course on Principles of Colon and Rectal Surgery, pp. 263-9. October 5, 1989, Minneapolis, MN.
40. **Dunn DL**. Transplantation in the 1990s. Internal Medicine Review Course, pp. 18-9. October 11, 1989, Minneapolis, MN.
41. **Dunn DL**. Pancreatic transplantation as a surgical adjuvant for the treatment of pancreatic disease. American College of Surgeons Postgraduate Course on Diseases of the Liver, Biliary Tract, and Pancreas, pp. 129-31. October 15-20, 1989, Atlanta, GA.
42. Gruessner RWG, Sutherland DER, Tzardis PJ, Tomadze G, Adamec M, Moudry-Munns KC, **Dunn DL**. An immunological comparison of pancreas transplants alone in nonuremic versus simultaneous pancreas/kidney transplants in uremic diabetic patients. 4th Congress of the European Society for Organ Transplantation. November 2, 1989, Barcelona, Spain.
43. Schlumpf RB, Morel P, Moudry-Munns KC, **Dunn DL**, Sutherland DER. An analysis of primary pancreas transplants versus retransplants. 4th Congress of the European Society for Organ Transplantation. November 4, 1989, Barcelona, Spain.
44. Mayoral JM, **Dunn DL**. Cross-reactive murine monoclonal antibodies directed against the core/lipid A region of endotoxin inhibit production of tumor necrosis factor. 23rd Annual Meeting of the Association for Academic Surgery, p. 70. November 15-18, 1989, Louisville, KY.
45. Alexander JW, Boyce S, Babcock GF, **Dunn DL**, Peck MD. The process of microbial translocation. 110th Annual Meeting of the American Surgical Association, p. 81. April 5-7, 1990, Washington, D.C.
46. Pirenne J, Mayoral J, Nakhleh, Wilson D, **Dunn DL**. A segment of small bowel protects from the graft versus host disease following entire small bowel transplantation. 25th Congress of the European Society for Surgical Research, #90. May 8, 1990, Berlin GDR.
- *47. Almond PS, Matas AJ, Escobar FS, Troppmann C, Payne WP, **Dunn DL**, Sutherland DER, Gillingham KJ, Najarian JS. The effects of cyclosporine and non-immunologic loss of the primary renal allograft on second renal transplants. 9th Annual Meeting of the American Society of Transplant Physicians, #P-1. May 29-30, 1990, Chicago, IL.
- *48. Fasola CG, Kim YS, **Dunn DL**, Payne WD, Sutherland DER, Matas AJ, Najarian JS. Kidney retransplantation at a single institution: prediction of the outcome of third kidney transplant based on the patient's previous transplant history. 9th Annual Meeting of the American Society of Transplant Physicians, #P-52. May 29-30, 1990, Chicago, IL.

- *49. Gruber SA, Tzardis P, Skjei KL, Sothern RB, Canafax DM, Matas AJ, **Dunn DL**. Incidence of malignancy in renal allograft recipients treated with conventional and cyclosporine immunosuppression at a single institution. 9th Annual Meeting of the American Society of Transplant Physicians, #P-53. May 29-30, 1990, Chicago, IL.
50. Pirenne JM, Mayoral JL, Williams JG, Nakhleh RE, Wilson DB, **Dunn DL**. Resistance to graft versus host disease after small bowel transplantation in the rat. 16th Annual Scientific Meeting of the American Society of Transplant Surgeons, p. 51. May 30-June 1, 1990, Chicago, IL.
51. **Dunn DL**, Mayoral JL, Gillingham KJ, Loeffler CM, Brayman KL, Kramer MA, Najarian JS. Treatment of invasive CMV disease in solid organ transplant patients with ganciclovir (DHPG). 16th Annual Scientific Meeting of the American Society of Transplant Surgeons, p. 117. May 30-June 1, 1990, Chicago, IL.
52. Schlumpf R, Morel P, Mayoral JL, Moudry-Munns KC, Gruessner RWG, **Dunn DL**. Combined procurement of pancreas and liver grafts does not affect transplant outcome. 16th Annual Scientific Meeting of the American Society of Transplant Surgeons, p. 169. May 30-June 1, 1990, Chicago, IL.
53. Mayoral JL, Loeffler CM, Kramer MA, Matas AJ, Sutherland DER, Najarian JS, **Dunn DL**. Diagnosis of CMV disease in transplant patients based upon gastrointestinal tract manifestations. 10th Annual Meeting of the Surgical Infection Society, p. 25. June 14-16, 1990, Cincinnati, OH.
- *54. Mayoral JL, Nguyen DT, Jechorek RP, Wells CL, **Dunn DL**. Anti-lipopolysaccharide (LPS) murine monoclonal antibody (mAb) increases intestinal bacterial translocation. 10th Annual Meeting of the Surgical Infection Society, p. 82. June 14-16, 1990, Cincinnati, OH.
55. **Dunn DL**. Effect of simultaneous liver retrieval team, retrieval team, and preservation time on cadaver whole organ bladder drained pancreatic allograft survival rates. 13th International Congress of the Transplantation Society, p. 303. August 19-24, 1990, San Francisco, CA.
- *56. Mayoral JM, Ortiz M, Figueroa BS, Singh H, **Dunn DL**. Murine monoclonal antibodies directed against endotoxin allow flow cytometry analysis of lipopolysaccharide binding to the murine monocyte. 24th Annual Meeting of the Association for Academic Surgery, p. 143. November 14-17, 1990, Houston, TX.
57. Pirenne J, Nakhleh RE, **Dunn DL**. Graft versus host disease after organ cluster transplantation. 24th Annual Meeting of the Association for Academic Surgery, p. 152. November 14-17, 1990, Houston, TX.
58. Mayoral J, Loeffler C, Ochoa A, **Dunn DL**. Liposomal interleukin-2: a potential clinical vaccine adjuvant? Fed Proc 2:1035, 1990.
- *59. Burd RS, Mayoral JL, Raymond CS, Ratz CA, **Dunn DL**. Anti-lipopolysaccharide monoclonal antibodies attenuate antibiotic induced endotoxin release during gram-negative bacterial peritonitis. 11th Annual Meeting of the Surgical Infection Society, p. 14. April 8-10, 1991, Fort Lauderdale, FL.
- *60. Mayoral JL, Cody CS, Burd RS, Sawyer MD, Singh HA, Raymond CS, Ratz CA, **Dunn DL**. Do anti-lipopolysaccharide murine monoclonal antibodies enhance lipopolysaccharide phagocytosis by macrophages. 11th Annual Meeting of the Surgical Infection Society, p. 55. April 8-10, 1991, Fort Lauderdale, FL.
- *61. Cody CS, Raymond CS, **Dunn DL**. Fluorescence microscopic examination of monoclonal antibody binding to deep core/lipid A epitopes on live and heat-killed bacteria. 11th Annual Meeting of the Surgical Infection Society, p. 59. April 8-10, 1991, Fort Lauderdale, FL.
62. Morrison V, **Dunn D**, Gruber S, Peterson B. Therapy and outcome of post-transplant lymphomas. American Association for Cancer Research Proceedings, p. 191. May 15-18, 1991, Houston, TX.

63. **Dunn DL**, Mayoral JL, Gillingham KJ, Statz CL, McHugh L, Najarian JS. Simultaneous treatment of concurrent rejection and tissue invasive cytomegalovirus disease without detrimental effects upon patient or allograft survival. 17th Annual Scientific Meeting of the American Society of Transplant Surgeons, p. 41. May 29-31, 1991, Chicago, IL.
64. Burd RS, Raymond CS, **Dunn DL**. Endotoxin is required for the synergistic lethality of combined gram-negative bacterial and fungal infection. 25th Annual Meeting of the Association for Academic Surgery, p. 89. November 20-23, 1991, Colorado Springs, CO.
- *65. Mayoral JL, Cody CS, Burd RS, Raymond CS, Ratz CA, **Dunn DL**. Anti-lipopolysaccharide monoclonal antibodies protect by enhancing endotoxin clearance. 25th Annual Meeting of the Association for Academic Surgery, p. 107. November 20-23, 1991, Colorado Springs, CO.
66. Cody CS, Burd RS, Mayoral JL, Singh HA, **Dunn DL**. Protective anti-lipopolysaccharide monoclonal antibodies inhibit tumor necrosis factor production. 25th Annual Meeting of the Association for Academic Surgery, p. 143. November 20-23, 1991, Colorado Springs, CO.
67. **Dunn DL**. Development and characterization of murine monoclonal antibodies directed against endotoxin. Keystone Symposia on Molecular and Cellular Biology: Recognition of Endotoxin in Biologic Systems, p. 157. March 1-7, 1992, Lake Tahoe, CA.
68. Burd RS, Cody CS, Raymond CS, **Dunn DL**. Anti-endotoxin monoclonal antibodies protect by enhancing bacterial and endotoxin clearance during murine gram-negative bacterial sepsis. 12th Annual Meeting of the Surgical Infection Society, p. 14. April 9-11, 1992, Los Angeles, CA.
69. Sawyer MD, Mayoral JL, Gillingham KJ, Kramer M, **Dunn DL**. Successful retreatment of tissue invasive cytomegalovirus disease after kidney and kidney pancreas transplantation. 12th Annual Meeting of the Surgical Infection Society, p. 47. April 9-11, 1992, Los Angeles, CA.
- *70. Cody CS, Burd RS, Ratz CA, **Dunn DL**. Correlation of protective capacity of anti-lipopolysaccharide monoclonal antibodies with *in vitro* assays of biologic function. 12th Annual Meeting of the Surgical Infection Society, p. 63. April 9-11, 1992, Los Angeles, CA.
71. Kim YS, Fasola CG, Schlumpf R, Nakhleh RE, Manivel JC, Payne WD, Sutherland DER, Najarian JS, **Dunn DL**. Successful canine small bowel preservation in simple cold storage for 48 hours using a dextran-40 based solution. 14th International Congress of the Transplantation Society, 149. August 16-21, 1992, Paris, France.
- *72. Burd RS, Battafarano RJ, Cody CS, Raymond CS, **Dunn DL**. Affinity of anti-LPS monoclonal antibodies correlates with protection during gram-negative bacterial sepsis. 26th Annual Meeting of the Association for Academic Surgery, p. 103. November 18-21, 1992, Montreal, Quebec, Canada.
73. Battafarano RJ, Burd RS, Cody CS, Kellogg TA, Raymond CS, Ratz CA, **Dunn DL**. Anti-lipopolysaccharide monoclonal antibodies act to inhibit the synthesis of tumor necrosis factor messenger RNA *in vitro*. 26th Annual Meeting of the Association for Academic Surgery, p. 135. November 18-21, 1992, Montreal, Quebec, Canada.
74. Burd RS, Battafarano RJ, Cody CS, Farber MS, Ratz CA, **Dunn DL**. Anti-endotoxin monoclonal antibodies inhibit secretion of tumor necrosis factor- by two distinct mechanisms. 113th Annual Meeting of the American Surgical Association, p. 19. April 1-3, 1993, Baltimore, MD.
- *75. Kim SK, Burd RS, Battafarano RJ, **Dunn DL**. GM-CSF improves survival during acute invasive aspergillosis in neutropenic mice. 13th Annual Meeting of the Surgical Infection Society, p. 50. April 29-May 1, 1993, Baltimore, MD.
76. Battafarano RJ, Burd RS, Kurrelmeyer KM, Ratz CA, **Dunn DL**. Inhibition of splenic macrophage TNF-secretion *in vivo* by anti-lipopolysaccharide monoclonal antibodies. 13th Annual Meeting of the Surgical Infection Society, p. 82. April 29-May 1, 1993, Baltimore, MD.
77. Cody CS, Burd RS, **Dunn DL**. Moxalactam enhances binding of monoclonal antibodies to the deep core/lipid A region of lipopolysaccharide. 13th Annual Meeting of the Surgical Infection Society, p. 86. April 29-May 1, 1993, Baltimore, MD.

78. **Dunn DL**, Farber MS, Kramer MA, Sawyer MD, Gruessner RW, Gillingham KJ, Najarian JS. A prospective randomized study of acyclovir versus ganciclovir plus human immune globulin prophylaxis of cytomegalovirus infection after solid organ transplantation. 19th Annual Scientific Meeting of the American Society of Transplant Surgeons, p. 43. May 19-21, 1993, Houston, TX.
79. Gruessner R, Gruessner A, **Dunn DL**, Moudry-Munns K, Sutherland DER. Recipient risk factors have an impact on technical failure and patient survival rates in bladder drained pancreas transplants. 19th Annual Scientific Meeting of the American Society of Transplant Surgeons, p. 127. May 19-21, 1993, Houston, TX.
80. Gruber SA, Gillingham K, Sothorn RB, Stephanian E, Chavers B, Matas AJ, **Dunn DL**. Cancer development in pediatric primary renal allograft recipients. 1st International Congress on Pediatric Transplantation, p. 1. August 29-September 1, 1993, Minneapolis, MN.
81. Troppmann C, Almond PS, Fasola C, Gruessner RWG, Gores PF, **Dunn DL**, Payne WD, Sutherland DER, Matas AJ, Najarian JS. The effect of Minnesota antilymphocyte globulin (MALG) on T-lymphocytes and their subsets during induction therapy in pediatric renal transplantation. 1st International Congress on Pediatric Transplantation, p. 6. August 29-September 1, 1993, Minneapolis, MN.
82. Granger D, Burd RS, Schmidt WJ, **Dunn DL**, Matas AJ. Incidence and timing of infections in pediatric renal transplant recipients. 1st International Congress on Pediatric Transplantation, p. 12. August 29-September 1, 1993, Minneapolis, MN.
83. Burd RS, Farber MS, Statz CL, Kramer MA, Najarian JS, **Dunn DL**. Age and preoperative donor/recipient cytomegalovirus (CMV) serology correlate with the development of CMV disease in pediatric renal transplant recipients. American Academy of Pediatrics, Section on Surgery. October 30, 1993, Washington, DC.
- *84. Kim SK, Battafarano RJ, Burd RS, **Dunn DL**. Administration of GM-CSF in combination with amphotericin B synergistically improves survival in leukopenic mice during acute disseminated candidiasis. 27th Annual Meeting of the Association for Academic Surgery, p. 135. November 10-13, 1993, Hershey, PA.
85. Everett JE, Wahoff DC, Statz C, Gillingham KJ, Gruessner A, Gruessner RWG, Gores PF, Sutherland DER, **Dunn DL**. Characterization and impact of wound infection after pancreas transplantation. 14th Annual Meeting of the Surgical Infection Society, p. 72. April 28-30, 1994, Toronto, Ontario, Canada.
- *86. Dahlberg PS, Battafarano RJ, Kim SK, Farber MS, Ratz CA, Johnston JW, **Dunn DL**. Splenic macrophage nitric oxide production, but not cytokine production is suppressed during experimental gram-negative bacterial sepsis. 28th Annual Meeting of the Association for Academic Surgery, p. 100. November 16-19, 1994, Albuquerque, NM.
87. Battafarano RJ, Kim SK, Dahlberg PS, Farber MS, Ratz CA, Johnston JW, **Dunn DL**. Lymphocyte-derived cytokines other than interferon-g amplify the host systemic inflammatory response during experimental gram-negative bacterial sepsis. 28th Annual Meeting of the Association for Academic Surgery, p. 163. November 16-19, 1994, Albuquerque, NM.
88. Battafarano RJ, Dahlberg PS, Ratz CA, Johnston JW, Gray BH, Haseman JR, Mayo KH, **Dunn DL**. Peptide derivatives of three different lipopolysaccharide (LPS) binding proteins inhibit LPS-induced tumor necrosis factor- secretion *in vitro*. 56th Annual Meeting of the Society of University Surgeons, p. 47. February 9-11, 1995, Denver, CO.
89. Sutherland DER, Wahoff DC, **Dunn DL**, Najarian JS. Islet autotransplantation after pancreatectomy for chronic pancreatitis. 115th Annual Meeting of the American Surgical Association, pp. 88-9, April 7-9, 1995, Chicago, IL.
- *90. Dahlberg PS, Acton RD, Battafarano RJ, Ratz CA, Johnston JW, Haseman JR, Gray BH, and **Dunn DL**. A novel endotoxin antagonist neutralizes lipopolysaccharide induced TNF- secretion. 29th Annual Meeting of the Association for Academic Surgery, p. 99, November 8-11, 1995, Dearborn, MI.

91. Battafarano RJ, Dahlberg PS, Uknis ME, Acton RD, Johnston JW, Ratz CA, **Dunn DL**. A monoclonal antibody designed to mimic LPS binds to the macrophage cell surface and inhibits LPS-induced TNF- α secretion in vitro. 29th Annual Meeting of the Association for Academic Surgery, p. 163, November 8-11, 1995, Dearborn, MI.
92. Acton RD, Dahlberg PS, Uknis ME, Klaerner HG, Fink GS, Norman JG, **Dunn DL**. IL-1 and TNF receptor knockout mice demonstrate differential sensitivity toward intraperitoneal E. coli infection. 16th Annual Meeting of the Surgical Infection Society, p. 12, April 25-27, 1996, Milwaukee, WI.
93. Dahlberg PS, Acton RD, Uknis ME, Klaerner HG, Johnston JW, Leville CD, Gray BH, **Dunn DL**. Macrophages expressing a BPI immunoglobulin fusion protein are resistant to endotoxin. 16th Annual Meeting of the Surgical Infection Society, p. 22, April 25-27, 1996, Milwaukee, WI.
- *94. Uknis ME, Johnson EM, Acton RD, Remucal M, Dahlberg PS, Kramer MA, **Dunn DL**. Trimethoprim-sulfamethoxazole prophylaxis prevents Nocardia infections in recipients of renal allograft. 16th Annual Meeting of the Surgical Infection Society, p. 98, April 25-27, 1996, Milwaukee, WI.
95. Matas AJ, Gillingham KJ, Elick B, **Dunn DL**, Gruessner RWG, Payne WD, Sutherland DER, Najarian JS. Risk factors for a prolonged stay after kidney transplant. 22nd Annual Scientific Meeting of the American Society of Transplant Surgeons, p. 183. May 29-31, 1996, Dallas, TX.
96. Dahlberg PS, Klaerner H, Battafarano RJ, Acton RD, Uknis ME, Ratz CA, **Dunn DL**. Regulation of novel murine macrophage LPS receptor. 30th Annual Meeting of the Association for Academic Surgery, p. 81, November 13-16, 1996, Chicago, IL.
97. Klaerner HG, Dahlberg PS, Battafarano RJ, Acton RD, Uknis ME, **Dunn DL**. Immunization with antibodies designed to mimic LPS protects against gram-negative bacterial peritonitis. 30th Annual Meeting of the Association for Academic Surgery, p. 124, November 13-16, 1996, Chicago, IL.
- *98. Klaerner HG, Uknis ME, Acton RD, Dahlberg PS, Carlone-Jambor C, **Dunn DL**. Candida albicans and Escherichia coli are synergistic pathogens in experimental mixed microbial peritonitis. 30th Annual Meeting of the Association for Academic Surgery, p. 182, November 13-16, 1996, Chicago, IL.
- *99. Uknis ME, Cody CS, Frethem C, Dahlberg PS, Acton RD, Klaerner JG, Harried R, **Dunn DL**. Moxalactam enhances the binding of anti-DCLA antibodies to live gram-negative bacteria. 30th Annual Meeting of the Association for Academic Surgery, p. 239, November 13-16, 1996, Chicago, IL.
100. Yakshe P, Kowalik K, McDevitt S, **Dunn D**, Gruessner R, Delaney J, Sutherland D, Hunter D, Nazarian W, Walsh J, Trenkner S, Kane R, Pyle R, Fredstrom S, Robertson P, Stuckey M, Hulbert J, Eckfeldt J, Jessurun J, Koch S, Katz M, J Vennes. Coordinated management of chronic pancreatitis. Pancreas 13:461, 1996.
101. Uknis ME, Acton RD, Klaerner HG, Dahlberg PS, Haseman JR, Wasiluk KR, Ilyina E, Gray BH, Mayo KH, **Dunn DL**. Design of a potent novel endotoxin antagonist. 58th Annual Meeting of the Society of University Surgeons, p. 50. February 13-15, 1997, Tampa, FL.
102. Klaerner HG, Acton RD, Dahlberg PS, Uknis ME, Johnston JW, Wasiluk KW, **Dunn DL**. Macrophages expressing a single chain Fv of an anti-deep core/lipid A monoclonal antibody are resistant to endotoxin. 17th Annual Meeting of the Surgical Infection Society, p. 65, May 1-3, 1997, Pittsburgh, PA.
- *103. Klaerner HG, Acton RD, Uknis ME, Dahlberg PS, Johnston JW, Wasiluk KW, **Dunn DL**. Mechanisms of binding of endotoxin antagonists. 17th Annual Meeting of the Surgical Infection Society, p. 82, May 1-3, 1997, Pittsburgh, PA.
104. Humar A, Gillingham KJ, Johnson E, Payne WD, **Dunn DL**, Sutherland DER, Gruessner RWG, Wrenshall LE, Najarian JS, Matas AJ. Effect of initial slow graft function on renal allograft rejection and survival. 23rd Annual Scientific Meeting of the American Society of Transplant Surgeons, A-44, May 14-16, 1997, Chicago, IL.
105. Matas AJ, Payne WD, Gruessner RWG, Wrenshall LE, **Dunn DL**, Sutherland DER, Najarian JS. Long-term quality of life (QOL) after kidney and kidney/pancreas transplantation. 23rd Annual Scientific Meeting of the American Society of Transplant Surgeons, A-95, May 14-16, 1997, Chicago, IL.

106. Humar A, Uknis M, Carlone-Jambor C, Gillingham KJ, **Dunn DL**, Matas AJ. Recurrent CMV disease after ganciclovir treatment in kidney and kidney-pancreas transplant recipients. 23rd Annual Scientific Meeting of the American Society of Transplant Surgeons, A-107, May 14-16, 1997, Chicago, IL.
- *107. Dahms RA, Johnson EM, Statz CL, Lee JT, **Dunn DL**, Beilman FL. Third generation cephalosporins as a risk factor for postoperative VRE infection: a retrospective case control analysis. 18th Annual Meeting of the Surgical Infection Society, p. 92, April 30-May 2, 1998, New York, NY.
- *108. Kellogg TA, Weiss CW, Johnston JW, Wasiluk KW, **Dunn DL**. Characterization of a monoclonal antibody which mimics the toxic lipid A region of lipopolysaccharide. 18th Annual Meeting of the Surgical Infection Society, p. 100, April 30-May 2, 1998, New York, NY.
109. Kellogg TA, Johnston JW, Weiss CW, Wasiluk KW, **Dunn DL**. Anti-endotoxin (LPS) agents demonstrate molecular homology within their LPS Binding Domains. 32nd Annual Meeting of the Association for Academic Surgery, p. 138, November 19-22, 1998, Seattle, WA.
110. Matas AJ, Humar A, Payne WD, **Dunn DL**, Sutherland DER, Najarian JS. Decreased acute rejection in kidney transplant recipients is associated with decreased chronic rejection. 119th Annual Meeting of the American Surgical Society, p. 70, April 15-17, 1999, San Diego, CA.
111. Beilman, GJ, Statz CL, Dahms RA, **Dunn DL**. Five years of surgical wound infection surveillance at a tertiary care center; a review of microbiology and epidemiology of 16,622 wounds. 19th Annual Meeting of the Surgical Infection Society, p. 36, April 29-May 1, 1999, Seattle, Washington.
112. Weiss III CA, Wasiluk, KR, Kellogg, TA, **Dunn, DL**. Localization of bactericidal and endotoxin neutralizing activity to a common determinant of bactericidal/permeability-increasing protein (BPI). 4th International Shock Congress and 22nd Annual Conference on Shock, Shock 11 (Supplement):52, June 12-15, 1999, Philadelphia, PA.
113. Weiss III CA, Wasiluk KR, Kellogg TA, **Dunn DL**. A peptide from the active domain of limulus anti-LPS factor (LALF) has potent bactericidal and LPS-neutralizing biological activity. 61st Annual Meeting of the Society of University Surgeons, p. 77, February 9-12, 2000, Toronto, Canada.
- *114. Kellogg TA, Lazon V, Wasiluk KR, **Dunn DL**. Endotoxin antagonists exhibit differential epitope binding. 20th Annual Meeting of the Surgical Infection Society, p. 92, April 27-29, 2000, Providence, RI.
- *115. Lazon V, Wasiluk KR, Weiss C, Kellogg T, Mayo K, **Dunn DL**. Sequence and structural requirements for anti-endotoxin activity in synthetic peptides. 20th Annual Meeting of the Surgical Infection Society, p. 96, April 27-29, 2000, Providence, RI.
116. Sutherland DER, Gruessner RW, **Dunn DL**, Matas AJ, Humar A, Kandaswamy R, Michael SM, Kennedy WR, Goetz FC, Robertson RP, Gruessner AC, Najarian JS. > 1,000 pancreas transplants at a single institution. 120th Annual Meeting of the American Surgical Association, p. 3 8-40, April 6-8, 2000, Philadelphia, PA.
- *117. Lazon V, Wasiluk K, Kellogg T, **Dunn DL**. Endotoxin antagonists of different classes alter macrophage uptake of lipopolysaccharide in disparate manners. 34th Annual Meeting of the Association for Academic Surgery, P70, November 2-4, 2000, Tampa, FL, JSR 93:375, 2000.
118. Lazon V, Leslie DB, Wasiluk KR, **Dunn DL**. Internalization and detoxification of lipopolysaccharide (LPS) by anti-LPS antibody is a Fc receptor-mediated process. 62nd Annual Meeting of the Society of University Surgeons, p. 60, February 7-10, 2001, Chicago, IL.
119. Lazon V, Leslie DB, Wasiluk KR, **Dunn DL**. Serum transferrin is a cofactor for macrophage activation via cell-surface binding of lipopolysaccharide. 21st Annual Meeting of the Surgical Infection Society, p.56, May 3-5, 2001, Snowbird, UT.
120. Lazon V, Leslie DB, Wasiluk KR, **Dunn DL**. Anti-endotoxin antibodies enhance binding and uptake of lipopolysaccharide (LPS) by hepatocytes. 21st Annual Meeting of the Surgical Infection Society, p.82, May 3-5, 2001, Snowbird, UT.

121. Lazaron V, Wasiluk KR, **Dunn DL**. Localisation and inhibition of pro-inflammatory response to endotoxin by peptides from the extra-cellular domain of toll-like receptor 4 (TLR4). 22nd Annual Meeting of the Surgical Infection Society, p. 41, May 2-4, 2002, Madrid, Spain.
122. Lazaron V, Leslie DB, Wasiluk KR, **Dunn DL**. Inhibition of proinflammatory response to endotoxin by peptides from the Toll-like receptor 4 (TLR4)-associated protein MD2 is LBP dependent. Surgical Forum LIII. Journal of American College Surgeons 195:S8 1, 2002.
123. Leslie DB, Lazaron V, Wasiluk KR, **Dunn DL**. Charge- and sequence-specific characteristics of the endotoxin-binding domain of LALF are critical to bactericidal activity. 36th Annual Meeting of the Association for Academic Surgery, p. 274, November 7-9, 2002, Boston, MA, JSR 107:274, 2002.
124. Lazaron V, Leslie DB, Wasiluk KR, **Dunn DL**. LBP catalyzes the inflammatory response to endotoxin via distinct domains within the LBP-carboxyl domain. 36th Annual Meeting of the Association for Academic Surgery, P58, November 7-9, 2002, Boston, MA. JSR 107:322, 2002.
125. Leslie DB, Vietzen PS, Wasiluk KR, **Dunn DL**. Cyclization of a peptide based on the LPS-Binding domain of LALF reduces LPS neutralization and bactericidal activity. 23rd Annual Meeting of the Surgical Infection Society, p. 68, April 10-12, 2003, San Antonio, TX.
126. Leslie DB, Vietzen PV, Lazaron V, Wasiluk KR, **Dunn DL**. Molecular characteristics of the endotoxin-binding domain of LALF. Surgical Forum LIV. J Am Coll Surg 197:S33-4, 2003.
127. Wasiluk KR, Leslie DB, Vietzen PV, **Dunn DL**. Enhanced endotoxin binding of a bioengineered single chain (scFv) monoclonal antibody (mAb). Surgical Forum LIV. J Am Coll Surg 197:S41, 2003.
- *128. Vietzen PS, Leslie DB, Wasiluk KR, Lazaron V, **Dunn DL**. Addition of positive charge augments the anti-endotoxin properties of LALF-based peptides. 37th Annual Meeting of the Association for Academic Surgery, P43, November 13-15, 2003, Sacramento, CA. J Surg Research 114:286-287, 2003.
- *129. Lazaron V, Leslie DB, Wasiluk KR, Vietzen PS, **Dunn DL**. Molecular anatomy of the pro-inflammatory catalytic activity of lipopolysaccharide-binding protein (LBP). 37th Annual Meeting of the Association for Academic Surgery, P52, November 13-15, 2003, Sacramento, CA. J Surg Research 114:289-290, 2003.
130. Wasiluk KR, Leslie DB, Vietzen PS, Mayo KH, **Dunn DL**. Structure/function studies of an endotoxin-neutralizing peptide derived from BPI. 65th Annual Meeting of the Society for University Surgeons. p.127, February 11-14, 2004, St. Louis, MO.
131. Wasiluk KR, McCulloch KA, Leslie DB, Vietzen PS, **Dunn DL**. Localization of transcriptional regulatory elements unresponsive to LPS within the TLR4 promoter. 24th Annual Meeting of the Surgical Infection Society, A-15, April 29-May 1, 2004, Indianapolis, IN.
- *132. Wasiluk KR, Leslie DB, Vietzen PS, **Dunn DL**. Design of a second-generation novel endotoxin antagonist. 24th Annual Meeting of the Surgical Infection Society, P-1, April 29-May 1, 2004, Indianapolis, IN.
133. Vietzen PS, Leslie DB, Lazaron V, Wasiluk KR, **Dunn DL**. The carboxyl terminus of toll-interleukin receptor adaptor protein is critical to MyD88-dependent toll-like receptor-4 signaling. Surgical Forum LV. J Am Coll Surg 197:S33-4, 2004.
- *134. Wasiluk KR, McCulloch KA, **Dunn DL**. Localization of transcriptional regulatory elements unresponsive to LPS within the murine MyD88 promoter. 66th Annual Meeting of the Society for University Surgeons, p.31, February 9-12, 2005, Nashville, TN.
135. Wasiluk KR, McCulloch KA, Banton KL, **Dunn DL**. Sp1 elements within the murine TLR4 promoter may regulate transcriptional activity. 25th Annual Meeting of the Surgical Infection Society and the 2nd Joint Meeting with the Surgical Infection Society-Europe, May 5-7, 2005, Miami, FL.

**Poster Presentation*

Meeting Presentations, Invited Symposia, and Lectureships

1. **Dunn DL.** *Lung abscess.* Combined medical-surgical infectious disease conference. September 12, 1978, Minneapolis, MN.
2. **Dunn DL.** *Monoclonal antibody therapy in E.coli interactions.* Symposium on Practical Use of Antibodies. 22nd Interscience Conference on Antimicrobial Agents in Chemotherapy. October 4, 1982, Miami, FL.
3. **Dunn DL.** *Effects of clindamycin on experimental intra-abdominal sepsis.* Symposium on the Influence of Clindamycin on Bacterial Virulence in Host Defense Mechanisms. Brook Lodge Symposium. June 21, 1983, Kalamazoo, MI.
4. **Dunn DL.** *Monoclonal antibodies protect against lethal effects of gram-negative bacterial sepsis.* 3rd Twin Cities Infectious Disease Research Conference. April 20, 1983, Minneapolis, MN.
5. **Dunn DL,** Bogard WC Jr. *An anti-E.coli 0111:B4 lipopolysaccharide murine monoclonal antibody protects against lethal bacterial sepsis.* 84th Annual Meeting of the American Society for Microbiology. March 4-9, 1984, St. Louis, MO.
6. **Dunn DL.** *Antibody protection in the therapy of sepsis.* North Central Critical Care Society. September 28, 1985, St. Paul, MN.
7. **Dunn DL.** *Vaccines in surgical infection.* Symposium on Critical Surgical Sepsis. November 13-14, 1985, Cincinnati, OH.
8. **Dunn DL.** *Renal and non-renal transplant strategies in diabete; Diabetic renal disease and special problems for native americans: Strategies for care.* 6th Annual Scientific Session ESRD Network 10 for Oklahoma and Arkansas. April 4-5, 1986, Oklahoma City, OK.
9. **Dunn DL.** *Advances in pancreas transplantation.* 9th Annual Symposium Nebraska Organ Retrieval System. May 2, 1986, Omaha, NB.
10. **Dunn DL.** *Surgical management of intra-abdominal infections.* 27th Annual Scientific Meeting of the Clinical Congress of Abdominal Surgeons. March 16-19, 1986, Las Vegas, NV.
11. **Dunn DL.** *Pancreatitis, pancreatic phlegmon and pancreatic abscess.* Symposium on Serious Infections in Surgery. September 13, 1986, Minneapolis, MN.
12. **Dunn DL.** *Antibody immunotherapy of gram-negative bacterial sepsis.* Visiting Professor of Surgery, Surgery Grand Rounds. Duke University Medical Center. September 23-24, 1986, Durham, NC.
13. **Dunn DL.** *Antibody immunotherapy of gram-negative bacterial sepsis.* Symposium on Immunotherapy for the Clinical Pharmacists. October 2-4, 1985, Phoenix, AZ.
14. **Dunn DL.** *Monoclonal antibodies: Target cell treatment.* Symposium on High Tech-High Touch Critical Care Nursing in the 80s. November 3, 1986, St. Paul, MN.
15. **Dunn DL.** *Management of pancreatitis, pancreatic infections and pancreatic abscess.* Surgery for the Primary Care Physician. May 30-31, 1987, Brainerd, MN.
16. **Dunn DL.** *Management of serious intra-abdominal infection.* Colon and Rectal Surgery Course. October 9-12, 1987, Minneapolis, MN.
17. **Dunn DL.** *New approaches to gram-negative infection in surgery.* Symposium on Surgical Infections. 32nd World Congress of Surgery. September 20-25, 1987, Sydney, Australia.
18. **Dunn DL.** *Immunotherapy of gram-negative bacterial sepsis; Necrotizing fasciitis; Pediatric renal transplantation.* 11th National Congress the Mexican Association of General Surgeons. November 18-21, 1987, Guadalajara, Mexico.
19. **Dunn DL.** *Transplantation in the 1980s.* Internal Medicine Grand Rounds. St. Paul-Ramsey Hospital. May 25, 1988, St. Paul, MN.
20. **Dunn DL.** *Management of serious surgical infections.* Surgery for the Primary Care Physician. July 8-10, 1988, Brainerd, MN.

21. **Dunn DL.** *Pancreaticobiliary sepsis.* 5th Annual Conference for the Directors of Surgery in New York City. September 28, 1988, New York, NY.
22. **Dunn DL.** Invited moderator of Immunology/Shock Session. 22nd Annual Meeting of the Association for Academic Surgery. November 17, 1988, Salt Lake City, UT.
23. **Dunn DL.** *Current management of surgical infections.* Presenter and invited moderator. Current issues in surgical management: Applications for the practicing physician. December 16, 1988, Minneapolis, MN.
24. **Dunn DL.** *Determination of fine binding specificity of monoclonal antibodies directed against endotoxin.* Current concepts in infectious diseases. January 9, 1989, Minneapolis, MN.
25. **Dunn DL.** *Clinical applicability of experimental models in surgical infection: Mediators and biological response modifiers.* Invited presentation and panel discussion. 9th Annual Meeting of the Surgical Infection Society. April 15, 1989, Denver, CO.
26. **Dunn DL.** *Immunotherapy of gram-negative bacterial sepsis.* Visiting Professor of Surgery; Surgery Grand Rounds. State University of New York at Syracuse. June 9-10, 1989, Syracuse, NY.
27. **Dunn DL.** *Transplantation in the 1990s.* Visiting Professor of Surgery; Surgery Grand Rounds. Virginia Mason Hospital and Clinics. July 12-13, 1989, Seattle, WA.
28. **Dunn DL.** Invited moderator of the Surgical Infection Society Free Paper Session I. 33rd World Congress of Surgery. September 11, 1989, Toronto, Canada.
29. **Dunn DL.** Invited moderator of Symposium 3: Procurement-Strategies. 4th International Symposium on Organ Procurement and Preservation. September 18, 1989, Minneapolis, MN.
30. **Dunn DL.** Invited Debate: *Rationale for Pancreas Transplantation Alone.* 2nd International Congress on Pancreatic and Islet Transplantation. September 21, 1989, Minneapolis, MN.
31. **Dunn DL.** *New modalities in the treatment of serious surgical infections.* Presenter and invited moderator. Infections in Surgery. Minnesota Chapter of the American College of Surgeons. October 7, 1989, Minneapolis, MN.
32. **Dunn DL.** *Prevention and treatment of infection occurring after solid organ transplantation; New approaches to the treatment of intraabdominal sepsis.* Visiting Professor of Surgery; Surgery Grand Rounds. University of British Columbia. November 2-3, 1989, Vancouver, BC, Canada.
33. **Dunn DL.** *Prophylaxis and treatment of infection in solid organ transplant patients.* Visiting Professor of Surgery; Surgery Grand Rounds. University of Michigan. January 19-20, 1990, Ann Arbor, MI.
34. **Dunn DL.** *Endotoxin and cytokines; Endotoxin clearance and inactivation.* Workshop on the Cellular Basis of Critical Illness. February 28-March 4, 1990, St. Paul-de-Vence, France.
35. **Dunn DL.** *Prophylaxis and treatment of infection in solid organ transplant patients; Management of serious surgical infections.* Visiting Professor of Surgery. Transplant and Intensive Care Conferences. University of Western Ontario. April 4-5, 1990, London, Ontario, Canada.
36. **Dunn DL.** *Immunotherapy of gram-negative bacterial sepsis; New modalities in the treatment of intraabdominal infection; Prophylaxis and treatment of infection in solid organ transplant patients.* Visiting Professor of Surgery. Lister Rounds, Surgery Grand Rounds, Transplant Conference. University of Toronto. April 5-6, 1990, Toronto, Ontario, Canada.
37. **Dunn DL.** *Infection after solid organ transplantation; Pancreatic transplantation; Transplantation in the '90s.* Dallas Transplant Institute. April 25, 1990, Dallas, TX.
38. **Dunn DL.** *Humoral immunity and antibody replacement therapy during gram-negative bacterial sepsis.* 1st International Johns Hopkins Seminar on the Biology of Injury. Johns Hopkins University. May 4-5, 1990, Baltimore, MD.
39. **Dunn DL.** *Prevention and treatment of infection after solid organ transplantation.* 1st Postgraduate Course of the American Society of Transplant Surgeons. June 2, 1990, Chicago, IL.

40. **Dunn DL.** *Infections in transplant patients.* National Association of Transplant Coordinators Organization. June 6, 1990, Tempe, AZ.
41. **Dunn DL.** Invited moderator. Panel on impact of clinical studies of surgical infection on surgical practice. 10th Annual Meeting of the Surgical Infection Society. June 14, 1990, Cincinnati, OH.
42. **Dunn DL.** *Immunotherapy during gram-negative bacterial sepsis.* Advances in Understanding Trauma and Burn Injury. National Institutes of Health. June 22, 1990, Washington D.C.
43. **Dunn DL.** *Surgical perspectives on radiologic intervention in gallbladder and biliary diseases.* 53rd Radiology Course. Radiology/90: GI Imaging and Intervention. September 10, 1990, Minneapolis, MN.
44. **Dunn DL.** *Applications of immunology in clinical surgery: Infection.* 1990 Surgical Research and Education Symposium. 76th Annual Clinical Congress of the American College of Surgeons. October 9, 1990, San Francisco, CA.
45. **Dunn DL.** Invited moderator of the Cytokine Surgical Forum session. 76th Annual Clinical Congress of the American College of Surgeons. October 9, 1990, San Francisco, CA.
46. **Dunn DL.** Invited moderator of the Shock B session. 24th Annual Meeting of the Association for Academic Surgery. November 17, 1990, Houston, TX.
47. **Dunn DL.** *New modalities in the prevention and treatment of infections in surgery: Antiviral therapy.* Invited presentation and panel discussion. 11th Annual Meeting of the Surgical Infection Society. April 9, 1991, Fort Lauderdale, FL.
48. **Dunn DL.** *Immunotherapy of gram-negative bacterial sepsis.* Visiting Professor of Surgery; Surgery Grand Rounds. University of Washington. June 4-6, 1991, Seattle, WA.
49. **Dunn DL.** *New modalities in the treatment of sepsis.* 55th Annual Course, Progress in Trauma and Critical Care Surgery. University of Minnesota. June 21, 1991, Minneapolis, MN.
50. **Dunn DL.** *Role of cytokines and endotoxin during multiple system organ failure.* Symposium on Multiple Organ Failure following Burn Injury. 34th World Congress of Surgery. August 28, 1991, Stockholm, Sweden.
51. **Dunn DL.** Invited moderator of the Surgical Infection Society Free Paper Session IV, 34th World Congress of Surgery. August 29, 1991, Stockholm, Sweden.
52. **Dunn DL.** *Cytokines, antibodies, and sepsis.* Visiting Professor of Surgery; Surgery Grand Rounds. Tulane University. November 2, 1991, New Orleans, LA.
53. **Dunn DL.** *Endotoxin, cytokines, and sepsis.* Surgery Grand Rounds. Mayo Clinic. November 16, 1991, Rochester, MN.
54. **Dunn DL.** *Anti-mediator antibodies.* The Immunocompromised Surgical Patient: Mechanisms and Therapy in Trauma and Burns (2nd Conference). University of Utah. January 26-29, 1992, Snowbird, UT.
55. **Dunn DL.** *Development and characterization of murine monoclonal antibodies directed against endotoxin.* Keystone Symposia on Molecular and Cellular Biology: Recognition of Endotoxin in Biologic Systems. March 1-7, 1992, Lake Tahoe, CA.
56. **Dunn DL.** *Immunomodulation for the treatment of infection.* Visiting Professor of Surgery. Surgery Research Day Forum. Michigan State University. March 11-12, 1992, East Lansing, MI.
57. **Dunn DL.** Invited Debate: *Primary closure of contaminated abdominal wounds.* Controversies in Surgery. American College of Surgeons 20th Annual Spring Meeting. March 22-25, 1992, Orlando, FL.
58. **Dunn DL.** *Antibody immunotherapy of gram-negative bacterial sepsis.* Visiting Professor of Surgery; Surgery Grand Rounds. Medical College of Wisconsin. April 15, 1992, Milwaukee, WI.
59. **Dunn DL.** *Sepsis and multiple organ failure.* Surgery Grand Rounds. George Washington University. May 13, 1992, Washington, D.C.

60. **Dunn DL.** *Prophylaxis and treatment of posttransplant infection.* Visiting Professor of Surgery. Ohio State University. May 22, 1992, Columbus, OH.
61. **Dunn DL.** *Immunomodulation during severe sepsis.* Visiting Professor of Surgery; Surgery Grand Rounds. Ohio State University. May 23, 1992, Columbus, OH.
62. **Dunn DL.** *The immunocompromised patient: Implications for surgical critical care.* Society of Critical Care Medicine 1992 Update on Surgical Critical Care. August 16, 1992, Minneapolis, MN.
63. **Dunn DL.** *The role of endotoxin and host cytokines in septic shock.* Society of Critical Care Medicine 6th Fellows Retreat. September 5, 1992, Napa, CA.
64. **Dunn DL.** *Application of monoclonal antibody technology in experimental and clinical surgery.* Festschrift for John S. Najarian. University of Minnesota. September 21, 1992, Minneapolis, MN.
65. **Dunn DL.** *The role of endotoxin and host cytokines in septic shock.* Department of Internal Medicine Grand Rounds. Rush University. September 25, 1992, Chicago, IL.
66. **Dunn DL.** *Appropriate use of antimicrobial agents -- nine principles.* Jack Fraser Smith Visiting Professor of Surgery; Surgery Grand Rounds. Rush University. September 25, 1992, Chicago, IL.
67. **Dunn DL.** *Prevention and treatment of wound infections.* 4th Annual Symposium on Surgical Infections. Saint Luke's Hospital of Kansas City. October 3, 1992, Kansas City, MO.
68. **Dunn DL.** *Antibody immunotherapy of gram-negative bacterial sepsis.* 4th Annual Symposium on Surgical Infections. Saint Luke's Hospital of Kansas City. October 3, 1992, Kansas City, MO.
69. **Dunn DL.** *Monoclonal antibodies in the treatment of surgical infection.* Committee for the Forum on Fundamental Surgical Problems. Invited presentation and panel Discussion. 78th Annual Clinical Congress of the American College of Surgeons. October 13, 1992, New Orleans, LA.
70. **Dunn DL.** *Development, characterization and testing of anti-endotoxin murine monoclonal antibodies; Immunotherapy of gram-negative bacterial sepsis.* Surgery Research Conference, Surgery Grand Rounds. Visiting Professor of Surgery, University of Utah. December 9, 1992, Salt Lake City, UT.
71. **Dunn DL.** *Prophylaxis and treatment of infections occurring after solid organ transplantation.* Renal Grand Rounds. Minneapolis Veterans Affairs Medical Center. December 14, 1992, Minneapolis, MN.
72. **Dunn DL.** *Immunotherapy.* Research Animal Resources Lecture Series. University of Minnesota. January 26, 1993, Minneapolis, MN.
73. **Dunn DL.** *Management of intraabdominal sepsis.* Visiting Professor of Surgery. University of North Dakota. January 28, 1993, Fargo, ND.
74. **Dunn DL.** *New agents for the treatment of gram-negative bacterial sepsis.* Visiting Professor of Surgery. University of North Dakota. January 29, 1993, Grand Forks, ND.
75. **Dunn DL.** *Cancer in immunosuppressed post-transplant patients.* Interdisciplinary Tumor Conference. University of Minnesota. February 4, 1993, Minneapolis, MN.
76. **Dunn DL.** *Strategy for success as an academic surgeon: Menus, mechanisms, models and mediators.* Committee on Social and Legislative Issues. Invited presentation and panel discussion. 54th Annual Meeting of the Society of University Surgeons. February 11, 1993, Seattle, WA.
77. **Dunn DL.** *Diagnosis and treatment of infection in immunocompromised patients.* Visiting Professor of Surgery. University of California, Irvine. March 6, 1993, Irvine, CA.
78. **Dunn DL.** *Antimicrobial therapy.* Medical Update 1993. March 8, 1993, Fort Lauderdale, FL.
79. **Dunn DL.** *Current management of intraabdominal infections.* Medical Update 1993. March 9, 1993, Fort Lauderdale, FL.
80. **Dunn DL.** *Therapeutic use of monoclonal antibodies in infectious disease.* Medical Update 1993. March 10, 1993, Fort Lauderdale, FL.
81. **Dunn DL.** *Diagnosis and management of infection in the surgical patient.* St. Paul Surgical Society. April 21, 1993, St. Paul, MN.

82. **Dunn DL.** *History repeats itself: Connections and causality in the study of surgical infections.* Presidential Address, 13th Annual Meeting of the Surgical Infection Society. April 30, 1993, Baltimore, MD.
83. **Dunn DL.** *Sepsis in the surgical patient.* Symposium on An Interdisciplinary Approach in the Management of Sepsis. Duke University. May 11, 1993, Durham, NC.
84. **Dunn DL.** *Septic shock pathogenesis and principles of therapy.* Symposium on Current Issues in Sepsis. University of California, Davis--East Bay. May 15, 1993, Oakland, CA.
85. **Dunn DL.** *Treatment of intra-abdominal infections.* 57th Annual Course, Advances in Gastrointestinal Surgery. University of Minnesota. June 19, 1993, Minneapolis, MN.
86. **Dunn DL.** Invited moderator of Scientific Session 2.A, Kidney I. 1st International Congress on Pediatric Transplantation. August 30, 1993, Minneapolis, MN.
87. **Dunn DL.** *Infectious diseases in transplanted children.* 1st International Congress on Pediatric Transplantation. August 31, 1993, Minneapolis, MN.
88. **Dunn DL.** *Infections in the critical care patient.* Visiting Professor of Surgery. Internal Medicine Grand Rounds. University of South Dakota. September 1, 1993, Sioux Falls, SD.
89. **Dunn DL.** *The impact of blood-borne pathogens on surgery practice: Barrier precautions.* Invited presentation and panel discussion. Career Pathways in Surgery Program. October 9, 1993, San Francisco, CA.
90. **Dunn DL.** *Academic fellowships.* Invited presentation and panel discussion. Career Pathways in Surgery Program. October 9, 1993, San Francisco, CA.
91. **Dunn DL.** Invited chairperson. *Cytomegalovirus in transplantation - What does it do and how do we deal with it?* North American Transplant Infectious Disease Symposium. November 18, 1993, Boston, MA.
92. **Dunn DL.** *Post transplant malignancy.* UNOS Region 7 Clinical Transplant Forum. November 19, 1993, Minneapolis, MN.
93. **Dunn DL.** *Diagnosis and treatment of sepsis syndrome.* Visiting Professor of Surgery; Surgery Grand Rounds. University of Tennessee. December 1, 1993, Memphis, TN.
94. **Dunn DL.** *Management of serious surgical infection* (Surgery Grand Rounds), *Diagnosis and treatment of systemic sepsis* (Edward R. Woodward Lecture). Edward R. Woodward Visiting Professor of Surgery. University of Florida, Gainesville. December 15, 1993.
95. **Dunn DL.** *Immunomodulation during infection.* The Immunocompromised Surgical Patient: Mechanisms and Therapy in Trauma and Burns (3rd Conference). University of Utah. January 16-19, 1994, Snowbird, UT.
96. **Dunn DL.** *Infections in the immunocompromised surgical patient.* Symposium on Changing Concepts in the Prevention and Management of Surgical Infections. Medical College of Wisconsin. January 21, 1994, Milwaukee, WI. and January 22, 1994, Chicago, IL.
97. **Dunn DL.** *Epidemiologic characteristics of infectious complication in solid organ transplantation - overview.* 3rd International Congress on The Immune Consequences of Trauma, Shock and Sepsis - Mechanisms and Therapeutic Approaches. March 4, 1994, Munich, Germany.
98. **Dunn DL.** *Monoclonal antibodies.* 3rd International Congress on The Immune Consequences of Trauma, Shock and Sepsis - Mechanisms and Therapeutic Approaches. March 4, 1994, Munich, Germany.
99. **Dunn DL.** *Local defense in the peritoneal cavity.* 3rd International Congress on The Immune Consequences of Trauma, Shock and Sepsis - Mechanisms and Therapeutic Approaches. March 5, 1994, Munich, Germany.
100. **Dunn DL.** *New treatment modalities for sepsis and septic shock.* Visiting Professor of Surgery; Surgery Grand Rounds. University of Hawaii. March 26, 1994, Honolulu, HI.

101. **Dunn DL.** *New modalities in the treatment of sepsis and sepsis syndrome.* Visiting Professor of Surgery; Surgery Grand Rounds. University of Colorado. April 2, 1994, Denver, CO.
102. **Dunn DL.** *Prophylaxis and treatment of infection in the solid organ transplant recipient.* Visiting Professor of Surgery; Surgery Grand Rounds. University of Pennsylvania. April 16, 1994, Philadelphia, PA.
103. **Dunn DL.** *The future of monoclonal antibodies and cytokine modulators in the management of sepsis.* Symposium on Contemporary Issues in Pharmacy. April 22, 1994, Minneapolis, MN.
104. **Dunn DL.** *Prevention and treatment of infection in solid organ transplant patients.* Visiting Professor of Surgery; Surgery Grand Rounds. University of Oregon. May 23, 1994, Portland, OR.
105. **Dunn DL.** *Diagnosis, prevention, and treatment of infection in transplant patients.* Referring Nephrologists Meeting. June 1, 1994, Minneapolis, MN.
106. **Dunn DL.** *Benign and malignant lesions of the ampulla of vater.* 58th Annual Course, Progress in Hepatic, Biliary and Pancreatic Surgery. University of Minnesota. June 16, 1994, Minneapolis, MN.
107. **Dunn DL.** *Hypothesis Formulation.* 5th Annual Fundamentals of Surgical Research Course. July 10, 1994, Durham, NC.
108. **Dunn DL.** *Surgical Research -- Who Will Do it and How?* Surgical Training: Strategies for the Year 2000. Meeting of the Association of Program Directors in Surgery. American College of Surgeons 80th Annual Clinical Congress. October 11, 1994, Chicago, IL.
109. **Dunn DL.** *Immunomodulation has a role in the management of sepsis.* Postgraduate Course No.1, Sepsis Syndrome Controversies. American College of Surgeons 80th Annual Clinical Congress. October 12, 1994, Chicago, IL.
110. **Dunn DL.** *Cellular pathophysiology of shock: Current and future therapies.* Postgraduate Course No. 9, Pediatric Surgery: Critical Care and Trauma. American College of Surgeons 80th Annual Clinical Congress. October 12, 1994, Chicago, IL.
111. **Dunn DL.** *Advances in the treatment of infection in surgical patients.* Visiting Professor of Surgery; Surgery Grand Rounds. The New York Hospital-Cornell Medical Center. November 2, 1994, New York, NY.
112. **Dunn DL.** *Diagnosis and treatment of serious infection in surgical patients: Standard therapy and new modalities.* Visiting Professor of Surgery; Surgery Grand Rounds. The Medical College of Pennsylvania. February 16-18, 1995, Philadelphia, PA.
113. **Dunn DL.** *Surgical and antibiotic therapy of intraabdominal infection; New modalities in the treatment of systemic sepsis; Diagnosis and treatment of necrotizing soft tissue infections; Appropriate use of antimicrobial agents.* 45th Surgical Forum of the Society of Graduate Surgeons of the Los Angeles County/University of Southern California Medical Center, March 16-18, 1995.
114. **Dunn DL.** Academic Visitor and External Judge for the Gallie-Bateman Annual Resident Research Competition. Department of Surgery, University of Toronto. *New agents for the treatment of sepsis syndrome.* Surgery Grand Rounds, Toronto General Hospital. April 20-21, 1995.
115. **Dunn DL.** *Surgical and antibiotic therapy of intraabdominal infection; New modalities in the treatment of systemic sepsis.* Columbus Surgical Society; Visiting Professor of Surgery; Surgery Grand Rounds. Ohio State University. June 2-3, 1995.
116. **Dunn DL.** *Staging laparotomy for lymphoma.* 59th Annual Course, Advances in Breast and Cancer Surgery. University of Minnesota. June 27, 1995, Minneapolis, MN.
117. **Dunn DL.** *The Resident Research Experience: Pragmatics and Philosophy.* 6th Annual Fundamentals of Surgical Research Course. July 9, 1995, Boston, MA.
118. **Dunn DL.** *Organ donor management.* Society of Critical Care Medicine Multidisciplinary Critical Care Board Review Course. August 19, 1995, La Jolla, CA.
119. **Dunn DL.** *Solid organ transplantation.* Society of Critical Care Medicine Multidisciplinary Critical Care Board Review Course. August 19, 1995, La Jolla, CA.

120. **Dunn DL.** *New modalities in the treatment of systemic sepsis.* Surgery Grand Rounds. University of Virginia. September 8, 1995, Charlottesville, VA.
121. **Dunn DL.** *Development and characterization of endotoxin antagonists.* Endotoxin-related Intracellular signalling pathways: Targets for therapeutics. National Institutes of Health. September 28, 1995, Bethesda, MD.
122. **Dunn DL.** *New modalities in the treatment of infection.* Update on Infection in the Surgical Patient: Assessment of risk and innovative strategies for prevention. Medical College of Wisconsin. October 6, 1995, Milwaukee, WI and University of Minnesota. October 7, 1995, Minneapolis, MN.
123. **Dunn DL.** *The impact of blood-borne pathogens on surgery practice: Barrier precautions.* Invited presentation and panel discussion. Career Pathways in Surgery. October 21, 1995, New Orleans, LA.
124. **Dunn DL.** *Pathophysiology of wound infection: Microbiology and endogenous host defenses.* Postgraduate Course No. 15, Surgical Basic Science: The microbiology and immunology of wound infection. American College of Surgeons 81st Annual Clinical Congress. October 26, 1995, New Orleans, LA.
125. **Dunn DL.** Invited moderator of General Session: *Antibiotic management of emerging resistant bacteria.* American College of Surgeons 81st Annual Clinical Congress. October 25, 1995, New Orleans, LA.
126. **Dunn DL.** *Status of Pancreas Transplantation.* Postgraduate Course No. 3, Diseases of the liver, biliary tract, and pancreas. American College of Surgeons 81st Annual Clinical Congress. October 26, 1995, New Orleans, LA.
127. **Dunn DL.** *Projections.* Presidential Address, 29th Annual Meeting of the Association for Academic Surgery. November 10, 1995, Dearborn, MI.
128. **Dunn DL.** *Development and Testing of Novel Endotoxin Antagonists.* Special Lecture, 1st Annual Meeting of the Japan Endotoxin Society. November 17, 1995, Yokohama, Japan.
129. **Dunn DL.** *Development and Characterization of Novel Endotoxin Antagonists.* Inflammation and Multiple Organ Failure: Mechanisms and Therapy in Trauma and Burns. University of Utah, January 20- 24, 1996, Snowbird, UT.
130. **Dunn DL.** *Diagnosis and Treatment of Serious Surgical Infections.* Minneapolis Surgical Society, March 7, 1996
131. **Dunn DL.** *Diagnosis and Management of Serious Surgical Infections.* Visiting Professor; Surgery Grand Rounds, Baylor College of Medicine, April 20, 1996, Houston, TX.
132. **Dunn DL.** *Management of Surgical Infection: Antimicrobial Agents and New Modalities.* Edwin C. James Memorial Lecture, North Dakota Chapter of the American College of Surgeons, May 2, 1996, Minot ND.
133. **Dunn DL.** *Principles of Antibiotic Therapy for Surgeons.* 60th Annual Course, Advances in Trauma and Critical Care Surgery. University of Minnesota. June 27, 1996, Minneapolis, MN.
134. **Dunn DL.** *Use of Antibiotics in the Surgical Patient.* Far Eastern University Dr. Nicanor Reyes School of Medicine Alumni Foundation Clinical Conference: Updates in Medicine and Surgery. July 11, 1996, Minneapolis, MN.
135. **Dunn DL.** *The Resident Research Experience: Pragmatics and Philosophy.* 7th Annual Fundamentals of Surgical Research Course. July 16, 1996, Minneapolis, MN.
136. **Dunn DL.** *Guidelines for Prophylaxis and Treatment of Fungal Infections in the Surgical Intensive Care Unit.* Postgraduate Course No. 1, Pre- and Postoperative Critical Care: Strategies for Development of Practice Guidelines. American College of Surgeons 82nd Annual Clinical Congress. October 10, 1996, San Francisco, CA.
137. **Dunn DL.** *Diagnosis and Management of Serious Surgical Infections.* Brooklyn Surgical Society. Visiting Professor of Surgery, SUNY Health Science Center; *Advances in the Treatment of Sepsis Syndrome.* Triboro Association Surgical Grand Rounds, January 9-11, 1997, New York, NY.

138. **Dunn DL.** *Diagnosis and Treatment of Surgical Infections: From bench to the bedside.* Surgery Grand Rounds. George Washington University. January 22, 1997, Washington, D.C.
139. **Dunn DL.** *Surgical Education in the Twin Cities: Can we build bridges?* Eitel-Wangensteen Lecture, Minneapolis Surgical Society. February 6, 1997, Minneapolis, MN.
140. **Dunn DL.** *Discovery.* Presidential Address, 58th Annual Meeting of the Society of University Surgeons. February 14, 1997, Tampa, FL.
141. **Dunn DL.** *SIRS, MODS/MOF and Sepsis. The Clinical Syndrome: Peritonitis.* 4th International Congress on the Immune Consequences of Trauma, Shock and Sepsis - Mechanisms and Therapeutic Approaches. March 5, 1997, Munich, Germany.
142. **Dunn DL.** *SIRS, MODS/MOF and Sepsis. Augmentation and Resolution of Systemic Inflammation: Adverse Interactions between Host and Microbes.* 4th International Congress on the Immune Consequences of Trauma, Shock and Sepsis - Mechanisms and Therapeutic Approaches. March 6, 1997, Munich, Germany.
143. **Dunn DL.** *Diagnosis and Treatment of Serious Surgical Infections.* Minneapolis Academy of Medicine. March 10, 1997, Minneapolis, MN.
144. **Dunn DL.** *New Modalities in the Treatment of Infection.* 97th Annual Congress of the Japan Surgical Society. April 10, 1997, Kyoto, Japan.
145. **Dunn DL.** *Intra-Abdominal Infection.* 61st Annual Course, Advances in Gastrointestinal and GI Laparoscopic Surgery. University of Minnesota. June 21, 1997, Minneapolis, MN.
146. **Dunn DL.** *The Scientific Method.* 8th Annual Fundamentals of Surgical Research Course. July 12, 1997, Los Angeles, CA.
147. **Dunn DL.** *Infections in Solid Organ Transplant Patients: Ongoing Clinical Trials; Diagnosis and treatment of Serious Surgical Infections; New Modalities in the Treatment of Sepsis Syndrome.* Visiting Professor of Surgery, Surgery Grand Rounds. University of Nebraska. September 26-27, 1997, Omaha, NE.
148. **Dunn DL.** *Novel Reagents for Preservation and Restoration of Cell Function.* Postgraduate Course No. 15, Surgical Basic Science: The Basic Science of Tissue injury and Repair. American College of Surgeons 83rd Annual Clinical Congress. October 14, 1997, Chicago, IL.
49. **Dunn DL.** Invited moderator, Critical Care II: Cell Signaling Surgical Forum Session. American College of Surgeons 83rd Annual Clinical Congress. October 13, 1997, Chicago, IL.
150. **Dunn DL.** *Research Relationships with Industry: Preservation of Research Integrity and Intellectual Property.* Invited presentation and panel discussion. 31st Annual Meeting of the Association for Academic Surgery. November 7, 1997, Dallas, TX.
151. **Dunn DL.** *Antibiotic Resistant Staphylococci and Enterococci: Clinical Implications.* Changing General Surgical Practices 1997. November 13, 1997, Minneapolis, MN.
152. **Dunn DL.** *Development and Characterization of Novel Endotoxin Antagonists.* Inflammation and the Surgical Patient. University of Utah. January 31-February 3, 1998, Snowbird, UT.
153. **Dunn DL.** *Characterization of the Host Septic Response: Mythologies and Reality.* 11th Annual J. Englebert Dunphy, M.D. Visiting Professor. University of California San Francisco. February 27, 1998, San Francisco, CA.
154. **Dunn DL.** *Diagnosis and Treatment of Serious Surgical Infections.* Madison Surgical Society. Visiting Professor of Surgery. *Sepsis Syndrome: Advances in Diagnosis and Treatment.* Surgery Grand Rounds. University of Wisconsin. April 16-18, 1998, Madison, WI.
155. **Dunn DL.** *Antibiotics in Clean Surgery: Fact or Fiction?* Invited debate and panel discussion. 18th Annual Meeting of the Surgical Infection Society. May 2, 1998, New York, NY.
156. **Dunn DL.** *Advances in the Diagnosis and Treatment of Sepsis Syndrome* Visiting Professor of Surgery, Surgery Grand Rounds. Ryder Trauma Center, University of Miami. June 11, 1998, Miami, FL.

157. **Dunn DL.** *Benign and Malignant Lesions of the Ampulla of Vater.* 62nd Annual Course, Advances in Hepatic, Biliary & Pancreatic Surgery. University of Minnesota. June 18, 1998, Minneapolis, MN.
158. **Dunn DL.** *Invasive Soft Tissue Infection.* Multidisciplinary Program: Invited moderator and presenter. American College of Surgeons 84th Annual Clinical Congress. October 26, 1998, Orlando, FL.
159. **Dunn DL.** *Drug-resistant Bacterial Infection: the Misuse of Antibiotics.* Multidisciplinary Program: Invited presentation and panel discussion. American College of Surgeons 84th Annual Clinical Congress. October 28, 1998, Orlando, FL.
160. **Dunn DL.** *Success in Academic Surgery: Rules, Recollections, Recommendations.* Invited presentation and panel discussion. 32nd Annual Meeting of the Association for Academic Surgery, November 19-22, 1998 Seattle, WA.
160. **Dunn DL.** *Use of the Environment at the Affiliated Medical Center.* Invited presentation and panel discussion. 32nd Annual Meeting of the Association for Academic Surgery, November 19-22, 1998 Seattle, WA.
161. **Dunn DL.** *Sepsis Syndrome.* Visiting Professor of Surgery, Surgery Grand Rounds. University of Pittsburgh. February 24, 1999, Pittsburgh, PA.
162. **Dunn DL.** Debate: Diagnosis and Prevention of Catheter Infections in the ICU. *Antibiotic Catheters are Unnecessary;* Debate: Infection vs. Inflammation in the ICU. Should we Empirically Treat Fever? *Treat only Documented Infection;* Debate: SIRS How do we Lower Mortality? *Cytokine Inhibition is the Future.* 2nd Annual Miami Trauma-Critical Care Symposium: Controversies in the Management of Infection in the ICU. March 19-20, 1999, Miami, FL.
163. **Dunn DL.** *Managing the Risk of Infection in Solid Organ Transplant Patients.* Surgery Grand Rounds. University of Florida, Gainesville. March 31, 1999, Gainesville, FL.
164. **Dunn DL.** *New OR Pathogens in a New Century.* General Session. American College of Surgeons 85th Annual Clinical Congress. October 11, 1999, San Francisco, CA.
165. **Dunn DL.** *Diagnosis and Management of Serious Surgical Infections.* Visiting Professor of Surgery, Surgery Grand Rounds. College of Physicians & Surgeons of Columbia University. October 28, 1999, New York, NY.
166. **Dunn DL.** *Emerging Antibiotic Resistance Problems in the SICU, Serious Surgical Infections, New Modalities for the Treatment of Sepsis.* Visiting Professor of Surgery, Surgery Grand Rounds. University of South Florida. November 4-5, 1999, Tampa, FL.
167. **Dunn DL.** *Emerging Resistance in Microbial Pathogens.* Surgery Grand Rounds. University of Chicago. November 10, 1999. Chicago, IL.
168. **Dunn DL.** *Diagnosis and Management of Serious Surgical Infections.* Medicine Grand Rounds, University of Minnesota, January 20, 2000, Minneapolis, MN.
169. **Dunn DL.** *Infections in the Immunocompromised Host.* Postgraduate Course on Surgical Infections, Southeastern Surgical Congress, February 5, 2000, Lake Buena Vista, FL.
170. **Dunn DL.** *Finance Issues in Managed Care.* Society of University Surgeons Management Course for Physician Leaders, February 9, 2000, Toronto, Ontario, Canada.
171. **Dunn DL.** *The High Risk Surgical Patient: IV. Peri-operative risk modulation. Immunomodulation- is there a role?* 5th World Congress on the Trauma, Shock, Inflammation and Sepsis - Pathophysiology, Immune Consequences and Therapy. March 3, 2000, Munich, Germany.
172. **Dunn, DL.** *Antibiotics in the Management of the Trauma and Critical Care Patient.* 64th Annual Course, Advances in Trauma and Critical Care Surgery, University of Minnesota, June 7, 2000.
173. **Dunn DL.** *To Close or Not to Close (the skin): Is That a Question?* Postgraduate Course, 86th Annual Clinical Congress of the American College of Surgeons, October 24, 2000, Chicago, IL.
174. **Dunn DL.** *Crossroads.* Committee on Education Panel —The Road Ahead. 34th Annual Meeting of Association for Academic Surgery, November 3, 2000, Tampa, FL.

175. **Dunn DL.** *Management of Intra-abdominal Infections.* 65th Annual Course, Advances in Gastrointestinal and GI Laparoscopic Surgery, University of Minnesota, June 15, 2001.
176. **Dunn DL.** *Pyogenic Hepatic Abscesses.* Postgraduate Course on Diseases of the Liver, Biliary Tract, and Pancreas, 87th Annual Clinical Congress of the American College of Surgeons, October 11, 2001.
177. **Dunn DL.** *Diagnosis and Management of Serious Surgical Infections.* Visiting Professor of Surgery, Surgery Grand Rounds, Robert Wood Johnson Medical School, April 3, 2002, New Brunswick, NJ.
178. **Dunn DL.** *Diagnosis and Management of Serious Surgical Infections.* Visiting Professor of Surgery, Zimmermann Lectureship, Department of Surgery, West Virginia University School of Medicine, April 22, 2002, Morgantown, WV.
179. **Dunn DL.** *Infection and Immunosuppression.* Critical Care Fellow Sepsis Retreat. September 15, 2002, Minneapolis, MN.
180. **Dunn DL.** *Modern Management of Intraabdominal Infections.* Colon and Rectal Surgery: Principals and Practice 2002. September 14, 2002, Minneapolis, MN.
181. **Dunn DL.** Invited moderator, Critical Care I: Sepsis and Immunity Surgical Forum Session. American College of Surgeons 88th Annual Clinical Congress. October 7, 2002, San Francisco, CA.
182. **Dunn DL.** *Diagnosis and Management of Serious Surgical Infections.* Minnesota Academy of Medicine. February 4, 2003. St. Paul, MN.
183. **Dunn DL.** *Update on the Management of Complicated Skin and Skin Structure Infections.* Visiting Professor of Surgery, Surgery Grand Rounds, Iowa Methodist Medical Center, February 20, 2003, Des Moines, IA.
184. **Dunn DL.** *The Lure of Academic Surgery.* 2003 Gordon Murray Lecture. University of Toronto, May 9, 2003. Toronto, Ontario, Canada.
185. **Dunn DL.** *Cytomegalovirus: Current Issues.* Transplant Immunosuppression 2003: the Continuing Challenge. October 3, 2003. Minneapolis, MN.
186. **Dunn DL.** *Appropriate Use of Antimicrobial Agents in Surgical Patients.* Fairview-Ridges Medical Center, December 17, 2004. Burnsville, MN.
187. **Dunn DL.** *Infection in Transplant Patients.* 6th Annual Emerging Technologies and Innovative Approaches for Managing Patients with Complex Medical Conditions Conference. April 1, 2005. Scottsdale, Az.
188. **Dunn DL.** *The Diagnosis and Management of Serious Surgical Infections.* Chair's Choice Visiting Professor, Surgery Grand Rounds, University of Southern California, January 27, 2006, Los Angeles, CA
189. **Dunn DL.** *The UB Academic Health Center: At the Crossroads of Health Science Professional Education, Biomedical Research, and Health Care in Western New York.* Surgical Grand Rounds, Roswell Park Cancer Institute, January 24, 2007, Buffalo, NY.
190. **Dunn DL.** *The UB Academic Health Center: At the Center of Health Science Professional Education, Biomedical Research, and Health Care in Western New York.* Western New York Chapter of the American College of Surgeons, October 27, 2007, Niagara on the Lake, Ontario, Canada.
191. **Dunn DL.** *Serendipity, Seccession, and the Rise of Modern American Surgery.* 2010 Edelstone-Bendix Lecture in Surgery, Department of Surgery, Feinberg School of Medicine, Northwestern University, June 18, 2010, Chicago, IL.